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Long-lived HIV-1 infected cells that form part of the latent HIV-1 reservoir represent a major 
barrier to HIV-1 cure despite antiretroviral therapy (ART). The majority of these cells 
contribute to a persistent HIV-1 infection through clonal expansion. Many methods exist to 
study clonal expansion by identifying identical integration sites in different cells. However, 
the majority of proviruses are defective and until recently, methods did not exist to enable 
the simultaneous characterisation of integration sites and integrated proviruses, to identify 
which HIV-1 infected cell clones harbour intact proviruses. As recent methods are laborious 
and expensive, more efficient methods of linking intact proviral sequences and their cognate 
integration site are required. In addition, third-generation sequencing platforms allow for 
real-time long read-length sequence data which is ideal to characterise proviruses. These 
methods provide faster and simpler genome assembly than short read length second-
generation sequencing platforms. Therefore, the overall aim of this study was to contribute 
to the HIV cure agenda, by improving our understanding of true HIV reservoirs by developing 
methods that would improve the characterisation of HIV-1 infected cell clones that harbour 
intact HIV genomes.  
 
Methods  
Intact proviral genomes are rare and attempts to enrich and link these proviral sequences 
to their integration site were investigated. The Integration Site Loop Amplification (ISLA) 
assay published by Wagner et al. (2014) was adapted for HIV-1 subtype C. Verification by 
Sanger sequencing showed that no integration sites were recovered and the “Premium 
whole genome amplification” method from Oxford Nanopore Technologies’ (ONT) 
third-generation sequencing technology was attempted as an alternative method. To 
investigate the utility of ONT sequencing, the “Amplicons by Ligation” method was utilised 
to sequence 9 near-full-length provisionally intact HIV-1 proviral sequences, previously 
sequenced by Illumina MiSeq. The consensus sequences for ONT sequencing were 
generated through a custom bioinformatic pipeline and compared to the Illumina MiSeq 
consensus sequences. 
 




The modified ISLA approach for HIV-1 subtype C or Premium whole genome amplification 
method did not succeed in recovering the HIV-1 proviral integration sites, of rare intact HIV-1 
genomes. For near-full-length HIV genome sequencing, the “Amplicons by Ligation” protocol 
ONT sequencing achieved high coverage across the HIV genome and apart from 
hypervariable HIV-1 envelope there was a near perfect concordance between the 
consensus sequences generated with ONT and the previous Illumina MiSeq sequences, 
with an overall concordance of >99% for 8 out of 9 samples.  
 
Conclusion 
HIV-1 integration sites were not recovered in this study and efficient methods for 
simultaneous and efficient identification of intact proviral genomes and their integration sites 
remain unavailable. ONT sequencing allows for efficient and accurate sequencing of long 
fragments in real-time which may overcome technical barriers and eliminate laborious, time-
consuming and expensive methods currently used for integration site identification and 
near-full-length HIV-1 genome sequencing. As part of the research towards future possible 
HIV cures, it remains a priority to investigate the persistence of cells harbouring intact HIV-1 
genomes, and the role of clonal cellular proliferation in their survival.  
 
  





Die grootste struikelblok om MIV-1 te genees, ten spyte van antiretrovirale terapie (ART), is 
langlewende MIV-1 geïnfekteerde selle wat deel uitmaak van die latente MIV-1 reservoir. 
Die meerderheid van hierdie selle dra by tot die handhawing van MIV-1 infeksie deur klonale 
vermeerdering. Verskeie bestaande metodes word gebruik om klonale vermeerdering te 
ondersoek deur die identifisering van identiese integrasie lokusse in verskillende selle. 
Nietemin is die meerderheid van proviruses defektief. Tot onlangs, het metodes wat die 
gesamentlike karakterisering van integrasie lokusse en geïntegreerde provirusse, moontlik 
maak, om vas te stel watter MIV-1 geïnfekteerde selklone intakte provirusse huisves, nie 
bestaan nie. Aangesien onlangse metodes baie moeisaam en duur is, is meer doeltreffende 
metodes wat intakte provirusse en hul onderskeie integrasie lokusse met mekaar verbind, 
benodig. Boonop laat derde generasie volgordebepalingstegnologie blitsvinnige lang-
leeslengte volgordebepaling toe, wat ideal is vir die karaktisering van provirusse. Hierdie 
metodes laat vinniger en makliker genoom samestelling toe in teenstelling met kort-
leeslengte tweede generasie volgordebepalingstegnologie. Gevolglik is die oorhoofse doel 
van hierdie studie om tot die MIV genesing-agenda by te dra deur ons begrip van MIV-1 
reservoirs te verbeter, met die ontwikkeling van metodes wat die karakterisering van MIV-1 
geïnfekteerde selklone wat ongeskonde MIV genome huisves, laat vooruitgaan. 
 
Metodes 
Ongeskonde provirale genome is skaars en pogings om hierdie provirusse te verryk en te 
verbind met hul onderskeie integrasie lokusse is ondersoek. Die “Integration Site Loop 
Amplification” (ISLA) metode wat deur Wagner et al. (2014) gepubliseer is, is aangepas vir 
MIV-1 subtipe C. Die nagaan hiervan deur Sanger volgordebepaling dui daarop dat geen 
integrasie lokusse herwin is nie; en is die “Premium whole genome amplification” metode 
van Oxford Nanopore Technologies (ONT) derde-generasie volgordebepaling as 
alternatiewe metode gebruik. Om die gebruiklikheid van ONT volgordebepaling te 
ondersoek, was die “Amplicons by Ligation” metode gebruik om 9 naby-vollengte voorlopig-
ongeskonde MIV-1 provirusse, waarvan die volgorde voorheen deur Illumina MiSeq bepaal 
is, gebruik. Die konsensusvolgordebepaling vir ONT is gegenereer deur ‘n pasgemaakte 
bio-informatika pyplyn en vergelyk met die Illumina MiSeq konsensus volgordebepalings.  
 




Die aangepasde ISLA MIV-1 subtipe C of “Premium whole genome amplification” metodes 
was nie suksesvol met die herwinning van die provirale integrasie lokusse van raar 
ongeskonde MIV-1 genome nie. Die “Amplicons by Ligation” metode van ONT was gebruik 
om die volgorde van naby-vollengte MIV genome te bepaal, met ‘n hoë leesdekking oor die 
MIV genoom. Buiten vir die hoogsveranderlike MIV-1 membraan geen was daar ‘n amper-
perfekte ooreenstemming tussen die konsensus volgordebepaling gegenereer met ONT en 




MIV-1 integrasie lokusse was nie ingesluit in hierdie studie bevindings nie en doeltreffende 
metodes vir gesamentlike identifisering van ongeskonde provirale genome en hul integrasie 
lokusse bly onverkrygbaar. ONT volgordebepaling laat doeltreffende en akkurate 
volgordebepaling en lang-leeslengte blitsvinnig toe. Dit kan moontlik tegniese versperrings 
van huidige tydrowende en duur metodes, om integrasie lokusse en naby-vollengte MIV-1 
genoom volgordes te bepaal, oorkom. As deel van die navorsing oor moontlike genesings 
vir MIV, bly dit ‘n prioriteit om die voortlewing van selle wat ongeskonde MIV-1 genome 
huisves, en die rol van klonale sellulêre vermeerdering in hul oorlewing te ondersoek. 
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1 Introduction  
1.1 HIV burden globally and in South Africa 
The Joint United Nations Programmed on HIV/AIDS (UNAIDS) devised the 90-90-90 
strategy which aimed to end the AIDS epidemic, caused by HIV infection, by the year 2030. 
By 2020, the strategy aimed to achieve the following; 90% of the individuals living with HIV 
should know their status, of those, 90% should be receiving sustained antiretroviral therapy 
(ART) and 90% of people receiving ART should be virally suppressed. In 2019, the UNAIDS 
global statistics reported 38 million individuals were estimated to be living with HIV of which 
approximately 81% knew their status, approximately 67% were accessing ART and 59% 
were virally suppressed (UNAIDS, 2020). South Africa’s National Department of Health 
adopted the 90-90-90 strategy in December 2014 as South Africa is reported to have the 
largest HIV epidemic worldwide and AIDS is one of the leading causes of death in the 
country (Health Systems Trust, 2016). The UNAIDs reported that approximately 7.7 million 
individuals were living with an HIV infection by 2018 in South Africa which accounted for 
almost 21% of the HIV infections globally that year. The latest 90-90-90 statistics for South 
Africa were released in 2018 and show that 90% of individuals knew their status, 62% of 
adults and 63% of children were receiving ART and 54% were virally suppressed (UNAIDS, 
2020). Steady progress towards achieving the 90-90-90 strategy goal has been made, 
however, it remains to be known whether these goals have been achieved by the end of this 
year. The development of a cure for HIV remains a priority research area as treatment with 
ART alone is not sufficient at eradicating HIV infection. Current cure research is aimed at 
identifying strategies that allow for effective drug-free control of HIV infection as a ‘functional 
cure’ and identifying drugs that can eradicate HIV as a ‘sterilising cure’. Vaccine 
development and drug resistance research also remain important areas of focus. The 
information generated in different disciplines aim to ultimately contribute towards ending the 
epidemic.  
 
1.2 HIV classification, structure and replication  
1.2.1. HIV classification  
HIV is classified in the Lentivirus genus within the family of Retroviridae. Based on the 
genetic characteristics and differences present in the viral antigens, two distinct HIV species 
have been identified, namely HIV-1 and HIV-2. HIV-1 is responsible for the global pandemic 
Stellenbosch University  https://scholar.sun.ac.za
2 
 
and contributes to 95% of the HIV infections worldwide. HIV-2 has a very low prevalence 
outside of West Africa, a much lower rate of transmission and a slower disease progression 
than HIV-1 (Zheng et al., 2004). 
 
HIV-1 is classified into four highly divergent groups: M (major), O (outlier), N (non-M, non-
O) and P. Group M is the pandemic branch that is further divided into subtypes based on 
the phylogenetic associations of the sequences, namely; A1, A2, A3, A4, A6, B, C, D, F1, 
F2, G, H, J, K and also includes circulating recombinant forms (CRFs). Unique recombinant 
forms occur as a result of recombination events between known and recognised subtypes 
and are constantly emerging and result in the formation of CRFs of HIV-1 once transmitted 
to three or more individuals who are not epidemiologically related (Leitner et al., 2005, 
Olabode et al., 2019). Currently, 102 CRFs are represented on the Los Alamos National Lab 
HIV Sequence Database [www.hiv.lanl.gov]. HIV-1 subtype C is the most prevalent subtype 
and accounts for approximately 50% of the infections worldwide (Taylor et al., 2008, 
Günthard & Scherrer, 2016, Gartner et al., 2020) and is predominant in Southern and 
Eastern Africa, India and Ethiopia (Gartner et al., 2020). 
 
1.2.2. HIV-1 structure  
Mature HIV virions, as depicted in Figure 1.1B, measure approximately 100-120 nm in 
diameter and are surrounded by an outer lipid membrane which serves as its envelope. The 
9.2 - 9.6 kilobase pair (kb) HIV genome (German Advisory Committee Blood, 2016) consists 
of two identical copies of positive single-stranded RNA which encodes for 16 proteins that 
can be divided into three protein categories; structural, regulatory and accessory. Structural 
proteins are essential in manufacturing components of the retroviral particle and are 
products of env, gag and pol genes depicted in Figure 1.1A. The outer surface of the virion 
is covered with 72 spikes that are produced by trimers of two env glycoproteins. The spikes 
consist of the surface gp120 trimer which is anchored to the membrane by the gp41 
transmembrane protein. Gag produces internal structural proteins p17, p24 and p7 which 
are responsible for producing the matrix, capsid and nucleocapsid, respectively. The cone-
shaped capsid of a mature virion houses the viral genome and the encoded viral enzymes; 
protease, reverse transcriptase and integrase which play essential roles in viral replication 
and are produced by the pol gene (Engelman & Cherepanov, 2013, Li & De Clercq, 2016). 
Regulatory proteins are encoded by tat (trans-activator of transcription) and rev (regulator 
of viral expression) and are essential in HIV replication initiation. Accessory or auxiliary 
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proteins; Nef (negative factor); Vpr (viral protein r), Vpu (viral protein u) and Vif (viral 
infectivity factor) impact on viral replication, virus budding and the pathogenesis of HIV. The 
HIV genome is flanked on both ends by long terminal repeat (LTR) sequences which 
collectively include the unique 5’ (U5), repeat (R) and unique 3’ (U3) regions. The 5’LTR 
region encodes for the promoter for the transcription of viral genes (German Advisory 
Committee Blood, 2016). 
 
 
Figure 1.1: The genome and structure of a mature HIV-1 virion. (A) Proviral HIV-1 genomic map showing the 
viral genes and the resulting structural and regulatory viral proteins. (B) A mature HIV-1 virion. (Adapted from 
sources: Nkeze et al., 2015 and National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, 2009). 
 
1.2.3. HIV-1 replication  
HIV primarily infects CD4+ T cells but is also capable of infecting other immune cells that 
have the CD4 receptor which includes monocytes, macrophages and dendritic cells 
(Engelman & Cherepanov, 2013). Viral replication occurs through a series of steps that 
begins with the productive engagement of the virus with host cell surface receptors and ends 
when nascent viral particles mature into infectious virions as shown in Figure 1.2. The viral 
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entry or fusion begins with the attachment of the host cell CD4 receptor via the C4 domain 
of gp120 which evokes a conformational change in CD4 and allows gp120 to bind to 
co-receptor CCR5 or CXCR4. The gp41 trimer mediates the fusion between the HIV virion 
and the host immune cell. Reverse transcription is initiated and the single-stranded RNA is 
converted into double-stranded DNA by the reverse transcriptase enzyme. The double-
stranded DNA and integrase form part of the preintegration complex (PIC) which enters the 
host’s cell nucleus. Integrase catalyses the integration of the viral DNA into the host cell’s 
genomic DNA. Successful integration relies on the occurrence of three sequence specific 
events which are facilitated by integrase; viral DNA is assembled, the 3’ ends of the viral 
DNA are endonucleolytically processed and the viral and host cellular DNA are joined. The 
integration step is critical as it finalises the infection of the host cell and the establishment of 
a persistent HIV infection. The integrated HIV genomes are referred to as proviruses. Viral 
gene expression follows where host cellular machinery such as transcription factors are 
utilised to transcribe new viral messenger RNA (mRNA) from the integrated proviral DNA. 
The transcribed mRNA contains the necessary information to produce new viral proteins 
that are required to assemble a new HIV virion. The viral RNA exits the cell nucleus and is 
translated into virus proteins which assemble at the inner plasma membrane of the host cell 
to allow for budding off and the formation of an immature HIV virion which is non-infectious. 
The newly formed immature HIV virion is released and the viral enzyme protease initiates 
proteolysis which cleaves the polyproteins to create a mature infectious virion (Arts & 
Hazuda, 2012). 
 




Figure 1.2: HIV-1 replication cycle (Source: National Institute of Allergy and Infectious Diseases, 2018. 
[Online]: https://www.niaid.nih.gov/diseases-conditions/hiv-replication-cycle). 
 
1.3. HIV-1 infection and immune function 
HIV primarily targets activated CD4+ T cells as this leads to a productive viral infection. 
These cells are involved in the co-stimulation and regulation of humoral and cellular 
immunity however, viral infection of these cells disables these functions. The HIV-infected 
CD4+ T cells are destroyed by the cytotoxic CD8+ T cells of the immune system. HIV 
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infection consists of several stages and without the intervention of ART can progress to 
AIDS in a median of ten years as indicated in Figure 1.3 (Tobin & Aldrovandi, 2013). The 
acute stage of infection is characterised by a very high HIV-1 RNA plasma viral load and a 
low CD4+ T cell count as the infected CD4+ T cells are destroyed by the immune system 
(Okoye & Picker, 2013). Regeneration from CD4+ memory T cells of the immune system 
restores the CD4+ T cell numbers and functions above the threshold that is associated with 
immunodeficiency, viral replication is controlled and the HIV-1 RNA plasma viral load 
decreases by 100 to 1 000-fold. The HIV-1 RNA plasma viral load and CD4+ T cell count 
remain relatively stable at this viral set-point for years (Tobin & Aldrovandi, 2013). Over time, 
immune exhaustion occurs and homeostasis of the CD4+ T cell population fails (Okoye & 
Picker, 2013) and the number of cells decline to below the level that is required to prevent 
opportunistic infections and the viral load increases which is concurrent with the onset of 
HIV related symptoms which leads to AIDS and death.  
 
 
Figure 1.3: Progression of HIV-1 infection measured by CD4+ T cell count and HIV-1 RNA plasma viral load 
in an ART naïve individual. (Adapted from source: Kogan & Rappaport, 2011). 
 
1.4. HIV-1 infection in paediatrics  
The progression of HIV infection is significantly different between adults and children and 
could be related to the reported differences in their immune systems. In adults, without ART 
intervention, progression to AIDS or death usually occurs within ten years following primary 
infection as discussed above. In contrast, without the intervention of ART, children living 
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with HIV have shown higher rates of mortality and faster disease progression as shown in 
Figure 1.4 (Tobin & Aldrovandi, 2013, Martinez et al., 2015). Approximately 20 to 30% of 
HIV-infected children usually die within the first year of life (Martinez et al., 2015). 
Furthermore, HIV-1 RNA plasma viral loads greater than 100 000 copies per millilitre have 
been reported in perinatally infected infants months after infection and are typically 10-fold 
higher than has been reported in adults. In children who do not progress to AIDS or death, 
a viral set-point is only achieved at five years of age. A lower number of circulating target 
HIV cells, CD4+ T cells with the CCR5 co-receptor (Shalekoff et al., 2004) are present in 
children although a high proportion of these cells have recently been reported in the gut 
(Bunders et al., 2012). Cellular immune responses to HIV infection also differ. In adults, prior 
to peak viremia, virus specific CD8+ T cells are present in blood and the cytotoxic T cell 
responses are associated with the observed decrease in viral load. In children, however, 
these cytotoxic responses are only detected after six months of age and viral replication is 
controlled to some extent by non-cytolytic CD8 cells (Martinez et al., 2015). Overall, the lack 
of viraemic control observed in children may be attributed to the immature immune system 
which is comprised of deficient HIV specific CD4+ T cell responses, ineffective CD8+ T cell 
responses and a delay in antibody-dependent cell-mediated cytotoxicity.  
 
 
Figure 1.4: Comparison of HIV-1 disease progression in adults and children without the intervention of ART. 
The relative HIV-1 RNA plasma viral load is shown in red and the CD4+ T cell count is shown in blue. (Adapted 
from source: Tobin & Aldrovandi, 2013) Image used with permission from Immunological Reviews.  
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1.5. Treatment of HIV-1 infection  
1.5.1. Antiretroviral drugs 
ART inhibits HIV replication by targeting various steps that are specific to the viral replication 
cycle. Currently, six distinct classes of ART have been licenced for use in patients and are 
classified according to their molecular mechanism and include nucleoside analogue reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
integrase inhibitors, protease inhibitors (PIs), fusion/entry inhibitors and chemokine 
coreceptor antagonists which consist of two subclasses, namely the CCR5 antagonist and 
the CXCR4 antagonist (Arts & Hazuda, 2012). Monotherapy was used as the initial 
treatment strategy for HIV infection however, sustained therapeutic success could not be 
achieved and failure was attributed to the build-up of antiretroviral drug resistance 
(Engelman & Cherepanov, 2013). The standard of care evolved into what is now known as 
combination antiretroviral therapy (cART) where at least three different antiretroviral drugs 
from two different classes are given to HIV infected individuals. The implementation of cART 
regimens improved the morbidity and mortality that was originally associated with HIV 
infection and AIDS. A rapid suppression of viral replication and a decrease in HIV-1 RNA 
plasma viral loads to below the limit of detection in sensitive clinical commercial assays 
(20 - 50 HIV-1 RNA copies/ml) were observed in individuals on suppressive cART 
(Vanhamel et al., 2019). cART is effective at preventing the infection of new cells, and when 
current regimens are prescribed it limits viral evolution and the generation of resistant 
escape variants, in the large majority of patients. Nevertheless, long-lived HIV reservoirs 
persist and therefore cART does not provide a curative strategy for HIV infection. Upon 
cART cessation HIV usually rebounds quickly from long-lived cellular viral reservoirs. 
Therefore, lifelong treatment for individuals with HIV infection is required and is the current 
standard of care.  
 
1.5.2. Benefits of early treatment with cART  
Multiple studies have reported significant benefits of early cART initiation in both adults and 
children. A study conducted in adults by Le and colleagues (2013) showed that treatment 
within the first four months of infection significantly correlated with a higher restoration of the 
CD4+ T cell counts in the blood to >900 cells/ml (median value of 992 CD4+ T cells/ml was 
measured for HIV seronegative individuals whereas with treatment initiation during chronic 
infection, enhanced restoration of these cells was less likely to occur. Therefore, cART 
initiation early in acute infection significantly improves the probability of immune recovery. 
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Approximately, 5 -15% of adults treated during acute infection maintained viraemic control 
following cART interruption whereas therapy initiation during chronic infection typically 
resulted in viral rebound following treatment interruption (Sáez-Cirión et al., 2013, Stohr et 
al., 2013). Another study reported that early initiation and lengthened cART adherence 
resulted in a slower disease progression and time to viral rebound (SPARTAC Trial 
Investigators et al., 2013). Similar findings have been observed in early cART treated 
children with HIV infection. The randomized children with HIV early antiretroviral (CHER) 
trial investigated the benefits of early treatment initiation and the effect of treatment 
interruption at two time points. Overall, the study reported that the risk of death was reduced 
by 75% with early initiation of cART and similar to SPARTAC Trial (2013), a longer duration 
on cART prior to treatment interruption resulted in slower time to viral rebound which could 
potentially assist in the development of a sterilising or functional cure (Cotton et al., 2013). 
Furthermore, Kuhn et al. (2018) reported higher levels of HIV-1 DNA in children who started 
cART at ≥4.5 months of age than those who started earlier and also provided strong 
evidence of an association between early cART initiation and a reduced size of the viral 
reservoir several years later in children on suppressive therapy. Taken together, initiation of 
cART shortly after infection allows for a greater recovery of CD4+ T cell numbers, assists in 
lowering virologic set points, limits viral diversity and the size of the reservoir of persisting 
HIV (Buzon et al., 2014) while preserving immune responses in children and adults with HIV. 
 
1.6. HIV-1 reservoir  
1.6.1. Establishment of the HIV-1 reservoir  
Current cART regimens are successful in suppressing viral replication in the majority of HIV-
infected individuals by targeting viral enzymes or viral entry. However, it cannot eradicate 
the virus as the long-lived HIV reservoir is established early in infection. Activated CD4+ T 
cells are the preferential targets for productive HIV infection, but they have short lifespans 
due to the cytopathic effects of the virus or cytotoxic T lymphocyte-mediated killing (Coffin 
& Swanstrom, 2013) as shown in Figure 1.5. The majority of newly HIV-infected CD4+ T 
cells die within the first 24 – 48 hours. The remaining cells either die within the next 2 – 4 
weeks or revert to a resting state and differentiate into long-lived memory CD4+ T cells 
(Coffin & Swanstrom, 2013, Maldarelli et al., 2014) depicted in Figure 1.5. The main immune 
cells comprising the reservoir are, therefore, memory CD4+ T cells which have an estimated 
half-life of 43 – 44 months. Due to the stability of the reservoir cells, cART would have to be 
administered for >73 years in order for the latent reservoir to decay to zero (Siliciano et al., 
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2003, Hosmane et al., 2017). The HIV reservoir, therefore, creates a major barrier to cure 
as the cells are stable, persist throughout the duration of suppressive cART and are capable 
of producing replication-competent virus upon cART cessation. The presence of a latent HIV 
reservoir is supported by clinical evidence showing that poor adherence or interruption of 
cART leads to viral rebound. Therapy is therefore administered for life in order to suppress 
viral replication and slow the progression of the disease. Recent studies have shown that 
various mechanisms may play a role in reservoir persistence: 1) intact proviruses are able 
to persist in long-lived latently infected cells, 2) possible low level and ongoing viral 
replication may occur due to insufficient levels of intracellular drug concentrations 
(Lorenzo-Redondo et al., 2016) although data provided by van Zyl and colleagues in 2017 
provides strong evidence against ongoing viral replication and evolution and 3) the 
proliferation of HIV-1 infected cells also known as clonal expansion (Maldarelli et al., 2014, 




Figure 1.5: Comparison of a productive and latent HIV infection. The normal process of memory cell generation 
is shown in the boxed area. HIV infects activated CD4+ T cells and results in a productive HIV infection where 
most infected cells die. A proportion of HIV-infected activated CD4+ T cells can revert to resting state and form 
part of the latent reservoir where they contribute to a persistent HIV infection. (Source: Murray et al., 2016) 
Image used with permission from The Journal of Immunology. 
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1.6.1.2. The HIV-1 latent reservoir undergoes clonal expansion  
Long-lived cells infected by HIV before the initiation of cART are the most important part of 
the latent HIV reservoir and are capable of persisting for years despite fully suppressive 
treatment. Evidence has shown that within a patient, a large number of infected CD4+ T 
cells have proviral integration into the exact same position in the human genome, which is 
extremely unlikely to have resulted from multiple integration events. This provides strong 
support for clonal expansion of HIV-infected cells. These expanded clones can be detected 
in patients on long-term therapy and may show integration in the same orientation as growth 
genes (Wagner et al., 2014 and Maldarelli et al., 2014). HIV integration is a relatively 
nonspecific process; however, evidence has shown that integration preferentially occurs in 
expressed genes throughout the genome (Schröder et al., 2002; Han et al., 2004) which can 
be explained by the proliferation of infected cells after integration.  
 
HIV integration can involve the insertion of an intact, full-length, replication-competent 
provirus or a defective provirus into the host genome prior to latency. However, the 
integration of a defective provirus is more likely to occur, as cells carrying defective 
proviruses are less likely to die from viral cytopathic effects or lysis by host effector cells. 
More than 90% of latent HIV proviruses are defective in cART suppressed individuals. 
Defective proviruses are characterised by the presence of deletions, insertions, inversions 
or mutations in the HIV genome that are introduced by the error-prone reverse transcriptase 
enzyme, template switching during reverse transcription, APOBEC3G-induced 
hypermutations or point mutations (Ho et al., 2013, Bruner et al., 2016). Due to the high 
prevalence of defective latent proviruses, it was thought that the majority of clonally 
expanded cells would harbour defective HIV proviruses. Both defective and intact proviruses 
survive through clonal expansion.  However, it was previously not known whether intact 
proviruses were able to survive by clonal expansion without being purged by the immune 
system. 
 
Simonetti et al. (2016) was the first to report that an HIV infected individual with a highly 
expanded clone carried an intact provirus that was responsible for persistent, infectious 
viremia. In addition to this, three independent studies have shown that approximately 56% 
of cells that harbour replication-competent HIV proviruses undergo clonal expansion 
(Bui et al., 2017, Lorenzi et al., 2016, Hosmane et al., 2017). The study carried out by Bui 
and colleagues in 2017 demonstrated that cells carrying intact proviruses can clonally 
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expand in vivo and recovered identical sequences in six out of eight participants. Lorenzi 
and colleagues (2016) showed that more than 50% of replication-competent isolates from 
four patients on suppressive cART had identical env sequences to other isolates from the 
same individual. However, this study did not investigate other regions in the HIV genome 
and although env showed identical sequences, the sequence may differ elsewhere in the 
genome (Laskey et al., 2016). Hosmane et al. (2017) not only showed that 57% of latently 
infected cells carried identical env sequences to other isolates from the same patient but 
further showed that these sequences were identical throughout the entire genome. Taken 
together, these studies provide strong support for clonal proliferation as a mechanism of 
survival of replication-competent proviruses and suggest that the majority of the latent 
reservoir is likely maintained by clonal proliferation.  
 
1.6.1.2.1. Assays investigating clonal proliferation  
Clonal expansion is reported as the major mechanism of latent reservoir persistence and 
supporting evidence has been provided by the identification of identical integration sites in 
infected cells using integration site assays. Considering the size of the human genome 
statistically, two infected cells harbouring identical proviral integration sites are more likely 
to have emerged as a result of a single infection event followed by the proliferation of the 
infected cell, as opposed to two separate integration events. Therefore, infected cells with 
identical HIV integration sites are indicative of clonal expansion.  
 
Most assays used to determine the human genome integration position of particular 
proviruses include short stretches near the respective 5’ or 3’ ends of the HIV genome only 
and do not enable one to assess proviral intactness nor confidently link the integration sites 
and their respective proviruses. It is likely that the majority of the expanded clones detected 
in these assays represent defective proviruses (Cohn et al., 2015). Approaches frequently 
utilised for integration site identification include the linker mediated polymerase chain 
reaction (LM-PCR), the Alu-HIV assays and the Integration Site Loop Amplification (ISLA) 
assay. The LM-PCR approach ligates a DNA linker to the ends of fragmented DNA and 
selectively amplifies the junctions between the host and viral DNA using primers that are 
specifically designed for viral DNA (often positioned in LTR) and the linker. Recent 
improvements to this assay have been described by Wells and colleagues in 2020, where 
DNA sample fragmentation, end-repair and linker-ligation are completed in a single 
enzymatic random cleavage step which replaced the original multistep process that utilised 
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mechanical shearing by a double-stranded DNA fragmentase to fragment the DNA followed 
an independent linker-ligation step. Overall, this assay targets the LTR ends of the HIV 
genome and 5–15% of HIV integration sites are recovered with the improved method (Wells 
et al., 2020). The Alu-HIV assays are more widely utilised than LM-PCR methods, and the 
real-time Alu-PCR assays have been used to quantify integrated HIV relative to unintegrated 
HIV. The first step utilises a forward primer which binds to the human Alu element, a repeat 
element that is encountered every 3 000 base pairs, and a HIV specific reverse primer. 
Different HIV specific primers have been utilised by different research groups and are 
chosen based on the research question. Both an Alu-Gag (Alu and HIV Gag specific 
primers) and an Alu-LTR (Alu and HIV LTR specific primers) (Vandergeeten et al., 2014) 
approach have been described. Comparisons between the two approaches have shown that 
the Alu-LTR approach is capable of capturing all integrated HIV DNA thereby increasing the 
approach’s sensitivity. The second step in the assay utilises a real-time PCR that targets 
HIV LTR. The distances between the Alu element and the integrated provirus varies for each 
infected cell and different amplification efficiencies are encountered which are distance 
dependent. In order to overcome the variations in efficiency, repeated sampling is required 
(Pinzone & O’Doherty, 2018). Significant weaknesses are also observed in this approach 
as integration sites linked to defective proviruses cannot be distinguished from intact and 
potentially replication-competent proviruses. The ISLA assay developed by Wagner and 
colleagues in 2014 is a unique approach that was designed to identify integration sites in 
single cells and determine whether integration into specific genes may promote the 
proliferation of HIV-infected cells. The assay utilised two forward primers in HIV env and HIV 
nef to linearly amplify the proviral DNA and the adjacent integration site. A random priming 
step followed where oligos with 3’ random decamers and a 5’ reverse complement 
U5-specific primer sequence were used to incorporate a self-complementary tail, which after 
complementary strand synthesis and denaturation, would loop back onto the 
complementary U5 sequence of the HIV template. The generated loop contained the human 
genomic sequence with complementary HIV ends. Three rounds of exponential amplification 
followed and the templates were sequenced to identify the integration sites. The proviral 
integrity was not confirmed with this assay as the ends of the HIV genome were targeted for 
integration site identification. The molecular-based integration site assays as described here 
and published by Madarelli (2014) and Cohn (2015) randomly fragment the sample to 
investigate HIV integration sites. And although these methods allow for the recovery and 
identification of integration sites, random fragmentation disrupts the HIV genome and 
prevents simultaneous identification of the proviral integrity and the respective integration 
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site. Further challenges encountered with integration site assays and analyses include that 
direct evidence for clonal expansion is provided but the replication competence of the 
provirus cannot be established.  
 
The standard method for identifying replication-competent proviruses is investigated through 
a culture-based method known as a viral outgrowth assay (VOA). Although replication 
competence can be inferred through this method, identifying the clonality of these viruses 
poses further problems. Multiple rounds of in vitro infection are required in VOA cultures and 
the HIV integration sites that are captured are no longer a true reflection of those that occur 
in vivo (Bui et al., 2017, Lorenzi et al., 2016, Hosmane et al., 2017).  
 
Additionally, full-length HIV proviral sequencing methods aimed at identifying clonally 
expanded HIV, amplify regions spanning the HIV genome but exclude information on 
integration sites and replication competence (Ho et al., 2013, Bruner et al., 2016). The 
integration sites of intact replication-competent or potentially replication-competent 
proviruses need to be efficiently and simultaneously obtained to bypass the problems 
encountered by the methods mentioned above, which creates a technical challenge. 
 
Several methods have been developed to simultaneously identify intact HIV proviruses and 
integration sites. Similar methods were developed by Einkauf et al. (2019) and Patro et al. 
(2019) to identify expanded clones of cells from donors infected with HIV and utilise a 
combined approach to characterise proviral integrity and the respective integration sites. 
Both methods utilised a whole genome amplification approach using the isothermal phi29 
polymerase enzyme to generate 1 000 to 10 000 copies of an individual provirus. The study 
by Einkauf and colleagues (2019) showed that three donors carried expanded clones and a 
portion of clones contained intact proviruses matching viral outgrowth in culture. Similarly, 
Patro and colleagues (2019) showed that the majority of the clones were defective in the 
five donors investigated except for one, which was identified as intact and was further 
confirmed to be replication-competent as the proviral sequence was also recovered by VOA. 
A limiting dilution culture and CD3/CD28-mediated proliferation method was utilised by the 
Siliciano group to sequence HIV integration sites and the proviral genome, however, only 
defective proviral clones were identified as viral cytopathic effects killed cells harbouring 
replication-competent provirus as a result of maximum T cell activation (Liu et al., 2020). 
Overall, the methods described by Einkauf (2019) and Patro (2019) allow for simultaneous 
identification of rare intact HIV proviruses and integration sites, however, both methods 
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utilise a multiple step process of confirmation and are laborious, time-consuming and 
expensive. An efficient and cost-effective method for identifying, enriching and linking intact 
HIV proviruses and their integration sites is required as more than 50% of cells harbouring 
infectious HIV proviruses are maintained by clonal expansion. 
 
1.7. Sequencing generations and technologies 
Various sequencing platforms and chemistries have been used to facilitate investigations of 
clonal expansion as a mechanism of latent HIV reservoir persistence. DNA was first 
sequenced by Sanger sequencing in 1977 (Sanger et al., 1977). However, low throughput 
and increased costs were encountered when long stretches of DNA for larger-scale projects 
were sequenced, which brought about the next generation sequencing era which aimed to 
address these issues. Second-generation sequencing also known as massively parallel 
sequencing was developed as a means to cheaply generate millions of sequences per 
reaction per run in a short period of time. Second-generation sequencing includes various 
sequencing instruments developed by Roche, Applied Biosystems, Ion Torrent and 
Illumina®. Each sequencing platform utilises unique sequencing chemistries and methods 
to generate libraries which are presented in Table 1.1. The generation of short read lengths 
in all of the second-generation sequencing platforms is a significant drawback. Overall. no 
second-generation sequencing approach provides reads longer than 1 000 base pairs as 
shown in Table 1.1 (Weirather et al., 2017). Although these sequencing platforms are 
cost-effective, accurate and are supported by a wide range of analysis tools and pipelines, 
the generation of short reads make resolving repetitive regions in genomes difficult, as 
misassembles and gaps are regularly encountered (Rhoads & Au, 2015, Amarasinghe et 
al., 2020). In addition, large structural variations are more challenging to detect and 
characterise with these sequencing platforms. Second-generation sequencing heavily relies 
on PCR to enrich the DNA template and regions with high GC% are inefficiently amplified 
(Lu et al., 2016). 
 
Third-generation sequencing overcomes the limitations identified in second-generation 
sequencing as it offers the ability to sequence single nucleic acid molecules in real-time and 
generates long read lengths at high resolution. Two sequencing platforms currently 
dominate this market, namely Pacific Bioscience’s (PacBio®) single-molecule, real-time 
(SMRT) sequencing and Oxford Nanopore Technologies’ (ONT) nanopore sequencing 
which were commercially released in 2011 and 2014, respectively (Amarasinghe et al., 
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2020). A major advantage of these technologies is that the native DNA or RNA is sequenced 
which eliminates biases that are potentially introduced by PCR amplification, thereby 
preserving base modifications. The generation of long reads further improves de novo 
assemblies of genomes that include large stretches of repetitive regions, mapping certainty, 
detection of structural variants, transcriptome analysis and also plays an important role in 
metagenomic research (Rhoads & Au, 2015, Lu et al., 2016, Amarasinghe et al., 2020). 
 
Major technical differences separate PacBio®’s SMRT sequencing and ONT’s nanopore 
sequencing, however, both sequencing technologies are capable of directly sequencing 
single nucleic acid molecules and generating long reads of between 1 – 100 000 base pairs 
in length (Lu et al., 2016, Weirather et al., 2017, Krishnakumar et al., 2018). Further 
differences between the two sequencing technologies are highlighted in Table 1.1 and the 
sequencing approaches are briefly explained in sections 1.7.1 and 1.7.2.  
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by SMRTbell* 
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• Real-time measurement of 
base incorporation 
• Large number of reads per 
single molecule  
• Fast run times  
• Long read lengths  
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≤2 300 000 
Ultra-long 
reads 
• High error rate in variable 
regions and 
homopolymers 
• Very high concentration 
nucleic acids need to be 
prepared prior to 
sequencing  
• Real-time sequencing with 
real-time data output 
• Large number of reads per 
single molecule  
• Long read lengths  
• No amplification required  
• Fast run times  
• Low instrument and 
reagent cost  
• Multiplexing capabilities 
• Portable and scalable  
* SMRTbell is a double-stranded DNA template that has hairpin loops ligated at both ends, it forms the DNA library for Pacific Biosciences SMRT sequencing.  
Sources: Ion Proton vs Illumina HiSeq2500 vs SOLiD 5500, 2013, Buermans & den Dunnen, 2014, Rhoads & Au, 2015, Illumina®, 2017, De Maio et al., 2019, PacBio®, 2020, Oxford Nanopore Technologies, 2020. 
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1.7.1. PacBio® SMRT sequencing 
SMRT sequencing detects fluorescence events that correspond to the addition of a 
fluorescently-labelled nucleotide by a polymerase that is tethered to the bottom of a small 
well surrounded by aluminium walls called Zero-mode waveguide (ZMW) measuring 70nm 
by 100nm with about 150 000 ZMW in one SMRT cell. The DNA polymerase in the ZMW 
binds to a DNA molecule and incorporates fluorescently-labelled nucleotides that emit light 
pulses. The replication process in all of the wells on the SMRT cell are recorded and the 
light pulses correspond to the sequence of the nucleic acid, which is also known as a 
continuous long read (CLR) (Pacific Bioscience, 2020, Quainoo et al., 2017). The process 
has a high read error, but this can be overcome by the use of the SMRTbell sequencing 
library approach: the sample is prepared by ligating hairpin adaptors to the ends of a double-
stranded DNA fragment creating a circular template referred to as a SMRTbell. The circular 
template allows the polymerase enzyme to replicate both strands multiple times, increasing 
the accuracy of the sequencing read. CLRs can be split into multiple reads known as 
subreads by recognizing and removing the adaptor sequences. The consensus of multiple 
subreads in a single well yields a circular continuous sequence (CCS) read with higher 
accuracy as shown in Figure 1.6 (Rhoads & Au, 2015). The read length is dependent on 
polymerase longevity and library insert sizes range from 250 base pairs to 50 000 base 
pairs. However, larger inserts can prevent multiple replications of the circular template which 
affects the CCS quality. The average error rate of this third-generation sequencing 
technology is estimated at <1% (Amarasinghe et al., 2020). CCS reads retain errors and 
exhibit bias for insertions and deletions in homopolymer regions (Wenger et al., 2019). 
PacBio® constantly improves their sequencing technology by providing regular updates to 
hardware, chemistry and software in an attempt to compete with the sequencing accuracy 
achieved by second-generation sequencing technologies.  
 




Figure 1.6: Library preparation, SMRT sequencing and the generation of CCS sequencing reads. (Source: 
PacBio®, 2020. [Online]: https://www.pacb.com/smrt-science/attachment/how-to-get-hifi-reads_v2/). 
 
1.7.2. ONT nanopore sequencing 
ONT’s nanopore sequencing measures the changes in ionic current that occur across an 
electrically resistant polymer membrane as single-stranded nucleic acids pass through 
biological nanopores that are present on a flow cell. The nucleic acid sequence is inferred 
as each nucleotide confers a different resistance which is measured by an arrayed sensor 
chip and passed to an Application-Specific Integrated Circuit (ASIC) which controls and 
measures the experiments. The sequence data is processed by the MinKNOW specialist 
software that is responsible for carrying out several core functions which includes; data 
acquisition, real-time analysis and feedback, data streaming while providing device control, 
sample identification and tracking to ensure that the chemistry of the platform performs 
optimally while the samples are processed. ONT offers a customisable sequencing 
approach in which various sequencing devices with different throughputs and library 
preparation methods can be chosen based on the purpose of the experiment. Three 
sequencing devices are currently available, namely; the MinION (sequences one flow cell), 
GridION (up to five flow cells) and PromethION (up to 48 flow cells). In addition, three types 
of flow cells are available for use on these sequencing devices. The MinION and GridION 
devices use the FLO-MIN106D flow cell and the PromethION uses the FLO-PRO002 flow 
cell. The third flow cell is used with the Flongle which is an adaptor for the MinION or GridION 
and uses single-use FLO-FLG001 flow cells for small sequencing tests (Oxford Nanopore 
Technologies, Nanoporetech, 2020). Three different library preparation options can be 
utilised to ligate sequencing adaptors to the ends of DNA or RNA fragments. The two most 
commonly used library preparations known as the 1D and Rapid approaches, allow for the 
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template and complement strands to be individually sequenced whereas the 1D2 library 
preparation uses special adaptors to increase the probability that the complement strand will 
immediately follow the template strand to increase read accuracy (Oxford Nanopore 
Technologies, 2018). The single pass accuracy of these library preparation protocols is 95% 
and 98%, respectively and an overall average accuracy of 97% (Amarasinghe et al., 2020). 
ONT sequencing provides the longest read lengths of all sequencing technologies, with a 
current record length of 2 300 000 base pairs (Payne et al., 2019) and library inserts of 
10 000 to 30 000 base pairs are commonly generated. Insertions, deletions and 
substitutions are frequently observed in ONT nanopore sequencing data which is influenced 
by the biological nanopore present on the flow cell. Resolving low complexity stretches and 
homopolymer sequences is difficult as the current that is measured is a function of the 
particular k-mer that resides in the nanopore at the time, and because translocation of 
homopolymers does not change the sequence of the nucleotides within the pore, it results 
in a constant signal that makes determining homopolymer length difficult. This problem was 
mostly encountered with the R9 nanopores however, the latest R10 nanopores increase 
accuracy over homopolymer regions (Brown, 2019). Similar to PacBio®, ONT regularly 
release new chemistry and software updates that improve read quality.  
 
 
Figure 1.7: ONT library preparation and sequencing. (Adapted from sources: Oxford Nanopore Technologies: 
Amplicons by Ligation protocol, 2019 and Oxford Nanopore Technologies, 2017. [Online]: 
https://www.youtube.com/watch?v=GUb1TZvMWsw&feature=youtu.be). 
 
ONT’s nanopore sequencing offers several advantages over PacBio®’s SMRT sequencing, 
although the technology is still in active optimisation and has a higher reported sequencing 
error rate. All three sequencing devices offered by ONT are smaller than those developed 
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by PacBio® which offers portability. PacBio® platforms have relatively low operating costs 
when assessed on a per sample basis but the initial investment cost is much larger than for 
ONT devices. ONT offers a MinION starter kit at $1 000 which includes a MinION 
sequencing device, two flow cells and two preparation kits (Oxford Nanopore Technologies, 
Nanoporetech, 2020). Furthermore, ONT flow cells are reusable, provided sufficient active 
nanopores are available on the flow cell and multiplexing is possible which significantly 
lowers the cost per sample. ONT nanopore sequencing does not rely on sequence 
replication and therefore, is not limited by the longevity of an enzyme. The nanopores of the 
flow cell will proceed to read more DNA molecules until the life span of the nanopore is 
exhausted, current standard sequencing times are set to 72 hours. ONT has reported longer 
average read lengths than PacBio® which could facilitate the assemblies of longer 
genomes. Individual light signals are recorded in real-time with SMRT sequencing but data 
output can only be accessed if the run is stopped. In comparison, ONT’s data output occurs 
in real-time which allows for almost real-time data analysis within 2 minutes of run initiation 
and the sequencing run can be terminated by the user when sufficient sequence coverage 
is obtained or when the desired mutation is detected in real-time (Quainoo et al., 2017).  
 
A major gap in the field of HIV research presents itself, an efficient method to identify HIV 
integration sites of an intact proviral genome is currently not available. Third-generation 
sequencing may help overcome the current technical barriers and eliminate laborious and 
time-consuming methods that are currently utilised and may help facilitate the development 
of methods that are more efficient and allow for simultaneous investigation of these features 
of HIV. Long-lived HIV infected cells, which constitute HIV reservoirs are currently the most 
important barrier to achieving HIV cures. The field of HIV cure research aims to eliminate 
the latent reservoir, or prevent viral rebound from these reservoirs. The development and 
implementation of efficient methods to sequence full-length HIV proviruses and link these to 
integration sites, which uniquely define the cell clones that harbour these proviruses, would 
aid in the characterization of HIV reservoirs. This improved understanding of the nature of 
HIV reservoirs is pivotal for the advancement of the field of HIV cure research.  
 
In this study, an assay was designed to efficiently link and sequence integration sites of 
provisionally intact proviral sequences, previously identified by Illumina MiSeq sequencing, 
belonging to HIV-1 subtype C as many protocols have been designed and optimised for 
HIV-1 subtype B. The third-generation sequencing platform developed by ONT was utilised 
to sequence these samples and near-full-length HIV-1 amplicons to determine the efficiency 
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of this sequencing technology in comparison to the reference Illumina® MiSeq™ 
sequencing platform.  
 
1.8. Research question, Hypothesis, Aims and Objectives of the study  
This is a descriptive retrospective design study. 
 
1.8.1. Research questions 
This study aimed to address the following questions: 
1. Where do HIV proviruses preferentially integrate into the human genome?  




The study is further driven by two hypotheses based on the research questions posed 
above: 
1. HIV-1 integration sites can be recovered from pre-nested PCR products that yield 
intact or potentially intact proviruses. 
2. ONT sequencing will provide an efficient approach to sequence NFL HIV-1 
proviruses and their integration sites. 
 
1.8.3. Aim of the study 
To investigate the integration sites of proviral HIV-1 DNA in children with HIV early 
antiretroviral (CHER) and post-CHER cohort to determine preferential sites of integration in 
the human genome.  
 
1.8.4. Specific study objectives 
1. To establish and optimise an ISLA for HIV-1 subtype C. 
2. To use the optimised assay to detect integration sites in pre-nested PCR products 
of intact or likely intact proviruses in the CHER/post-CHER cohort. 
3. To sequence ISLA amplification products using Sanger sequencing to determine 
where the provirus integrates into the human genome. 
4. To establish and determine if ONT sequencing is an effective sequencing platform 
for the detection of proviruses. 




2 Materials and methods 
2.1. Ethical approval 
This study was granted initial ethical approval on 20 September 2017 through the Health 
Research Ethics Committee of Stellenbosch University, ethics reference number 
M14/07/029. Prior to the lapse of the above-mentioned ethical approval, a new application 
was submitted on 15 February 2018 and granted approval on 27 March 2018, ethics 
reference number N18/02/020. Informed consent was obtained before patients were 
included in the study.  
 
2.2. CHER and Post-CHER cohort background 
Participants meeting the following criteria were recruited as part of a clinical trial and formed 
the CHER cohort; infants aged <12 weeks with a confirmed HIV infection by a positive PCR 
test, plasma HIV RNA viral load of >1000 copies/ml and a CD4 percentage ≥25%. Infants 
with CD4% >25% were randomised into three study arms with different treatment strategies. 
The three study arms were defined as follows; 1) deferred ART, where infants were not 
immediately initiated on therapy, 2) immediate ART treatment with a subsequent interruption 
at 40 weeks post-ART initiation and 3) immediate ART treatment with a subsequent 
interruption at 96 weeks post-ART initiation. The trial was conducted in two locations in 
South Africa which included the HIV Research Unit at Chris Hani Baragwanath Hospital in 
Johannesburg and the Children’s Infectious Disease Clinical Research Unit at Tygerberg 
Hospital in Cape Town (Cotton et al., 2013, Violari et al., 2008). Following the conclusion of 
the initial trial, a subset of children were retained in a Post-CHER descriptive study to 
investigate neurocognitive outcomes and HIV-1 reservoirs.  
 
2.2.1. Criteria of the participants used in this study  
The inclusion criteria for participant selection will be briefly described and is detailed in 
Katusiime et al. 2020. Initially, eight participants enrolled in the Post-CHER follow up studies 
were selected based on having sufficient sample material available for investigation and to 
increase the likelihood of obtaining NFL amplicons, samples with HIV-cell associated DNA 
loads higher than 40 copies per million peripheral blood mononuclear cells (PBMCs) at the 
6 to 7-year sampling period were used. Overall, nine provisionally intact NFL amplicons 
belonging to four participants were initially identified by Illumina MiSeq and investigated in 
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this study. Seven of these NFL amplicons were later confirmed to be intact while the 
remaining two were identified as non-intact as their sequences contained deletions. All of 
the participants maintained undetectable viral loads within the most recent 36 months of the 
sampling time point that was utilised for NFL amplification. 
 
2.3. Methods 
2.3.1. Project rationale 
Intact HIV-1 NFL proviruses were previously identified in children belonging to the CHER 
and post-CHER cohorts (Katusiime et al., 2020), showing that these intact proviruses belong 
to CD4+ T cell clones require a technique to link intact proviruses to their respective 
integration sites. The large majority of integration sites represent that of defective proviruses, 
therefore it is more efficient to identify intact proviruses first and then attempt to recover their 
integration sites. A method to achieve this is currently unavailable. The aim of this project 
was to develop a technique that efficiently recovers integration sites of known intact HIV-1 
proviruses and to efficiently sequence NFL proviruses using the third-generation sequencing 
technology developed by Oxford Nanopore Technologies (ONT). 
 
2.3.2. General molecular methods 
2.3.2.1. Peripheral blood mononuclear cell isolation 
PBMCs were isolated from ethylenediaminetetraacetic acid (EDTA) whole blood samples 
which were collected from patients belonging to the CHER and post-CHER cohorts. The 
isolation protocol used was adapted from the University of Pittsburgh (Brown & Buffo, 2007) 
and uses density gradient centrifugation and Histopaque®-1077 (Sigma-Aldrich, Missouri, 
USA) to remove erythrocytes and retain the PBMC population which include, B cells, T cells, 
Natural Killer cells, monocytes and dendritic cells. Isolated PBMCs were stored in 
cryopreservation media consisting of 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, 
Missouri, USA) and 90% fetal bovine serum (FBS) (Thermo Scientific, Waltham, 
Massachusetts) determined by an average live count of the isolated PBMCs performed on 
Bio-Rad’s TC20TM Automated Cell Counter (Bio-rad, California, USA). The PBMC’s were 
stored in Mr Frosty™’s (Nalgene, New York, USA) at - 80°C for 24 hours and then moved 
into a rack in a liquid nitrogen (LN2) tank.  
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2.3.2.2. Nucleic acid extraction 
Viral nucleic acid was extracted from PBMCs using a method published by Hong et al. in 
2016. PBMCs stored in cryopreservation media were removed from the LN2 tank and 
allowed to equilibrate overnight at -80°C. Following the overnight step, the PBMCs were 
thawed in a bead bath at 37°C for 2 minutes. An equal volume of Roswell Park Memorial 
Institute (RPMI) Medium 1640 (BioWhittaker®, Lonza, Basel, Switzerland) heated to 37°C 
was added dropwise to thawed cryopreserved PBMCs. The PBMCs were pelleted by 
centrifugation at 500 RCF for 5 minutes and the supernatant was removed. One milliliter of 
Lysis buffer 1 consisting of 3 M guanidinium hydrochloride (GuHCl) (Sigma-Aldrich, 
Missouri, USA), 50 mM trisaminomethane hydrochloride (Tris-HCl) (Sigma-Aldrich, 
Missouri, USA) and 1 mM Calcium chloride (CaCl2) (Sigma-Aldrich, Missouri, USA) was 
prepared. Prior to use, 50 µl of proteinase K (ProK) (20 mg/ml) (Ambion®, Texas, USA) was 
added to Lysis buffer 1 and 100 µl was added to the cell pellet and sonicated for 10 seconds 
using the Omni Sonic Ruptor-400 Ultrasonic Homogenizer (Omni International, Georgia, 
USA) in a Branson Sonifier ultrasonic cell disrupter cup horn (Branson, Connecticut, USA) 
at an amplitude of 60% in pulse mode. Following sonication, the sample was incubated for 
1 hour at 42°C. A second buffer, Lysis buffer 2, consisting of 5.7 M guanidinium 
isothiocyanate (GuSCN) (Sigma-Aldrich, Missouri, USA), 50 mM Tris-HCl and 1 mM EDTA 
was prepared. Prior to use, 30 µl of glycogen (20 mg/ml) (Roche, Basel, Switzerland) was 
added to 1 ml of Lysis buffer 2 and 400 µl was added to the sample which was mixed and 
incubated for a further 10 minutes at 42°C. Five hundred microliters of room temperature 
100% isopropanol (Sigma-Aldrich, Missouri, USA) was added to the sample, vortexed and 
centrifuged at 21 000 RCF for 10 minutes to pellet the nucleic acids. The supernatant was 
removed and the pellet was washed with 750 µl of 70% ethanol (Sigma-Aldrich, Missouri, 
USA), vortexed and centrifuged at 21 000 RCF for 10 minutes. After centrifugation, the 
supernatant was removed and the pellet was air-dried until nearly transparent in 
appearance. Lastly, the pellet was gently resuspended by centrifugation in 70 µl of 5 mM 
(Tris-HCl). Isolated viral nucleic acids were stored at - 80°C.  
 
2.3.2.3. Single genome amplification 
Single genome amplification (SGA) is based on limiting dilution and a highly sensitive nested 
PCR amplification method. In short, DNA is diluted to an endpoint at which 30% of replicates 
are positive. At this concentration, according to the Poisson distribution, each positive PCR 
reaction most likely represents the amplification of a single genome. The PCR methods 
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mentioned in sections 2.3.2.3.1. and 2.3.2.3.2. are SGA approaches to ensure that 
downstream methods and results are only as a result of a single genome. Extracted viral 
DNA is therefore serially diluted with cold 5 mM Tris-HCl, each dilution was done in replicate 
and viewed as mentioned in section 2.3.2.3.3.1. to identify which dilution is the target that 
gives a 30% positive amplification result. Once identified, viral DNA is diluted at the target 
and amplification occurs in replicates of 84 in a 96 well PCR plate. Four of the remaining 
wells on the plate were used to include controls, 2 wells were used as non-template controls 
and 2 wells were used as positive controls. The non-template controls contained no DNA 
template and functioned to ensure that no contamination occurred during the reaction set-
up. The positive controls contained a DNA template that was known to contain the target 
and functioned to ensure that the primer set, reaction and thermocycling conditions were set 
up correctly. 
 
2.3.2.3.1. Near-full-length HIV-1 proviral amplification 
Extracted samples from patients meeting specific criteria mentioned in section 2.2.1 were 
subject to amplification using HIV near-full-length primer sets for the pre-nested and nested 
PCR reactions. Initial PCRs were conducted using published primer sets from Li et al. 
(2010). Pre-nested reactions used primer set Li_OuterF (5’-AAA TCT CTA GCA GTG GCG 
CCC GAA CAG-3’) and Li_OuterR (5’-TGA GGG ATC TCT AGT TAC CAG AGT C-3’)  and 
nested reactions used primer set Li_InnerF (5’-GCG GAG GCT AGA AGG AGA GAG ATG 
G-3’) and Li_InnerR (5’-GCA CTC AAG GCA AGC TTT ATT GAG GCT TA-3’). Amplification 
using these primer sets would produce an amplicon size of 8 700 base pairs (8.7kb). The 
nested primer set was later changed to include Li_OuterR and a newly designed primer 
published in Katusiime et al. (2020) NFL_alt_in_F (5’-CCG AAC AGG GAC BHG AAA GCG 
AA-3’) to amplify an important region of HIV that included the packaging signal, as this was 
recently shown to be essential for replication competence (Das et al., 2019). Positive 
amplification using these primers resulted in an amplicon size of 9 000 base pairs (9kb).  
 
The pre-nested PCR reaction was performed in a 0.2 ml 96 well PCR plate, to which 5 µl of 
2X RANGER Mix from Bioline’s RANGER Mix kit (Bioline, London, United Kingdom) were 
added. In addition to the aforementioned, 0.4 µl of both the forward and reverse primer at a 
concentration of 10 µM each and 2.2 µl of nuclease-free water were added. Two microliters 
of serially diluted or target diluted DNA template was added to the reaction mixture bringing 
the total reaction volume to 10 µl. Pre-nested amplicons are diluted with 83 µl of cold 
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Tris-HCl prior to the nested PCR reaction. Two microliters of the diluted pre-nested 
amplicons were added to their respective wells containing the nested PCR reagents. These 
reagents and their respective concentrations were used in the original and adapted NFL 
PCR approaches for both the pre-nested and nested reactions. 
 
The PCR programme that was utilised for the pre-nested reaction consisted of an initial 
denaturation step at 95ºC for 2 minutes followed by 30 cycles, each consisting of cycling 
through 98ºC for 10 seconds and 61ºC for 10 minutes, followed by a final elongation step at 
72ºC for 10 minutes. The original nested PCR programme used an initial denaturation step 
at 95°C for 2 minutes followed by 30 cycles, cycling through denaturation at 98°C for 10 
seconds and an annealing and extension step at 65.5°C for 10 minutes, this was followed 
by a final extension at 72°C for 10 minutes. The adapted NFL nested PCR programme used 
an annealing temperature of 61.5°C instead of 65.5°C, but the duration and temperature of 
the remaining steps remained the same. 
 
2.3.2.3.2. p6-PR-RT HIV-1 amplification 
The presence of viral HIV DNA in extracted samples was determined using a published 
qualitative nested PCR method that amplified the p6 in gag, protease and reverse 
transcriptase (p6-PR-RT) regions of the HIV genome as shown in Figure 2.1. The pre-nested 
reaction used primer set, 1849+ (5’-GAT GAC AGC ATG TCA GGG AG-3’) and 
3500- (5’- CTA TYA AGT CTT TTG ATG GGT CAT AA-3’) and the nested reaction used 
primer set, 1870+ (5’-GAG TGT TGG CTG AGG CAA TGA G-3’) and 3410- (5’-CAG TTA 
GTC GTA CTA TGT CTG TTA GTG CTT-3’) (van Zyl et al., 2017). Successful amplification 
with the above-mentioned primers yield a product of 1 200 base pairs (1.2kb) in size.  
 




Figure 2.1: HIV-1 HXB2 reference genome indicating the primer binding sites and area amplified by the 
p6-PR-RT PCR primer sets. (Source: Los Alamos National Laboratory, 2020). 
 
The PCR reaction was performed in a 0.2 ml 96 well PCR plate, to which reagents from 
Invitrogen’s™ Platinum™ Taq DNA Polymerase High Fidelity kit (Invitrogen, Carlsbad, 
California, USA) were added at the supplied concentrations. This included 1 µl of 10X High 
Fidelity PCR Buffer, 0.4 µl of 50 mM MgSO4 and 0.08 µl of 5 U/μl Platinum® Taq DNA 
Polymerase High Fidelity enzyme. In addition to the aforementioned, 0.2 µl of Invitrogen’s 
dNTP Mix supplied at a concentration of 10 mM of each dNTP was added. Each primer was 
added at a volume of 0.04 µl and a concentration of 50 µM respectively. Lastly, 6.24 µl of 
nuclease-free water and 2 µl of serially or target diluted DNA template was added to each 
well for the pre-nested PCR reactions. For nested PCR reactions, 2 µl of pre-nested 
amplicons diluted with 83 µl cold 5 mM Tris-HCl were transferred to a plate containing the 
nested primer set, maintaining their alphanumerical position on each plate. For both 
pre- nested and nested PCR reactions the reagent volumes and concentrations remained 
the same.  
 
The PCR programme that was utilised for the pre-nested PCR reaction consisted of an initial 
denaturation at 94°C for 2 minutes followed by 35 cycles, each consisting of cycling through 
94°C for 30 seconds, 50°C for 30 seconds (annealing step) and 72°C for 3 minutes 
(extension step) followed by a final extension step at 72°C for 3 minutes. The nested PCR 
programme consisted of an initial denaturation at 94°C for 2 minutes followed by 40 cycles 
of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute. A final extension of 3 









1.2kb amplified region 
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2.3.2.3.3. Viewing of single genome amplified products 
To determine whether successful amplification has occurred, two different viewing 
approaches were utilised. The first approach is called a plate view (2.3.2.3.3.1.) and the 
second approach is the standard gel electrophoresis method (2.3.2.3.3.2.).  
 
2.3.2.3.3.1. Plate view of amplicons 
Once the nested PCRs were completed the amplified products were diluted with cold 5 mM 
Tris-HCl, the NFL nested PCR was diluted 1:4 and the p6-PR-RT nested PCR was diluted 
1:5. Five microliters of the diluted nested PCR product was transferred to a new 96 well 
plate.  
 
EZ Vision™ DNA Dye (VWR Life Science, Pennsylvania, USA) was diluted 1:10 000 with 
5 mM Tris-HCl in a reagent reservoir and 15 µl of this was added to each well of the plate 
containing 5 µl of diluted nested PCR product. The presence of amplified products that 
complexed with the dye were visualised under ultraviolet light and photographed using the 
UVIprochemi II D-77LS-26M instrument (Uvitec, Cambridge, United Kingdom). The wells 
that contain amplified products that have complexed with the EZ Vision™ DNA Dye 
fluoresce, however this method does not confirm that the product represents the DNA 
sequence of interest. 
 
2.3.2.3.3.2. Gel electrophoresis of amplicons 
Wells that fluoresced with the plate view method described in the section above 
(2.3.2.3.3.1.) were subject to separation by gel electrophoresis to determine if the amplicon 
of interest was present. Ten microliters of amplified product was mixed with 1 µl of EZ 
Vision™ DNA Dye and was loaded into the well of a 1% agarose gel. Five microliters of 
Promega’s 1kb DNA Ladder (Promega, California, USA) was loaded into the first and last 
well of each gel to serve as a reference for determining amplicon size. Gel electrophoresis 
was performed with the ENDURO™ Gel XL Electrophoresis System (Labnet, New Jersey, 
USA) by applying a voltage of 90V for 1 hour and 30 minutes using 1X SB buffer. The results 
of gel electrophoresis were visualised by exposure to ultraviolet light and photographed 
using the UVIprochemi II D-77LS-26M instrument.  
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2.3.3. Integration site loop amplification assay  
2.3.3.1. Rationale 
A technique to efficiently detect the integration sites linked to intact proviruses is not 
currently available. Intact proviruses are very rare, therefore, first identifying them and then 
attempting to obtain the linked integration site from linearly amplified products produced 
during a first round (pre-nested) PCR reaction (sections 2.3.2.3.1. and 2.3.2.3.2.) would 
provide the most efficient method of linking integration sites and intact proviruses.  
 
2.3.3.2. HIV-1 subtype C integration site loop amplification assay 
The ISLA protocol published by Wagner et al. in 2014 provided a method that could amplify 
across integration sites from linear amplification products and allow for the detection of HIV 
integration sites. The published method was optimised for the detection of HIV-1 subtype B 
integration sites however, as HIV-1 subtype C is the most prevalent subtype in Africa, the 
protocol was modified to target this subtype. 
 
The ISLA assay was initially attempted using the pre-nested products from a NFL amplified 
patient sample that potentially contained an intact proviral HIV-1 sequence, identified by a 
PhD student in the research group at the time. However, due to the rarity of intact proviral 
HIV sequences and the limited number of patient PBMCs remaining for specific time points, 
the DNA amplified to generate the starting template for ISLA was changed. To further 
develop and optimise the ISLA assay, nucleic acid was extracted as mentioned in section 
2.3.2.2. from the human lymphoblastic leukaemia cell clone 8E5/LAV (8E5) which contains 
a single integrated HIV-1 provirus and results in the production of defective virions (Folks 
et al., 1986, Quillent et al., 1993). The cells were originally stored at a concentration of 
1.25 million cells per millilitre. Prior to use the concentration of the extracted DNA was 
measured using a DS-11 FX Series Spectrophotometer/Fluorometer (Denovix, Delaware, 
USA) and was initially diluted 1:100 with 5 mM Tris-HCl to start with 125 copies of HIV-1. A 
2- or 3-fold serial dilution of the initial 125 copies of HIV-1 DNA was performed for the 
screening plates where the 8E5 template was diluted in HIV negative DNA or 5 mM Tris-HCl. 
At each dilution, each of 12 replicates were tested with a nested PCR reaction to determine 
the presence of an HIV genome. The final target dilution was chosen to achieve a 30% 
positivity rate, which according to the Poisson’s distribution, would most likely represent a 
single genome in each replicate. A negative control and a non-template control were 
included on the plates where the provisionally intact HIV-1 patient sample and the 8E5 
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diluted in HIV negative DNA were amplified. The negative control contained DNA from HIV 
uninfected PBMCs as a template whereas the non-template control contained nuclease-free 
water. Further ISLA optimisations were conducted on 8E5 diluted in 5 mM Tris-HCl to target. 
 
Step 1: Linearly amplified products from a pre-nested PCR reaction served as a template 
for ISLA subtype C 
A PCR is typically used to exponentially amplify a specific segment of DNA or a gene 
however, PCR is also capable of generating linear-amplified templates in the background 
as shown in Figure 2.2. 
 
 
Figure 2.2: Overview of the production of linear amplified products during PCR. 
 
Products from NFL PCR (section 2.3.2.3.1.) pre-nested reactions that underwent linear 
amplification served as a template for the initial attempts of ISLA as depicted in Figure 2.3. 
 
Step 2: Random priming with nanomers tailed with a U5-specific primer sequence  
A reverse primer site was created in this step by hybridising random nanomers tailed with a 
U5-specific sequence with an aliquot of the linear amplified single-stranded template. This 
step played an integral part in allowing for the formation of a loop containing the site of 
integration and the adjacent human genomic sequence which is described in Step 4 of ISLA. 
The reaction consisted of adding 5 µl of 2X RANGER Mix, 4 µl of 10 µM random nanomer 
and 2 µl of nuclease-free water to a 0.2 ml PCR tube. Lastly, 9 µl of undiluted pre-nested 
product was added to the reaction. 
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The reaction was incubated at 68°C for 2 minutes, cooled to 65°C for 1 minute followed by 
gradual cooling 1°C per minute until reaching 25°C. The reactions were then reheated to 
60°C and gradually cooled by 1°C per minute until reaching 20°C. The reaction was stored 
at -20°C if Step 3 was not continued immediately. 
 
Step 3: Single-stranded fragments were digested by Exo I and filled with Taq DNA 
polymerase 
Exonuclease I (Exo I) (New England Biolabs, Massachusetts, USA) digested 
single-stranded DNA present on the 3’ end of the random primer binding site (indicated with 
 in Figure 2.3). Ten units of Exo I was directly added to the reaction from Step 2.  
 
The reaction was incubated at 37°C for 45 minutes, the temperature was then increased by 
1°C every 3 minutes until reaching 43°C to ensure complete digestion by Exo I and to 
denature template that partially annealed to the U5 region of the primer. An incubation at 
72°C for 15 minutes followed to allow Taq polymerase present in RANGER Mix to extend 
the region complementary to the U5-specific primer sequence indicated with  in 
Figure 2.3 and this was followed by a final incubation at 95°C for 5 minutes to inactivate 
Exo I. 
 
Step 4: Formation and extension of the loop containing the integration site and the adjacent 
human genome sequence 
This step is divided into 3 sub-steps to simplify the process of loop formation and comprises 
Steps 4a, 4b and 4c depicted in Figure 2.3, respectively. Step 4a, the previous steps allowed 
for the 3’ end to be processed in such a way that the generated reverse complement 
sequence (indicated with  in Step 4a in Figure 2.3) could bind to its complementary 
site in U5 and form the loop. Step 4b, the addition of Taq polymerase present in RANGER 
Mix would result in the extension from the U5 priming site through the end of the fragment 
thereby creating a loop that contains the human genomic sequence with a HIV LTR that is 
duplicated on each end once the loop has formed. Primer RF2 binds and initiates 
exponential amplification as shown in Step 4c. This reaction was carried out in a 0.2 ml PCR 
tube to which the following reagents were added; 3 µl of 10 µM primer RF2, 25 µl of 2X 
RANGER Mix, 2 µl of nuclease-free water and 20 µl of the product formed in Step 3.  
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The thermocycling parameters of this step of ISLA included an initial denaturation at 95°C 
for 2 minutes followed by an initial 10 cycles cycling through, 94°C for 20 seconds, 60°C for 
30 seconds and 72°C for 2 minutes; followed by 40 cycles cycling through, 92°C for 10 
seconds, 65°C for 15 seconds and 72°C for 2 minutes and a final extension at 72°C for 5 
minutes.  
 
Step 5: Nesting of the first round PCR products 
The first round PCR products were exponentially amplified by a second round of PCR 
amplification. Three microliters of 10 µM primer RF1, 25 µl of 2X RANGER Mix and 17 µl of 
nuclease-free water were added to a 0.2 ml PCR tube. Lastly, 5 µl of product from Step 4 
was added to the reaction. 
 
The thermocycling parameters for this step consisted of an initial denaturation at 95°C for 2 
minutes followed by 34 cycles cycling through, 94°C for 20 seconds, 65°C for 30 seconds 
and 72°C for 2 minutes with a final extension at 72°C for 5 minutes. 
 
Step 6: Visualisation and Sanger sequencing of ISLA amplified products  
ISLA amplified products measuring approximately ≥300 base pairs in length were identified 
through separation by gel electrophoresis. Sufficient stretches of HIV and the human 
genomic sequence contained in the loop were necessary to allow for the identification and 
linkage of the intact proviral sequence and the respective integration site. Products with an 
estimated base pair length of less than 300 would not allow for this identification as 
approximately 180 base pairs of the amplified product is designated to the duplicated LTR 
regions on both ends (approximately 90 base pairs each) and the remaining base pairs do 
not allow for a sufficient stretch of human genome to accurately determine the site of 
integration. ISLA products meeting the criteria of ≥300 base pairs were purified and 
sequenced by Sanger sequencing.  
 




Figure 2.3: Subtype C ISLA approach outline adapted from the Wagner et al. (2014) supplementary materials. 
 indicate strands being generated in the current step.  indicate strands that have been 
generated in the previous step.  
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The protocol was further adapted to include independent amplification from either the 3’LTR 
or the 5’LTR end of the HIV genome and is explained in sections 2.3.3.2.2 and 2.3.3.2.3. 
HIV-1 subtype C specific primers were designed for these separate approaches. 
 
2.3.3.2.1. Generating linear-amplified products for ISLA 
Initial attempts at ISLA used linearly amplified NFL PCR products from pre-nested reactions 
(section 2.3.2.3.1.). Both the 3’LTR and 5’LTR ISLA approaches used these products as a 
template.  
 
The NFL PCR primers overlapped with the primers used in ISLA and the approach to 
generating the starting template was adapted and changed, as shown in Figure 2.4, to the 
p6-PR-RT approach as no overlapping was present between the p6-PR-RT and ISLA 
primers. 
 
2.3.3.2.2. ISLA assay from the 3’ LTR end of HIV-1 
The 3’LTR approach was attempted first as the NFL PCR enriched for the 3’ end of the 
HIV-1 genome. 
 
Table 2.1: Primers used in the 3’LTR ISLA approach and the respective steps 
Primers 3’LTR amplification 
ISLA step Primer Name Primer Sequence (5’-3’) 
2 3’LTR-RP GTG CCC GTC TGT TGT GTG ACT CTG GTN NNN NNN NN 
4 3’LTR-RF2 AGA TCT GAG CCT GGG AGC TCT C  
5 3’LTR-RF1 TTA AGC CTC AAT AAA GCT TGC CTT  
 
2.3.3.2.3. ISLA assay from the 5’ LTR end of HIV-1 
This approach was attempted after unsuccessful amplification resulted from the 3’ LTR ISLA 
approach. 




Table 2.2: Primers used in the 5’LTR ISLA approach and the respective steps 
Primers 5’ LTR amplification 
ISLA step Primer Name Primer Sequence (5’-3’) 
2 5’LTR-RP CCT GTG TGT GAT AGA CCC ACA AAT CNN NNN NNN N  
4 5’LTR-RF2 CAA GGC AAG CTT TAT TGA GGC TTA A 
5 5’LTR-RF1 GAG AGC TCC CAG GCT CAG ATC T  
 
2.3.3.2.4. Determining optimal annealing temperatures for Step 4 and Step 5 of ISLA 
The majority of the unique products produced by the initial ISLA attempts were <300 base 
pairs in length. The annealing temperatures of the primers utilised in Steps 4 and 5 of ISLA 
were investigated as optimal annealing temperatures are required to avoid primer 
misbinding and also aid in yielding products of the required size to successfully identify 
integration sites. Therefore, two annealing temperatures were simultaneously investigated 
to ensure that the products being amplified were treated under the same conditions prior to 
PCR amplification. Lower annealing temperatures were selected based on the melting 
temperatures (Tm) of the primers.  
 
The initial annealing temperatures of 60°C (10 cycles) and 65°C (40 cycles) were compared 
to the lowered annealing temperatures of 57°C (10 cycles) and 61°C (40 cycles) for Step 4 
of ISLA. Step 5 of ISLA included comparing the initial annealing temperature of 65°C to a 
lowered annealing temperature of 53°C.  
 
2.3.3.2.5. Increasing the input concentration of linear-amplified products for ISLA 
A further adaption to the Wagner et al. (2014) method was the inclusion of a multiple 
displacement amplification (MDA) (shown in Figure 2.4) approach prior to Step 2 of ISLA, 
based on personal communication with Dr Lisa Frenkel, who co-developed ISLA. This 
approach was added as the concentration of the input template was thought to be low as 
first round PCR products were used and the target, linear-amplified product was likely 
present at very low concentrations in comparison to exponentially amplified products. The 
MDA approach, which uses an isothermal enzyme, was used to amplify single-stranded 
fragments thereby increasing the concentration of the linear-amplified products.  
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Qiagen’s REPLI-g® Mini Kit (Qiagen, Hilden, Germany) was used for the MDA step. The 
following reagents from Qiagen’s REPLI-g® Mini Kit were added to a 0.2 ml PCR tube at 
the supplied concentrations; 14.5 µl of Reaction Buffer and 0.5 µl of REPLI-g Mini DNA 
Polymerase. For one MDA reaction, 5.5 µl of nuclease-free water and 4.5 µl of undiluted 
pre-nested PCR product was added to the reaction.  
 
The MDA reaction mixture was incubated at 30°C for 16 hours with the thermocycler’s lid 
temperature at 70°C followed by an enzyme inactivation step at 65°C for 3 minutes. The 
concentrations of these MDA amplified products were measured using NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific, Waltham, Massachusetts) to prevent adding a very 
high concentration of template to Step 2 of ISLA. The concentration of the input templates 
needed to be at a concentration of ≤260 ng/µl. MDA produces hyperbranched structures 
which needed to be denatured prior to use in Step 2 of ISLA. The branched products were 
incubated at 98°C for 5 minutes and snap cooled for 1 minute on ice to prevent 
single-stranded products from rebinding and forming branched structures again.  
 
 
Figure 2.4: Diagram showing the change in the starting template for ISLA subtype C.  
 
2.3.3.2.6. Investigating optimal random primer concentration 
In an attempt to optimise Step 2 of ISLA, a range of primer concentrations were investigated. 
The following concentrations of the random nanomer primer were investigated; 2 µM, 
1.5 µM, 1 µM and 0.75 µM. The incubation temperatures and durations for Step 2 remained 
the same for all primer concentrations investigated.  
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2.3.3.2.7. Comparison of different DNA polymerase enzymes 
The protocol published by Wagner and colleagues used the MyTaq™ DNA polymerase 
enzyme (Bioline, London, UK) for the ISLA subtype B assay. The efficacy of RANGER Mix 
was compared to MyTaq™ Mix (Bioline, London, UK) which contained the MyTaq™ DNA 
polymerase enzyme in a ready-to-use mixture. MyTaq™ Mix replaced RANGER Mix in all 
ISLA steps and the incubation and PCR amplification steps remained the same as described 
in section 2.3.3.2.  
 
2.3.3.2.8. Investigating the published subtype B ISLA assay 
The published subtype B ISLA assay was investigated in our laboratory setting to determine 
its success in comparison to the modified subtype C ISLA assay. The subtype B ISLA assay 
was performed on 8E5 using the primers and methods described in the article published by 
Wagner et al. (2014). 
 
Step 1 of the subtype B ISLA assay utilised a linear amplification step using two forward 
primers namely, ENV-WF (5’-CCC CGG CTG GTT TTG CGA TTC TAA AGT GTA-3’) and 
NEF-WF (5’-CCA ATG CTG ATT GTG CCT GGC TAG AAG CA-3’). 
 
The reaction consisted of adding 1.5 µl of each forward primer at 10 µM concentrations, 5 U 
of NotI, 25 µl of RANGER Mix and 19.5 µl of nuclease-free water to a 0.2 ml PCR tube. 
Lastly, 2 µl of 8E5 template diluted to target (1:27) with Tris-HCl was added bringing the final 
reaction volume to 50 µl. 
 
The cycling parameters used during Step 1 of the subtype B ISLA were as follows, 37ºC for 
30 minutes, 95ºC for 2 minutes, followed by 30 cycles cycling through 94°C for 20 seconds, 
60ºC for 30 seconds and 72ºC for 3 minutes. 
 
Steps 2 to 5 used the primers described in Table 2.1. Furthermore, the incubation and 
thermocycling conditions for each step described in section 2.3.3.2. were used. An additional 
primer was included in this approach as described in the Wagner et al. (2014) method which 
served as a third round PCR amplification. Primer WF-1.U5 (5’-TCA AGT AGT GTG TGC 
CCG TCT GT-3’) was used in this step and the thermocycling parameters were the same 
as described for Step 5 of ISLA (section 2.3.3.2.). 
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2.3.3.3. Visualisation of ISLA assay products 
All the wells that were amplified by the ISLA assay were initially visualised for the presence 
of positive amplification by using the plate viewing method as described in section 
2.3.2.3.3.1. The sizes of the amplified products were visualised by separation through gel 
electrophoresis. The gel electrophoresis conditions were the same as described in section 
2.3.2.3.3.2. 
 
2.3.3.4. Purification of amplified products 
Products successfully amplified with ISLA were purified for sequencing and cloning. Due to 
the presence of non-specific amplified products, products meeting the size requirement of 
≥300 base pairs were identified by gel electrophoresis and wells containing products of the 
correct size were separated for a second time through gel electrophoresis on a 0.8% 
agarose gel, excised with a scalpel, placed into a 1.5 ml Eppendorf tube and subject to 
purification using Macherey-Nagel’s NucleoTraP®CR kit for gel extraction following the 
manufacturer’s instructions. The concentration and purity of the purified products were 
measured with the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.3.5. Sanger sequencing of ISLA assay products 
Purified products were prepared for sequencing with reagents from the BigDye™ Terminator 
v1.1 Cycle Sequencing Kit (Applied Biosystems™, California, USA). Prior to the sequencing 
reaction, the concentrations of the purified products were measured with the NanoDrop™ 
1000 Spectrophotometer and diluted to have a DNA concentration measuring between 
15 - 25 ng/µl. Reagents from Applied Biosystems’™ BigDye™ Terminator v1.1 Cycle 
Sequencing Kit were added to a 0.2 ml PCR tube; 1 µl of BigDye® Terminator v1.1 Ready 
Reaction Mix and 3 µl of 5X Sequencing Buffer at the supplied concentrations. The 
sequencing reaction for products generated by ISLA subtype C contained 1 µl of 5 µM 3’LTR 
Junction_seq (5’- TCTGGTAACTAGAGATCCCTCA -3’) for the 3’LTR ISLA approach or 
Junction_seq (5’- CTT TTC TTR GAG TAA ATT AAC C -3’) for the 5’LTR ISLA approach 
and the products generated by ISLA subtype B contained 1 µl of 5 µM WF-2.U5 (5’- GTT 
GTG TGA CTC TGG TAA CTA GAG AT-3’). Four microlitres of nuclease-free water and 
lastly 1 µl of purified product diluted to 20 ng/µl in nuclease-free water were added to the 
tube to bring the final volume of the reaction to 10 µl. 
 
Stellenbosch University  https://scholar.sun.ac.za
41 
 
The thermocycling parameters that were used were as follows; 96°C for 0.10 seconds, 50°C 
for 0.05 seconds and 60°C for 4 minutes cycling through 25 cycles.  
 
Plates containing these reactions were sent to the Central Analytical Facilities (CAF) at 
Stellenbosch University for sequencing clean-up and DNA sequencing. 
 
2.3.3.6. Ligation of ISLA products in kit plasmid vectors 
The purified ISLA products were ligated using the InsTAclone™ PCR Cloning Kit (Thermo 
Scientific, Massachusetts, USA) or the CloneJET™ PCR Cloning Kit (Thermo Scientific™, 
Massachusetts, USA) into the respective kit plasmid vectors. The InsTAclone™ PCR 
Cloning Kit was initially used for the ligation of ISLA products, the kit was discontinued while 
the project was ongoing and the CloneJET™ PCR Cloning Kit was used as the replacement.  
 
2.3.3.6.1. Preparations of media and reagents prior to cloning 
2.3.3.6.1.1. Luria broth 
Sigma-Aldrich’s Miller Luria broth (LB) powder medium (Sigma-Aldrich, Missouri, USA) was 
used to prepare LB culture medium for the growth of the transformed E. coli. The 
manufacturer’s instructions were followed to prepare the culture medium and 25 g of LB 
powder was added to 1 litre of distilled water and mixed. The mixture was autoclaved for 15 
minutes at 121°C to sterilise the medium. The medium was allowed to cool to room 
temperature and 100 µg/ml of ampicillin was added and thoroughly mixed. The prepared LB 
culture medium was stored at 4°C. 
 
2.3.3.6.1.2. LB agar plates 
Sigma-Aldrich’s Lennox LB broth powder medium with agar (Sigma-Aldrich, Missouri, USA) 
was used to prepare petri dishes containing LB agar. The manufacturer’s instructions were 
followed and 35 g of LB medium powder was added to 1 litre of distilled water. The total 
volume of LB agar medium to be made was adjusted by the number of LB agar petri dishes 
required for the spread plating (Figure 2.5) step of the cloning procedure. The medium was 
sterilised by following the standard autoclaving parameters of 15 minutes at 121°C. 
Ampicillin was added once the medium reached 55°C at a final concentration of 50 µg/ml in 
the InsTAclone™ PCR Cloning procedure and 100 µg/ml in the CloneJET™ PCR Cloning 
procedure and was gently mixed by swirling to avoid the introduction of bubbles. 
Approximately 25 ml of medium was poured into the required number of petri dishes and 
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Figure 2.5: Diagram showing the spread plating method. Bacterial cells are added onto the surface of a 
solidified LB agar plate, a sterile plastic hook known as a hockey stick is used to evenly spread bacterial cells 
across the surface. The plate is inverted and incubated at 37°C to allow for the growth of bacterial cells. 




An ampicillin stock solution (50 mg/ml) was prepared by dissolving 2.5 g ampicillin sodium 
salt (Tocris Bioscience, Bristol, UK) in 50 ml of deionized water. The solution was filter 
sterilized with a 0.22 μm syringe filter and stored in 1 ml aliquots at -20°C. 
 
2.3.3.6.2. InsTAclone™ PCR Cloning Kit 
Cloning Principle 
This kit uses a TA cloning technique for direct cloning of products with 3’-dA overhangs that 
have been generated by the terminal transferase activity of Taq DNA polymerase during 
PCR amplification. The manufacturer’s instructions were followed to ligate ISLA products 
into pTZ57R/T, a linearized cloning vector with a single 3’-ddT overhang at each end. The 
3’-ddT overhangs at the ends of the vector promote cloning and prevent recircularisation of 
the vector during ligation, therefore 90% of recombinant clones contain the vector with an 
insert and have low background. Recombinant clones are selected using a process known 
as blue/white colony selection. 
 
In brief blue/white colony selection works by manipulating the lacZ gene which is naturally 
found in bacterial cells. The lacZ gene encodes for β-galactosidase, an enzyme responsible 
for breaking lactose down into glucose and galactose. This enzymatic action is induced in 
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the presence of lactose but can also be induced by a lactose analogue known as isopropyl 
β-D-1-thiogalactopyranoside (IPTG) which is used in molecular cloning. In this molecular 
cloning technique, IPTG is used together with a dye-linked substrate, 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside, known as X-gal which results in the production of galactose 
and an insoluble blue pigment. The multiple cloning site (MCS) as shown in Figure 2.6, is 
contained within a partially deleted lacZ gene in pTZ57R/T which produces non-functional 
β-galactosidase. When pTZ57R/T is transformed into a bacterial cell with the lacZΔM15 
mutation that encodes for the deleted section of the lacZ gene, the process known as alpha 
complementation occurs and functional β-galactosidase is produced. Successful ligation of 
the DNA fragment of interest into the pTZ57R/T MCS results in the interruption of the lacZ 
gene and the production of non-functional β-galactosidase which yields white-creamy 
coloured bacterial colonies. Unsuccessful ligation of the fragment into pTZ57R/T results in 
the production of blue coloured bacterial colonies as a result of functional β-galactosidase 
enzymatic activity in the presence of X-gal. 
 
Figure 2.6: Map of the pTZ57R/T cloning vector from the InsTAclone™ PCR Cloning Kit. The MCS is shown 
in orange on the vector map. (Source: Thermo Scientific InsTAclone™ PCR Cloning Kit Manual, 2016). 
 
Two control experiments were done in parallel. The positive control experiment used the 
Control PCR Fragment (0.52 pmol ends) provided in the kit. Nuclease-free water was used 
in the negative control experiment. The purpose of including the positive control was to 
ensure that the cloning procedure was optimal and the negative control was included to 
ensure that kit reagents were not contaminated. 
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2.3.3.6.2.1. Ligation of ISLA products into pTZ57R/T 
The volume of PCR product added into the ligation reaction was calculated based on the 
information provided in the manufacturer’s product information sheet, which stipulated that 
0.17 ng per base pair be added into a reaction. The equation that was used to calculate the 
PCR product volume was 
0.17 × size of fragment to be ligated
ng/µl
. According to the manufacturer’s 
instructions, the optimal ratio of insert to vector is 3:1. The following reagents from Thermo 
Scientific’s InsTAclone™ PCR Cloning Kit were added into a 1.5 ml tube for the ligation 
reaction; 3 µl of vector pTZ57R/T (0.17 pmol ends), 6 µl of 5X Ligation Buffer and 1 µl of T4 
DNA Ligase. The volume of ISLA product added was calculated using the equation above 
and 4 µl of the Control PCR Fragment (0.52 pmol ends) was added to the positive control 
reaction. Nuclease-free water was added to each reaction to bring the final volume to 30 µl. 
The ligation mixtures were incubated at room temperature for 1 hour. 
 
2.3.3.6.2.2. Bacterial transformation of the recombinant pTZ57R/T  
Invitrogen’s One Shot™ TOP10 Chemically Competent E. coli (Invitrogen, California, USA) 
was in the bacterial transformation step. A tube containing 50 µl of the chemically competent 
E. coli was thawed on ice and 2.5 µl of the ligation mixture containing the ISLA product was 
added into the tube and gently mixed by flicking. For the positive control, 1 µl of the ligation 
mixture was added to 50 µl of chemically competent bacterial cells and gently mixed by 
flicking. The tubes were incubated on ice for 30 minutes followed by a heat shocking step 
for 30 seconds at 42°C to allow for the uptake of the plasmid vector into the bacterial cell. 
The tubes were immediately placed on ice following the heat shocking step for 2 minutes. 
Super Optimal broth with Catabolite repression (S.O.C.) Medium (Sigma-Aldrich, Missouri, 
USA) was prewarmed to 37°C and 250 µl was aseptically added to each tube containing the 
transformed E. coli. The tubes were incubated at 37°C in the Labcon Shaking Incubator 
3081U (Labcon, California, USA) for 1 hour at 225 RPM. LB agar plates were removed from 
4°C storage and 50 µg/ml of X-Gal ready-to-use Solution, 20 mM of IPTG ready-to-use 
Solution and 100 µg/ml of ampicillin were added to room temperature plates and spread 
across the surface using the spread plating technique. Three different volumes of the 
transformed bacterial solutions were selected for the spread plating step; 50 µl, 100 µl and 
150 µl were used for each transformation. Each volume was spread across the surface of 
an LB agar plate that was prewarmed to 37°C for 30 minutes and was left to dry for between 
20 to 30 minutes. The plates were inverted and incubated at 37°C overnight for a maximum 
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of 16 hours to avoid overgrowth and the formation of satellite colonies which are small 
colonies that do not contain the plasmid vector. 
 
2.3.3.6.2.3. Colony Screening  
The incubated plates were viewed for the presence of colonies. Blue and white-creamy 
coloured colonies were observed on the surface of the LB agar plates inoculated with the 
ISLA recombinant clones. The blue/white colony selection principle was explained in section 
2.3.3.6.2. where blue colonies indicate that the colony does not contain the ISLA fragment 
and white-creamy colonies suggest that ligation was successful and these colonies were 
chosen for further analysis. A lawn of only blue colonies were present on the LB agar plates 
inoculated with bacteria transformed with the negative control. The LB agar plate inoculated 
with the positive control contained mostly white-creamy coloured colonies present on the 
surface apart from a few blue colonies that occurred as a result of unsuccessful ligation with 
the Control PCR Fragment.  
 
2.3.3.6.2.4. Bacterial culture of the picked colony in LB broth 
The chosen white-creamy colonies were carefully picked from the surface of the LB agar 
with a P10 pipette tip without piercing the agar. The P10 pipette tip used to pick the colony 
was carefully transferred into a 15 ml Falcon™ Round-Bottom Polypropylene Tube 
containing 5 ml of LB broth prewarmed to 37°C. These tubes were incubated at 37°C at a 
60° angle in the Labcon Shaking Incubator rotating at 225 RPM for 12 to 16 hours. 
 
2.3.3.6.2.5. Plasmid DNA purification of the overnight bacterial culture with the 
GeneJET Plasmid Miniprep Kit 
The bacteria from the overnight culture were harvested by centrifugation at 4000 RPM for 5 
minutes at room temperature. The bacterial cells formed a pellet at the base of the tube and 
the supernatant was discarded. Reagents from Thermo Scientific’s GeneJET Plasmid 
Miniprep Kit (Thermo Scientific, Massachusetts, USA) were used to isolate the plasmid DNA 
from the bacterial cells. The cell pellet was resuspended in 250 µl of the Resuspension 
Solution and mixed by vortexing. The bacterial cells were lysed by adding 250 µl of the Lysis 
Solution and mixed by inverting the tube six times, after which 350 µl of the Neutralisation 
Solution was added and was mixed by inversion. The tube was centrifuged at maximum 
speed for 5 minutes. The supernatant was transferred into a Thermo Scientific GeneJET 
Spin Column, provided in the GeneJET Plasmid Miniprep Kit and centrifuged for 1 minute 
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at maximum speed to bind the DNA to the column filter. The bound DNA was washed by 
adding 500 µl of the Wash Solution, centrifuged for 1 minute and the flow-through was 
discarded. This step was repeated for a second wash. The empty column was centrifuged 
for 1 minute at maximum speed to remove any remaining Wash Solution. The filter column 
containing the bound plasmid DNA was transferred into a new 1.5 ml tube and 50 µl of 
Elution Buffer prewarmed to 70°C was added to the column and incubated for 2 minutes at 
room temperature. The tube was centrifuged for 2 minutes at maximum speed to collect the 
purified plasmid DNA and was visualised by separation through gel electrophoresis and the 
vector plasmids containing the fragment of interest, based on the base pair length of the 
fragment, were used for Sanger sequencing (2.3.3.6.4).  
 
2.3.3.6.3. CloneJET™ PCR Cloning Kit  
Cloning principle  
A blunt-end cloning technique is used to ligate PCR products into the pJET1.2/blunt cloning 
vector provided in the CloneJET™ PCR Cloning Kit. The linearized cloning vector, 
pJET1.2/blunt shown in Figure 2.7, contains a lethal gene that is disrupted when a product 
is inserted into the cloning site which means that only cells with recombinant plasmids 
(vector containing a ligated insert) are able to propagate. Recircularised pJET1.2/blunt 
vector molecules that do not contain an insert will express a lethal restriction enzyme which 
will kill the host E. coli after transformation has occurred. This is a form of positive selection 
which accelerates the process of colony screening and eliminates additional costs required 
for blue/white colony selection. Phosphorylated (sticky-end) or non-phosphorylated (blunt-
end) products can be ligated into pJET1.2/blunt. Products with overhangs will be processed 
with the sticky-end cloning protocol which removes phosphorylated ends and produces 
blunt-ended products prior to the ligation reaction. Recombinant clones are produced 99% 
of the time with this kit and all available E. coli strains can be directly transformed with the 
ligation product. The protocol described in the manufacturer’s protocol was followed with 
some adjustments. 
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Figure 2.7: Map of the pJET1.2/blunt vector from the CloneJET™ PCR Cloning Kit. (Source: Thermo Scientific 
CloneJET™ PCR Cloning Kit Manual, 2019). 
 
A control experiment was done in parallel following the manufacturer’s instructions using the 
Control PCR Product (24 ng/µl) provided in the kit. 
 
2.3.3.6.3.1. Ligation of ISLA products into pJET1.2/blunt  
RANGER mix uses a Taq polymerase enzyme which generates products with 3’-dA 
overhangs, the sticky-end protocol was therefore followed with the purified ISLA PCR 
products. The overhangs were removed prior to ligation into pJET1.2/blunt in a reaction 
known as the blunting reaction. This reaction used 10 µl of 2X Reaction Buffer and 1 µl of 
DNA Blunting Enzyme from Thermo Scientific’s CloneJET™ PCR Cloning Kit. Lastly, 7.5 µl 
of PCR product was added. For the positive control reaction, 2 µl of Control PCR Product 
(24 ng/µl) was added and 5 µl of nuclease-free water. The reactions were incubated at 70°C 
for 5 minutes and briefly chilled on ice. 
 
The ISLA product was inserted into the vector in a reaction known as the ligation reaction 
and comprised of 0.5 µl of the pJET1.2/blunt Cloning Vector (50 ng/µl) and 1 µl of T4 DNA 
Ligase which was directly added to the blunting reaction. One microlitre of pJET1.2/blunt 
Cloning Vector and 1 µl of T4 DNA Ligase were added to the positive control reaction and 
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2.3.3.6.3.2. Bacterial transformation of the recombinant pJET1.2/blunt  
Invitrogen’s One Shot™ TOP10 Chemically Competent E. coli was thawed on ice. Four 
microliters of the ligation reaction was combined with approximately 16 µl of the thawed 
chemically competent E. coli and incubated on ice for 30 minutes. Following the incubation, 
the E. coli cells were heat-shocked for 30 seconds at 42°C to allow for the uptake of the 
recombinant plasmid vector and immediately cooled on ice for 2 minutes. S.O.C. Medium 
was prewarmed to 37°C, 400 µl was added to the bacterial cells and incubated for 1 hour at 
250 RPM in the Labcon Shaking Incubator at 37°C. After the 1-hour incubation, 100 µl of 
the transformed E. coli was spread across the surface of a LB agar plate prewarmed to 37°C 
using the spread plating technique. The remaining transformed E. coli was centrifuged at 
3000 RPM for 3 minutes, 200 µl of supernatant was removed and the cell pellet was gently 
resuspended by pipetting and spread across a second prewarmed LB agar plate. The plates 
were left to dry for 20 to 30 minutes, inverted and incubated overnight for a maximum of 16 
hours at 37°C. 
 
2.3.3.6.3.3. Colony screening  
The LB agar plates were viewed for the presence of white-creamy colonies following the 
overnight incubation. As the vector in this kit contains a lethal gene, all colonies present on 
the LB agar plate contain an insert.  
 
2.3.3.6.3.4. Colony PCR with a high-fidelity enzyme  
Single colonies present on the LB agar plates were carefully picked using a P10 pipette tip 
without piercing the agar. The P10 tip with a single colony was swirled in a 0.2 ml PCR tube 
containing the following PCR reagents for a confirmatory colony PCR; 10 µl of 2X RANGER 
Mix, 9.2 µl of nuclease-free water, 0.4 µl of pJET1.2 Forward Sequencing Primer (5’- CGA 
CTC ACT ATA GGG AGA GCG GC -3’) and 0.4 µl of pJET1.2 Reverse Sequencing Primer 
(5’- AAG AAC ATC GAT TTT CCA TGG CAG -3’) each at 10 µM.  
 
The cycling parameters for the PCR step included an initial denaturation at 95°C for 
3 minutes, 25 cycles cycling through 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 
1 minute. 
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2.3.3.6.3.5. Visualisation of the colony PCR products 
The results of the colony PCR products were visualised through separation by gel 
electrophoresis and exposure to ultraviolet light as described in section 2.3.2.3.3.2 to 
determine whether ISLA products successfully ligated into pJET1.2/blunt. The base pair 
length of the ISLA fragment inserted into the vector is known and therefore, the expected 
size of the fragment present on the gel can be pre-calculated. Based on the information 
shown in Figure 2.8, the expected fragment size can be calculated by adding 118 base pairs 
to the inserted ISLA fragment length. The colony PCR products meeting this criterion were 
directly sequenced by Sanger sequencing. 
 
 
Figure 2.8: DNA sequence preceding the MCS of pJET1.2/blunt and indicating the binding sites of the 
sequencing primers. The red arrows indicate how the 118 base pair length that is added to determine the 
expected size of a successfully ligated fragment is calculated. (Adapted from Source: Fermentas. [Online]: 
http://www.bioinfo.pte.hu/f2/pict_f2/pJETmap.pdf). 
 
2.3.3.6.4. Sanger sequencing of the purified products from InsTAclone™ and 
CloneJET™ PCR Cloning Kits 
The GeneJET purified products and the colony PCR products from the respective cloning 
kits were diluted to 20 ng/µl in nuclease-free water and prepared for sequencing with 
reagents from the BigDye™ Terminator v1.1 Cycle Sequencing Kit. The reagent volumes 
used for the preparation of the sequencing reaction was the same as described in 2.3.3.5.  
 
The purified products cloned with the InsTAclone™ PCR Cloning Kit were sequenced using 
1 µl of 5 µM M13/pUC Forward (5’- CCC AGT CAC GAC GTT GTA AAA CG -3’) and 1 µl of 
5 µM M13/pUC Reverse (5’- AGC GGA TAA CAA TTT CAC ACA GG -3’) in two separate 
sequencing reactions. The thermocycling conditions used were as follows; 96°C for 
0.10 seconds, 50°C for 0.05 seconds and 60°C for 4 minutes cycling through 25 cycles.  
 
The selected colony PCR products generated through cloning with the CloneJET™ PCR 
Cloning Kit were sequenced using 1 µl of the pJET sequencing primers, pJET1.2 Forward 
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Sequencing Primer and pJET1.2 Reverse Sequencing Primer, at a concentration of 3.2 µM 
and in two separate sequencing reactions. The thermocycling parameters that were used 
included 25 cycles cycling through 96°C for 0.10 seconds, 60°C for 0.05 seconds and 60°C 
for 4 minutes. 
 
Plates containing these reactions were sent to CAF at Stellenbosch University for 
sequencing clean-up and DNA sequencing. 
 
2.3.3.6.5. Analysis of Sanger sequencing  
NCBI’s Nucleotide BLAST® (blastn) algorithm and program was used to align the raw 
Sanger sequences generated by direct sequencing (2.3.3.5.) or cloning followed by 
sequencing (2.3.3.6.4), to the nucleotide sequences present in the GenBank database 
(NCBI Resource Coordinators, 2016). The Sanger sequencing results were further aligned 
to the South African subtype C reference sequence Ref.C.ZA.04.04ZASK146.AY772699 
(HIV Consensus C sequence) and/or the HXB2 HIV subtype B reference genome 
(GenBank: K03455.1) to analyse, generate consensus sequences and identify the sites of 
integration and the adjacent human genomic sequence using Geneious R11.1 (Biomatters 
Ltd, Auckland, New Zealand).  
 
2.3.4. Oxford Nanopore Technologies– GridION sequencing 
2.3.4.1. Rationale  
The GridION sequencing device from ONT was investigated due to the several advantages 
this technology has to offer. The real-time sequencing technology was used to determine 
whether integration sites and provisionally intact NFL HIV-1 proviral sequences were 
recoverable and comparable to other sequencing platforms. The overall methodological 
approach is shown in Figure 2.9. Two different ONT protocols were investigated for these 
purposes. ONT’s Premium whole genome amplification protocol was utilised in an attempt 
to identify HIV-1 integration sites from MDA amplified single genome NFL or p6-PR-RT pre-
nested products and ONT’s Amplicons by Ligation protocol was used to sequence 
provisionally intact NFL HIV-1 proviruses. 
 




Figure 2.9: Overview of the methods used for ONT sequencing to recover HIV-1 integration sites and 
provisionally intact NFL HIV-1 proviruses. 
 
2.3.4.2. Steps used in both ONT sequencing protocols 
Step 1: Determining the number of nanopores on the flow cell sensor array available for 
sequencing 
As part of ONT’s quality control (QC), a minimum number of active nanopores are required 
to ensure successful sequencing which is determined by the type of flow cell that is used. 
ONT’s FLO-MIN106D flow cells, depicted in Figure 2.10, were used for all sequencing 
experiments conducted on the GridION sequencing device. A flow cell was inserted into one 
of the five ports available on the device and the number of active nanopores was determined 
prior to sequencing initiation. The operating software that ONT uses to drive their 
sequencing devices, MinKNOW, was used to perform the Platform QC/flow cell check test 
to determine the number of available nanopores. The minimum number of active nanopores 
was limited to ≥800 of the 2048 nanopores present on the sensor array. 
 




Figure 2.10: The components of the FLO-MIN106D flow cell used for sequencing with ONT’s GridION. (Source: 
Oxford Nanopore Technologies, 2020. [Online]: https://www.youtube.com/watch?v=zC6lAtzqi_k). 
 
Step 2: Repairing and preparing the ends of DNA for sequencing adaptor attachment 
The ends of the DNA fragments were repaired to increase the library yield to generate more 
data and a higher percentage of coverage. The ends of the DNA fragments were repaired 
with the NEBNext® FFPE DNA Repair Mix (New England Biolabs, Massachusetts, USA) 
that contains enzymes that repair the deamination of cytosine to uracil, nicks and gaps, 
oxidised bases and the blocked 3’ends of DNA. The ends of the DNA were prepared for the 
attachment of the sequencing adaptors with the NEBNext® Ultra™ II End Repair/dA-tailing 
Module (New England Biolabs, Massachusetts, USA) which processes the 3’ and 5’ ends of 
DNA to contain 3’ dA-tailed ends and 5’ phosphorylated ends. 
 
The reparation and preparation of the ends of the DNA was carried out in a 0.2 ml PCR tube. 
The concentration of DNA added was dependent on the ONT sequencing protocol that was 
followed. The input concentrations were 1.5 µg of MDA amplified DNA for the Premium 
whole genome amplification protocol and 1 µg of nested NFL amplicons for the Amplicons 
by Ligation protocol. For both protocols, the DNA was diluted to a total volume of 48 µl in 
nuclease-free water. Reagents from the two NEB kits were added to the 0.2 ml PCR tube in 
the following order; 3.5 µl of NEBNext® FFPE DNA Repair Buffer, 2 µl of NEBNext® FFPE 
DNA Repair Mix, 3.5 µl of NEBNext® Ultra™ II End Repair Reaction Buffer and lastly 3 µl 
of NEBNext® Ultra™ II End Repair Enzyme Mix. The reaction was gently mixed by flicking 
and incubated in a thermocycler for 5 minutes at 20°C to repair and prepare the ends of the 
DNA and 5 minutes at 65°C to inactivate the enzymes. 




Step 3: Attaching the sequencing adaptors to the ends of the prepared DNA fragments 
ONT’s 1D sequencing adaptors contain a leader sequence and a motor protein. The leader 
sequence assists the DNA in locating and binding to the nanopores on the sensor array 
which facilitates in initiating sequencing. The motor protein assists in unwinding the 
double-stranded DNA fragment and slows the rate at which the single-stranded DNA is 
sequenced by the nanopore. 
 
The end-repaired and prepared DNA from Step 2 was either used directly (Premium whole 
genome amplification) or purified (Amplicons by Ligation) prior to use in this step depending 
on the ONT protocol that was followed. Sixty microliters of the product directly from Step 2 
or the purified end prepared product (2.3.4.4.2.) was added into a 1.5 ml Eppendorf® LoBind 
DNA tube. In addition to this, 25 µl of Ligation Buffer (LNB) and 5 µl Adaptor Mix (AMX) from 
ONT’s Ligation Sequencing Kit (SQK-LSK109) were added followed by 10 µl of Quick T4 
DNA Ligase from NEB’s NEBNext® Quick Ligation Module (New England Biolabs, 
Massachusetts, USA). The tube was incubated at room temperature for 10 minutes to attach 
the 1D sequencing adaptors to the ends of the DNA fragment. 
 
Step 4: Priming the flow cell for sequencing 
All ONT flow cells are shipped with a storage buffer that covers the sensor array and protects 
the nanopores. The storage buffer is replaced with a priming solution prior to sequencing. 
The priming solution is comprised of a tether and a buffer. The tether plays an essential role 
in concentrating the DNA at the surface of the membrane and streamlines the sequencing 
while the buffer is a mixture of running buffer and nuclease-free water which provides 
optimal conditions and the fuel required for successful sequencing. 
 
The priming port cover is opened and 20 – 30 µl of the storage buffer is carefully aspirated 
using a P1000 pipette from the port to remove the air bubble and ensure that bubbles are 
not introduced into the sensor array in later steps which will damage and inactivate the 
nanopores. The priming solution was prepared by adding 30 µl of Flush Tether (FLT) directly 
to a tube of Flush Buffer (FB) from ONT’s Flow Cell Priming Kit (EXP-FLP002). The priming 
solution was mixed by pipetting and 800 µl was slowly added into the priming port without 
introducing bubbles thereby displacing the storage buffer from the sensor array into the 
waste channel. After adding the priming solution, the flow cell is incubated for 5 minutes at 
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room temperature followed by slowly adding a further 200 µl of the priming solution into the 
priming port after opening the SpotON port cover and avoiding the introduction of bubbles. 
 
Step 5: Preparing the library for loading into the SpotON port of the flow cell  
The prepared DNA library (DNA with adaptors attached) is combined with loading beads 
that function to bring the DNA closer to the pores at the start of sequencing and also result 
in high-yield and high-speed sequencing.  
 
The DNA library was purified prior to sequencing and 12 µl was added into an Eppendorf® 
LoBind DNA tube. The Loading beads (LB) from ONT’s Ligation Sequencing Kit were 
vortexed to form a homogenous mixture and 25.5 µl was added to the purified DNA library. 
Lastly, 37.5 µl of Sequencing Buffer (SQB) from ONT’s Ligation Sequencing Kit was added 
into the tube. The mixture was gently mixed before it was added into the SpotON port on 
the flow cell. After priming the flow cell (Step 4), 75 µl of the prepared library was loaded 
into the SpotON port in a dropwise fashion ensuring that each drop successfully flowed into 
the port before closing the SpotON port cover. 
 
Step 6: Initiating the sequencing run with ONT’s MinKNOW software 
The MinKNOW software is also responsible for controlling the sequencing device and 
includes the ability to select the running parameters, sample identification and tracking and 
also ensuring that the platform chemistry is optimal for successful sequencing. Furthermore, 
MinKNOW ensures the following core functions are carried out; data acquisition, real-time 
analysis and feedback, local basecalling and data streaming (Oxford Nanopore 
Technologies, Nanoporetech, 2020). The running parameters are selected by the operator 
and allow for the type of sequencing to be selected which is determined by the sequencing 
kit used to prepare the sample, the preferred method for basecalling, the duration of the 
sequencing run and the preferred output of the sequencing data in FAST5 and/or FASTQ 
files. 
 
The sequencing runs were initiated after Steps 1 to 5 were completed and the flow cell 
stabilised at 34°C. The selected samples were sequenced under the following run 
parameters; LSK-SQK109 Kit for DNA sequencing, fast-basecalling method and both 
FAST5 and FASTQ files were selected as outputs for the sequencing data. The duration of 
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the run was left as standard and the run was stopped when sufficient coverage was 
obtained. 
 
2.3.4.3. ONT’s Premium whole genome amplification protocol 
ONT’s Premium whole genome amplification protocol was utilised in an attempt to recover 
the 8E5 HIV-1 integration site from NFL or p6-PR-RT pre-nested single genome products 
that were MDA amplified. An overview of the Premium whole genome amplification protocol 
is highlighted in Figure 2.11. 
 
 
Figure 2.11: Flow diagram showing the steps involved in ONT’s Premium whole genome amplification protocol 
(version: WAL_ 9070_v109_revK_14Aug2019). (Adapted from source: Oxford Nanopore Technologies’ 
Premium whole genome amplification protocol, 2019). 
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2.3.4.3.1. Purification of MDA amplified PCR products prior to ONT sequencing 
Successful sequencing with ONT is dependent on good DNA yield and high purity. The 
products, therefore, need to be free of impurities created by excessive amounts of salts from 
buffers, unincorporated dNTPs, primers, primer dimers and other contaminants, as these 
may result in the blockage of the nanopores leading to unsuccessful sequencing. Several 
methods were investigated to determine the best method of purification. 
 
2.3.4.3.1.1. AMPure XP paramagnetic bead purification of PCR products 
ONT recommends purifying products for sequencing with Agencourt AMPure XP PCR 
Purification beads (referred to as AMPure XP beads in the following sections) (Beckman 
Coulter Life Sciences, California, USA) which uses a buffer to bind DNA fragments to 
paramagnetic beads, removes contaminants and results in the best recovery of the fragment 
of interest. 
 
The manufacturer's instructions were followed and 50 µl of the MDA amplified sample was 
transferred into a 1.5 ml Eppendorf® LoBind DNA tube (Sigma-Aldrich, Missouri, USA). The 
AMPure XP beads were equilibrated to room temperature. The beads were vortexed to form 
a homogenous mixture before being added to the sample. The ratio of sample to beads that 
was used was 1:1.8, therefore 90 µl of resuspended AMPure XP beads were added to the 
sample. The mixture was gently mixed by pipetting and incubated at room temperature in 
the Labnet Vortemp 56 shaking incubator (Labnet International Incorporated, New Jersey, 
USA) for 5 minutes at 90 RPM. The sample was briefly centrifuged and placed onto the 
DynaMag™-2 Magnet’s magnetic rack (Invitrogen, California, USA) to pellet the beads. The 
supernatant was removed and the sample was washed with 500 µl of freshly prepared 70% 
ethanol without disturbing the pellet. The ethanol was carefully removed and the ethanol 
wash step was repeated. The tube was briefly centrifuged after removing the supernatant 
from the second wash step. The tube was placed onto the magnetic rack to remove any 
residual supernatant and the lid of the tube was opened to dry the pellet for 1 minute. The 
tube was removed from the magnetic rack and the pellet was resuspended in 50 µl of 5 mM 
Tris-HCl. The resuspended mixture was incubated at room temperature for 2 minutes. The 
beads were pelleted after placing the tube onto the magnetic rack and the eluate containing 
the purified nucleic acid was transferred into a new 1.5 ml Eppendorf® LoBind DNA tube. 
The purity and concentration of the DNA was measured using the NanoDrop™ 1000 
Spectrophotometer. 




2.3.4.3.1.2. Ethanol precipitation 
Ethanol precipitation is a method that is commonly used to purify and/or concentrate DNA 
present in aqueous solutions by adding ethanol as an antisolvent. The basic principle is that 
molecular grade ethanol and a salt, usually sodium acetate, are added to the aqueous 
solution with ethanol being more soluble, displacing nucleic acid salt, which precipitates out 
of the solution. The nucleic acid salt separation is accelerated by centrifugation, with the 
precipitant forming a pellet on the outer side of the tube. The pellet is usually washed with 
cold 70% ethanol to dissolve residual salt, however, the concentration of the ethanol used 
is dependent on the precipitation method. The ethanol is removed without disturbing the 
pellet and the pellet is dried before being resuspended in an aqueous buffer such as 
nuclease-free water, 5 mM Tris-HCl or 1x TE buffer (pH 8.0) as nucleic acids are soluble in 
these solutions. 
 
2.3.4.3.1.2.1. Qiagen’s purification of MDA amplified products 
The MDA amplified products were purified using Qiagen’s Purification of DNA amplified 
using REPLI-g® Kits (version RG21 Nov-12). The manufacturer’s instructions were followed 
and 50 µl of MDA amplified product was equilibrated to room temperature and transferred 
into a 1.5 ml tube. Following this, 150 µl of 96 – 100% molecular grade ethanol was added 
to the tube and gently mixed by flicking. The mixture was centrifuged at maximum speed for 
2 minutes to pellet the DNA. The supernatant was carefully removed without disturbing the 
pellet and 100 µl of freshly prepared 80% ethanol was carefully added without resuspending 
the pellet. The mixture was centrifuged at maximum speed for 2 minutes. The supernatant 
was discarded and the tube was briefly centrifuged to collect and remove any residual 
supernatant at the bottom of the tube. The precipitated nucleic acid was incubated at room 
temperature for 5 minutes to evaporate any remaining ethanol. The precipitated nucleic acid 
was resuspended in 50 µl of 1x TE buffer (pH 8.0) and was measured with a Qubit® 2.0 
Fluorometer (Invitrogen, California, USA) and the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.3.1.2.2. MRC Holland ethanol precipitation 
The ethanol precipitation protocol published by MRC Holland was also investigated. Fifty 
microliters of MDA amplified product, 5 µl of 3 M sodium acetate (pH 5.2) and 150 µl of 
≥95% molecular grade ethanol was added to a 1.5 ml tube and mixed by pipetting. The 
reaction mixture was incubated on ice for 15 minutes. Following the incubation, the reaction 
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mixture was centrifuged at maximum speed for 30 minutes at room temperature and the 
supernatant was carefully removed without disturbing the pellet. The pellet was washed with 
1 ml of freshly prepared 70% ethanol and centrifuged at maximum speed for 15 minutes. 
The supernatant was discarded and the pellet was briefly centrifuged to remove any residual 
supernatant. The pellet was air-dried with an opened lid until the area around the pellet 
changed colour and the pellet was resuspended in 50 µl of 5 mM Tris-HCl. The concentration 
of the purified DNA was measured with the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.3.1.2.3. In-house ethanol precipitation protocol  
The purification protocol was carried out in a 1.5 ml tube to which 50 µl of MDA amplified 
product, 5 µl of 125 mM EDTA, 5 µl 3 M sodium acetate (pH 5.2) and 125 µl 100% molecular 
grade ethanol was added. The reaction mixture was vortexed and incubated at room 
temperature for 15 minutes. The tube was centrifuged for 20 minutes at maximum speed. 
The supernatant was discarded without disturbing the pellet and 500 µl of freshly prepared 
70% molecular grade ethanol was added without resuspending the pellet. The reaction was 
centrifuged for 10 minutes at maximum speed and the supernatant was carefully removed. 
The pellet was dried for 5 minutes or until no ethanol was visible in the tube. The pellet was 
resuspended in 50 µl of 5 mM Tris-HCl and the purified DNA was measured with a Qubit® 
2.0 Fluorometer and the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.3.2. Removing the hyperbranched structures produced by MDA amplification 
The purified MDA amplified products were treated with the T7 Endonuclease I enzyme (New 
England Biolabs, Massachusetts, USA) to resolve the hyperbranched structures generated 
by MDA amplification to allow for a higher average ONT Q score to be obtained when 
sequencing. Sequencing hyperbranched structures results in a rapid blockage of nanopores 
and therefore a decline in sequencing yield and the average Q score. 
 
According to ONT’s protocol, 1.5µg of purified MDA amplified DNA was added to a 0.2 ml 
PCR tube together with 3 µl of NEBuffer 2, 1.5 µl T7 Endonuclease I and lastly nuclease-free 
water to bring the final reaction volume to 30 µl. The reaction was incubated for 15 minutes 
at 37°C in a thermocycler.  
 
A large decrease in the concentration of the product was observed following the T7 
Endonuclease I digestion. This problem was also encountered by other ONT users and this 
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step was optimised by increasing the input concentration of the purified MDA amplified DNA 
to 3.5 µg as recommended on ONT’s community dashboard. The remaining reagents were 
added in the volumes mentioned above and the nuclease-free water volume was adjusted 
to bring the final reaction volume to 30 µl. The reaction was incubated at 37°C for 10 minutes 
and 80°C for 5 minutes to inactivate the enzyme.  
 
2.3.4.3.3. Purification of the T7 Endonuclease I digested products using AMPure XP 
beads  
The T7 Endonuclease I digested products were purified prior to Step 2 to remove the 
remaining buffer and T7 Endonuclease I enzyme. Several purification methods were 
investigated to determine which would give the best purity and DNA yield as a large 
decrease in the concentration of the MDA amplified product was seen following the T7 
Endonuclease I digestion. 
 
2.3.4.3.3.1. AMPure XP bead purification using a custom buffer system 
The Premium whole genome amplification protocol from ONT recommended that T7 
Endonuclease I digested products be purified with AMPure XP beads that have been 
resuspended in a custom buffer. The original AMPure XP bead buffer was therefore 
replaced with a custom buffer. The custom buffer comprised of 10 mM Tris-HCl, 1 mM EDTA 
(pH 8.0), 1.6 M NaCl, 10 mM PEG 8000 and 444 µl of nuclease-free water in a final volume 
of 996 µl. To replace the original buffer with the custom buffer, the AMPure XP beads were 
resuspended to form a homogenous mixture and 1 ml was transferred into a 1.5 ml 
Eppendorf® LoBind DNA tube. The beads were pelleted by placing the tube onto the 
magnetic rack and the original buffer was removed. The beads were resuspended and 
washed in 1 ml of nuclease-free water. The tube was returned to the magnetic rack and the 
supernatant was removed after the beads formed a pellet. The nuclease-free water wash 
step was repeated to remove any remaining original buffer. After removing the nuclease-free 
water from the second wash step, the tube was briefly centrifuged and placed onto the 
magnetic rack to remove any residual supernatant. The pellet was first resuspended in 
200 µl of the custom buffer and then transferred into the tube containing the remaining 
custom buffer. 
 
The 30 µl reaction mixture from the T7 Endonuclease I step was added to 20 µl of 1X TE 
buffer (pH 8.0) in a 1.5 ml Eppendorf® LoBind DNA tube. The custom AMPure XP bead 
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suspension was vortexed to form a homogenous mixture and 35 µl was added to the sample. 
The reaction was mixed by flicking and incubated on the HulaMixer (Thermo Fisher 
Scientific, Massachusetts, USA) for 20 minutes at room temperature to mix the reaction. The 
tube was briefly centrifuged and placed onto the magnetic rack to pellet the beads. The 
supernatant was removed and the pellet was washed with 200 µl of freshly prepared 80% 
ethanol without disturbing the pellet. The supernatant was discarded and the ethanol wash 
step was repeated. After removing the supernatant from the second wash, the tube was 
briefly centrifuged and placed back onto the magnetic rack to remove any residual 
supernatant. The pellet was dried for 30 seconds with an opened lid and the pellet was then 
resuspended in 49 µl of nuclease-free water. The resuspended mixture was incubated for 
1 minute at 50°C in the Labnet AccuBlock™ Digital Dry Bath and was followed by a 5-minute 
incubation at room temperature. The tube was placed onto the magnetic rack to pellet the 
beads and the eluate was transferred into a new 1.5 ml Eppendorf® LoBind DNA tube. The 
quantity and quality of the purified nucleic acid was measured with the NanoDrop™ 1000 
Spectrophotometer. 
 
2.3.4.3.3.2. AMPure XP bead purification  
The purification of T7 Endonuclease I digested products was attempted using the AMPure 
XP bead protocol described in section 2.3.4.3.1.1. 
 
The AMPure XP bead purification method was also attempted on a MDA amplified NFL 
pre-nested HIV-1 positive patient sample with a sample to bead ratio of 1:0.8. The 
purification results of the patient sample and both MDA amplified NFL and p6-PR-RT 
pre-nested products were compared in terms of purity and were also visualised by plate 
viewing (section 2.3.2.3.3.1.) and gel electrophoresis (section 2.3.2.3.3.2.). 
 
2.3.4.3.3.3. MRC Holland ethanol precipitation  
The MRC Holland ethanol precipitation method was identified as the best purification 
method for purifying MDA amplified products prior to sequencing (section 2.3.4.3.1.) and 
was therefore also investigated for the purification of T7 Endonuclease I digested products. 
The method described in section 2.3.4.3.1.2.2. was followed. An additional optimisation step 
to the method was investigated in this section where two different incubation conditions were 
simultaneously investigated to determine which would result in the best purity and DNA 
yield. Therefore, one reaction mixture was incubated on ice for 15 minutes as described 
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previously and a second reaction mixture was incubated at -20°C overnight. Following the 
two independent incubation steps, the reaction mixtures were processed as mentioned in 
section 2.3.4.3.1.2.2. After the pellets were resuspended in 50 µl of 5 mM Tris-HCl, the 
concentration of the purified DNA was measured and compared using the NanoDrop™ 1000 
Spectrophotometer. 
 
2.3.4.3.3.4. NucleoTraP®CR silica bead-based purification 
The NucleoTraP®CR Kit from Macherey-Nagel was investigated as a method for purifying 
the T7 Endonuclease I digested products. The manufacturer’s instructions for the direct 
purification of PCR products was followed. The reaction was carried out in a 2 ml tube to 
which 4 volumes of Buffer NT2 was added to 1 volume of MDA amplified sample. The 
NucleoTraP®CR Suspension, which contains activated silica beads, was vortexed to form 
a homogenous mixture and 10 µl was added to each 100 µl of reaction mixture. The mixture 
was incubated at room temperature for 10 minutes and vortexed every 2 minutes during the 
incubation step to bind the DNA to the silica beads. The reaction mixture was centrifuged 
for 30 seconds at 10 000 RCF to pellet the silica beads and the supernatant was discarded. 
The pellet was washed with 400 µl of Buffer NT2 and the mixture was briefly vortexed to 
resuspend the pellet. The tube was centrifuged at 10 000 RCF for 30 seconds and the 
supernatant was removed. The next wash step was carried out by adding 400 µl of the 
ethanolic Buffer NT3 and resuspending the pellet by vortexing. The tube was centrifuged for 
30 seconds at 10 000 RCF and the supernatant was discarded. A wash with Buffer NT3 was 
repeated and after removing the supernatant, the pellet was centrifuged for a second time 
to remove any residual Buffer NT3. The pellet was dried at 37°C for 15 minutes using the 
Labnet AccuBlock™ Digital Dry Bath (Labnet International Incorporated, New Jersey, USA). 
The pellet was resuspended in 50 µl of 5 mM Tris-HCl. The mixture was incubated at room 
temperature for 15 minutes and vortexed every 2 minutes during the incubation step. The 
sample was centrifuged for 30 seconds at 10 000 RCF to pellet the silica beads and the 
purified DNA was transferred into a new 1.5 ml tube. The quality and quantity of the purified 
DNA was measured with the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.3.3.5. NucleoSpin® column-based purification 
Macherey-Nagel’s NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel, Düren, 
Germany) was also investigated and the manufacturer’s instructions were followed to purify 
the T7 Endonuclease I digested products. The total volume of the sample to be purified was 
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determined and 1 volume of sample was mixed with 2 volumes of Buffer NTI from the 
NucleoSpin® Kit. A maximum of 700 µl of the sample and Buffer NTI mixture was added 
into a NucleoSpin® Gel and PCR Clean-up Column in a 2 ml collection tube. The column 
and collection tube was centrifuged for 30 seconds at 11 000 RCF to bind the DNA to the 
silica membrane in the column and the flow-through was discarded. This step was repeated 
if any sample and Buffer NTI mixture remained. The bound DNA was washed by adding 
700 µl of Buffer NT3 to the column. The tube was centrifuged for 30 seconds at 11 000 RCF 
and the flow-through was discarded. The wash step with Buffer NT3 was repeated and the 
tube was centrifuged for 30 seconds at 11 000 RCF. The silica membrane was dried by a 
centrifugation step at 11 000 RCF for 1 minute to ensure that any remaining Buffer NT3 was 
removed. The column was placed into a new 1.5 ml tube. Buffer NE was prewarmed to 70°C 
and 20 µl was added directly to the silica membrane to elute the bound DNA. The column 
was incubated at room temperature for 1 minute and this was followed by a 1-minute 
centrifugation at 11 000 RCF to collect the eluate. The purified DNA was measured by the 
NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.3.4. Purification of the DNA library using AMPure XP beads 
The purification of the DNA library from the Premium whole genome amplification protocol 
was followed with an adjustment to the ratio of AMPure XP beads added and the incubation 
instrument. The ONT protocol used a sample to AMPure XP bead ratio of 1:0.4, however, 
this ratio was changed to 1:0.8 to ensure that the product of interest was present in the 
eluate. The 100 µl reaction mixture from the adaptor ligation step was transferred into a 
1.5 ml Eppendorf® LoBind DNA tube and 80 µl of resuspended AMPure XP beads were 
added. The reaction was mixed by flicking and the tube was placed into the Labnet Vortemp 
56 shaking incubator rotating at 90 RPM for 5 minutes at room temperature. The beads were 
pelleted by placing the tube onto the magnetic rack and the supernatant was removed. The 
pellet was resuspended and washed in 250 µl of the Short Fragment Buffer (SFB) from 
ONT’s Ligation Sequencing Kit and returned to the magnetic rack. The supernatant was 
removed after a pellet formed and the SFB wash was repeated. After the second wash and 
removal of the supernatant, the tube was briefly centrifuged to remove any residual 
supernatant. The pellet was dried for 30 seconds and resuspended in 15 µl of Elution Buffer 
(EB) from ONT’s Ligation Sequencing Kit. The reaction mixture was incubated at 37°C in 
the Labnet AccuBlock™ Digital Dry Bath for 10 minutes. The tube was placed onto the 
magnetic rack to pellet the beads and the eluate was removed and placed into a new 1.5 ml 
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Eppendorf® LoBind DNA tube. The concentration of the DNA library was measured with the 
Qubit® 2.0 Fluorometer.  
 
2.3.4.4. ONT’s Amplicons by Ligation protocol 
Provisionally intact NFL HIV-1 proviral sequences were previously identified through the 
Illumina® MiSeq™ sequencing platform. ONT’s GridION performance characteristics in 
terms of sequencing yield and read accuracy were compared to the Illumina® MiSeq™ using 
amplicons generated from the same single genome amplified pre-nested product. The 
original NFL nested product was depleted for Illumina® sequencing and the pre-nested NFL 
products were used to regenerate nested NFL amplicons. The Amplicons by Ligation 
protocol from ONT as indicated in Figure 2.12 was used to sequence the provisionally intact 
nested NFL amplicons on the GridION.  
 
 
Figure 2.12: Flow diagram of the steps in ONT’s Amplicons by Ligation protocol (version: ACDE_9064 
_v109_revN_14Aug2019) (Adapted from source: Oxford Nanopore Technologies’ Amplicons by Ligation, 
2019). 
 
Stellenbosch University  https://scholar.sun.ac.za
64 
 
2.3.4.4.1. Purification of provisionally intact NFL HIV-1 amplified PCR products prior 
to ONT sequencing 
The nested NFL amplicons were purified using AMPure XP beads prior to ONT sequencing. 
Thirty microliters of the nested NFL product was added to a 1.5 ml Eppendorf® LoBind DNA 
tube. The purification steps were the same as described in section 2.3.4.3.1.1. with a few 
adjustments which will be highlighted in this section. A sample to beads ratio of 1:0.8 was 
used and the initial incubation conditions remained the same. After placing the tube 
containing the beads and the sample mixture onto the magnetic rack, the pellet was washed 
with 250 µl of freshly prepared 80% ethanol in both wash steps. The ethanol was removed 
after being in contact with the pellet for 30 seconds. The ethanol wash was repeated and 
after removing the ethanol from the second wash, the pellet was left to dry until the surface 
of pellet changed from glossy to matte in appearance and no ethanol was visible around the 
pellet. The pellet was resuspended in 50 µl of 5 mM Tris-HCl and the tube was incubated in 
the Labnet Vortemp 56 for 5 minutes at 37°C rotating at 90 RPM to increase the recovery 
and yield of the nucleic acid. The beads were pelleted on the magnetic rack and the eluate 
was placed into a new tube. The concentration and purity of the purified amplicon was 
measured with the NanoDrop™ 1000 Spectrophotometer. 
 
2.3.4.4.2. Purification of the end-repaired and prepared DNA using AMPure XP beads 
The DNA from ONT’s DNA repair and end preparation step was purified with AMPure XP 
beads following the instructions in the Amplicons by Ligation protocol. The purification steps 
explained in section 2.3.4.3.1.1. was followed with a few adjustments aimed at increasing 
the recovery and purity of the prepared DNA. In brief, a 1:1 ratio of sample to AMPure XP 
beads was used. The initial incubation remained the same and both wash steps used 200 µl 
of freshly prepared 80% ethanol to wash the pellet. The ethanol was removed after being in 
contact with the pellet for 30 seconds. The pellet was dried until a change in appearance 
was observed and the pellet was resuspended in 60 µl of nuclease-free water. The 
resuspended reaction was incubated at room temperature for 2 minutes. The beads were 
pelleted on the magnetic rack and the eluate was removed and transferred into a new tube. 
 
2.3.4.4.3. Purification of the DNA library using AMPure XP beads 
The DNA library was also purified using AMPure XP beads as recommended by ONT and 
the steps described in the Amplicons by Ligation protocol were followed. In brief, a 1:0.4 
ratio of sample to beads was used. The DNA library and bead mixture was incubated in the 
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Labnet Vortemp 56 shaking incubator at room temperature for 5 minutes at 90 RPM. The 
sample was briefly centrifuged and placed onto the magnetic rack to pellet the beads and 
remove the supernatant. The pelleted beads were resuspended and washed in 250 µl of the 
Long Fragment Buffer (LFB) from ONT’s Ligation Sequencing Kit. The tube was returned to 
the magnetic rack to pellet the beads and remove the supernatant. The wash step was 
repeated for a second time using LFB, after the removal of the supernatant the tube was 
briefly centrifuged and returned to the magnetic rack to remove any residual LFB. The pellet 
was dried for 30 seconds and resuspended in 15 µl of EB. The reaction was incubated at 
37°C in the Labnet AccuBlock™ Digital Dry Bath for 10 minutes. The beads were pelleted 
on the magnetic rack and the purified DNA library was transferred into a new tube. 
 
2.3.4.5. Pipeline development for ONT analysis 
A pipeline was developed for analysing the large amount of data that was generated by ONT 
sequencing by a collaborator affiliated with Stellenbosch University. In brief, the bases were 
recalled from the FAST5-pass files using the Guppy basecaller v3.3.3+fa743a6 (Oxford 
Nanopore Technologies, Oxford, UK). The read files were concatenated and aligned to the 
HIV Consensus C sequence using minimap2v2.17-r974-dirty (Li, 2018). The mapped reads 
were sorted and indexed using Samtools v1.10 (Li et al., 2009). Nanopolish v0.11.3 (Loman 
et al., 2015) was used to index the reads and map them back to original FAST5-pass files. 
Nanopolish was used in the “faster” mode and with the “fix homopolymers” feature on to call 
variants from the mapping. The maximum haplotypes considered was increased to 3000. 
An initial consensus was generated using Nanopolish’s vcf2fasta tool. A second round of 
remapping was completed where only single nucleotide polymorphisms (SNP) were 
considered to allow more potential SNP haplotypes to be included in variable loops and to 
further polish the consensus. 
 
  




3 Results  
3.1 Single genome amplification  
3.1.1. Plate view of NFL and p6-PR-RT nested PCR amplicons 
The near-full-length (NFL) and p6-PR-RT PCRs were performed as described in sections 
2.3.2.3.1. and 2.3.2.3.2. and the nested amplicons from both PCRs were viewed using the 
plate viewing method described in section 2.3.2.3.3.1. The plate viewing method allowed for 
the estimation of the target dilution, a concentration at which a positive well would most likely 
represent a single genome in a well. A 2-fold and 3-fold serial dilution of 8E5 DNA was used 
and amplified with NFL and p6-PR-RT PCRs respectively, where each row on the plate 
represented a specific dilution ratio in the dilution series. According to Poisson’s distribution, 
at a dilution where 4 wells out of 12 (30%) wells are positive, as detected by fluorescence 
of the EZ Vision™ DNA Dye, it is likely that the large majority of positive wells represent 
amplification from a single genome. Figure 3.1 shows the results of serially diluted 8E5 DNA 
amplified by the p6-PR-RT PCR and identifies the encircled 1:27 row as the target dilution. 
The method for identifying the target dilution for NFL was the same, however, the endpoint 
dilution was calculated based on the number of 8E5 HIV copies added to the reaction and 
the dilution target was identified as 15 copies per reaction. 
  
 
Figure 3.1: Plate viewing result of nested p6-PR-RT amplicons using serially diluted 8E5 DNA as a template 
to determine the target dilution. The respective dilution factors are indicated by 1:3, 1:9, 1:27, 1:81 and 1:243. 
NTC, non-template control, PC, positive control. 
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3.1.2. Gel electrophoresis of NFL and p6-PR-RT amplified products 
3.1.2.1. Gel electrophoresis of single genome HIV-1 templates amplified by a nested 
NFL PCR 
The wells from NFL PCR plates that fluoresced at the 15 copies per reaction target dilution 
in the plate viewing were separated by gel electrophoresis to determine whether a band of 
the correct size was present when exposed to ultraviolet light. Successful amplification with 
the modified NFL PCR approach using the newly designed primer in the nested PCR 
reaction from Katusiime et al. (2020) yields a band of interest at 9kb. Figure 3.2 shows an 
encircled band corresponding to a 9kb fragment in the lane labelled 5 and represents the 
results that were observed when NFL PCRs were repeated to produce more template. The 
wells containing the 9kb fragments were noted and the corresponding pre-nested products 
were used in the downstream ISLA assays and MDA amplifications.  
 
 
Figure 3.2: Gel photo showing an example of the results for a nested NFL PCR using 8E5 DNA as a template. 
 
3.1.2.2. Gel electrophoresis of single genome HIV-1 templates amplified by a nested 
p6-PR-RT PCR 
The wells from the nested p6-PR-RT PCR plates that fluoresced at the 1:27 target dilution 
when plate viewed were separated through gel electrophoresis to determine if successful 
amplification occurred. Successful amplification with the van Zyl et al. (2017) primer sets 
yields a fragment of 1.2kb. The results of the gel electrophoresis separation of the 
fluorescent wells present at the 1:27 target dilution are shown in Figure 3.3. All the lanes in 
Figure 3.3 contain a 1.2kb fragment. The wells containing the pre-nested products 
 M    1      2     3     4     5     6 
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corresponding to these nested amplicons were used as a template for the ISLA assays and 
MDA amplification.  
 
 
Figure 3.3: Gel electrophoresis results of the fluorescent wells from a nested p6-PR-RT amplification at 1:27 
target dilution. M, 1kb molecular marker, 1 - 6, nested p6-PR-RT amplicons diluted to 1:27 in 5 mM Tris-HCl. 
 
3.2. Integration site loop amplification assay  
3.2.1. 3’LTR ISLA assay  
The ISLA assay was initially attempted using the pre-nested product of a provisionally intact 
HIV-1 patient sample that was amplified by the NFL PCR as a template. The template was 
replaced with extracted 8E5 DNA for optimisation purposes as patient samples are limited 
and provisionally intact samples are very rare. The 8E5 DNA was first diluted in HIV 
uninfected PBMC DNA as part of the dilution series and for these investigations, a negative 
control was included where DNA from HIV uninfected PBMCs replaced the diluted 8E5 DNA 
template. The 8E5 DNA was serially diluted in 5 mM Tris-HCl for subsequent optimisation 
investigations.  
 
3.2.1.1. ISLA on a HIV-1 patient sample  
A pre-nested provisionally intact HIV-1 patient sample initially served as a template for the 
3’LTR ISLA assay. A non-template control and negative control were included in the 
amplification steps. The result of the initial attempt of the 3’LTR ISLA assay is shown in 
Figure 3.4. No unique bands were identified in the HIV-1 sample lane as all the bands 
corresponded to the bands that were observed in either the non-template control or the 
negative control lane.  
 M    1      2     3     4     5    6 





Figure 3.4: 3’LTR ISLA assay using the pre-nested product of a provisionally intact NFL HIV-1 sample and a 
negative control. 100 bp, molecular marker, N, non-template control, nHIV, negative control (uninfected 
PBMCs), SAMPLE, provisionally intact NFL HIV-1 patient sample.  
 
The products amplified in the two PCR steps that target the R region of HIV (Step 4 and 
Step 5 of ISLA) were individually observed through gel electrophoresis. The amplicons from 
both PCRs were viewed to determine if the second PCR targeted a specific product that was 
produced during the first round of PCR. A non-template control and a negative control were 
included and subject to amplification by the 3’LTR ISLA assay. Figure 3.5 shows the results 
of the two PCR amplifications for the 3’LTR ISLA assay. One unique band was present in 
the PCR 2 HIV-1 sample lane (encircled), however, due to the proximity to the band below, 
gel excision and purification of the band was not possible. In addition to this, the unique 
band occurred below the lowest molecular marker of 250/253 base pairs and the fragment 
was, therefore, shorter than the minimum 300 base pair limit set for Sanger sequencing of 
an ISLA product as a minimum of 30 base pairs of the HIV genome needs to be accurately 
sequenced prior to the junction between HIV and human genomic sequence to link 
integration sites in downstream analysis. 
  




Figure 3.5: The first and second PCRs of the 3’LTR ISLA assay using a provisionally intact NFL HIV-1 patient 
sample. M, 1kb molecular marker, NTC, non-template control, N, negative control (uninfected PBMCs), 
S, ISLA on a provisionally intact HIV-1 patient sample.  
 
3.2.1.2. ISLA on extracted 8E5 DNA  
Extracted 8E5 DNA was diluted in the DNA of a HIV negative PMBC sample to the final 
HIV-1 DNA copies of 60, 30, 15, and 7,5 per reaction as part of a 2-fold dilution series to 
mimic a patient sample with a low concentration of HIV infected cells, amongst a background 
of cellular DNA. A negative control (uninfected PBMCs), a non-template control and 
12 replicates of each final copy number were subject to NFL amplification and the plate 
viewing method was used to view the results. The plate view of the nested NFL PCR 
amplicons are shown in Figure 3.6. All the pre-nested products corresponding to the 
fluorescent wells in Figure 3.6 were used as templates for the 3’LTR ISLA assay. The effect 
of using various HIV copy numbers and therefore multiple HIV genomes as a template for 
the ISLA assay was investigated. The results of using 15 or 7,5 copies of HIV per reaction 
are shown in Figure 3.7. The 60 and 30 copies per reaction yield no unique fragments. 
Overall, for all the copy numbers, most of the fragments present corresponded to those 
present in the non-template or negative control lanes. A unique fragment of approximately 
380 base pairs was observed in the first lane of the 7,5 cp/rxn and is encircled in Figure 3.7. 
The unique fragment was gel excised and purified by the NucleoTraP®CR Kit for direct 
Sanger sequencing with the designed 3’LTR Junction-seq primer (section 3.2.9.).  
 




Figure 3.6: Plate viewing of nested NFL amplicons using 8E5 DNA that has been diluted to various copy 
numbers as a template. 60 cp/rxn, 60 copies of HIV per reaction, 30 cp/rxn, 30 copies of HIV per reaction, 
15 cp/rxn, 15 copies of HIV per reaction, 7,5 cp/rxn, 7,5 copies of HIV per reaction, NTC, non-template control, 
Neg, negative control (uninfected PBMCs). 
  
 
Figure 3.7: 3’LTR ISLA assay using NFL pre-nested 8E5 DNA amplified products as a template for ISLA. 1kb, 
molecular marker, NTC, non-template control, Neg, negative control (uninfected PBMCs), 1c, 8E5 DNA diluted 
to 15 copies per reaction, 6d/8d, 8E5 DNA diluted to 7,5 copies per reaction.  
 
3.2.2. 5’LTR ISLA assay  
The 5’LTR ISLA assay approach was attempted after unsuccessful amplification was 
observed with the 3’LTR ISLA assay. The 5’LTR assay was initially investigated using the 
remaining 8E5 pre-nested templates generated by the NFL PCR shown in Figure 3.6. 
Figure 3.8 shows the results of using various copy numbers as a template for the 5’LTR 
ISLA assay. The encircled faint bands in Figure 3.8, which were brighter and clearer upon 
analysis, were present at the correct base pair length (350 – 400 base pairs) and were gel 
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excised and purified for sequencing using the NucleoTraP®CR Kit. The sequencing results 
are presented in section 3.2.9. The larger fragment encircled and present in the lane labelled 
B8 was the brightest of all the bands that were excised and resulted in the best purity ratio 
and was therefore cloned and sequenced (section 3.2.10.). 
 
 
Figure 3.8: 5’LTR ISLA assay using pre-nested NFL amplified 8E5 DNA at various copy numbers per reaction 
as a template. 1kb, molecular marker, NTC, non-template control, Neg, negative control (uninfected PBMCs), 
A10 - A12, 60 copies of HIV per reaction, B8 - B12, 30 copies of HIV per reaction, C1, 15 copies of HIV per 
reaction, D6 - D8, 7,5 copies of HIV per reaction.  
 
3.2.3. Optimal annealing temperature  
The Wagner et al. (2014) annealing temperatures were initially utilised in all ISLA assay 
approaches. Unsuccessful amplification across the 8E5 HIV-1 integration sites and the 
adjacent human genomic sequence, lead to the investigation of primer annealing 
temperatures. Two approaches to investigate the annealing temperature changes were 
established, the first ISLA approach used the Wagner et al. (2014) annealing temperatures 
and the second approach used lower annealing temperatures as described in section 
2.3.3.2.4. The results of utilising the different annealing temperatures for Step 4 and Step 5 
of ISLA are shown in Figure 3.9. The gel photo shows the Wagner et al. (2014) annealing 
temperatures on the left (1 - 12) and the lowered annealing temperatures on the right 
(13 - 24). Three unique and bright bands were observed in lanes 8, 9 and 17 and are 
indicated by arrows in Figure 3.9 and measure at 170, 200 and 450 base pairs, respectively. 
The bands in the lanes labelled 8 and 9 were smaller than the 300-base pair limit set for 
ISLA products to be Sanger sequenced but were the longest fragments observed in the first 
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approach and were investigated further. All three bands were gel excised and purified using 
the NucleoTraP®CR Kit for Sanger sequencing. In addition to this, the purified bands were 
cloned into the pJET1.2/blunt plasmid vector and sequenced.  
 
 
Figure 3.9: 5’LTR ISLA assay using p6-PR-RT pre-nested products as a starting template. N, negative control, 
P, positive control, L, 1kb molecular marker, 1 - 12, Wagner et al. (2014) annealing temperatures, 13 - 24, 
lowered annealing (modified) temperatures.  
 
3.2.4. Increasing the ISLA template concentration  
The concentration of the starting template for ISLA was increased by MDA. The effect of 
using linear products amplified by MDA as a template for the ISLA assay was investigated. 
Two investigations were conducted to determine the effect of using MDA.  
 
The first investigation used pre-nested NFL products at target dilution, 15 copies per 
reaction, followed by MDA amplification. The 8E5 DNA was diluted to target in 5 mM Tris-HCl 
for this experiment. The results of this attempt are shown in Figure 3.10. Three unique, very 
bright and large sized fragments measuring approximately 2 500 base pairs in length were 
observed and are encircled in the figure, although the fragments were much larger than the 
expected fragment length for ISLA, approximately 300-base pairs, they were selected for 
further investigation to determine their significance. No bands were present in the negative 
control lane which further encouraged the decision to sequence the bands present in lanes, 
5, 8a and 19. The fragments were gel excised and purified with the NucleoTraP®CR Kit for 
direct Sanger sequencing. Samples 8a and 19 were cloned into the CloneJET™ 
pJET1.2/blunt plasmid vector to determine their significance. The sequencing results are 
discussed in sections 3.2.9. and 3.2.10.2.2. 





Figure 3.10: 5’LTR ISLA assay using 8E5 DNA at 15 copies per reaction target dilution. 1kb, molecular marker, 
NTC, non-template control, Neg, negative control (uninfected PBMCs), 1 - 20, 8E5 DNA diluted in Tris-HCl to 
15 copies per reaction.  
 
The second investigation utilised two approaches using the same initial 8E5 NFL and/or 
p6-PR-RT pre-nested products. The pre-nested products from the NFL and p6-PR-RT PCRs 
at their respective target dilutions were divided into two separate tubes to investigate the 
approaches. The first approach used the pre-nested products that were amplified by MDA 
(section 2.3.3.2.5.) prior to Step 2 also known as the random priming step of ISLA. The 
second approach that was investigated, used the original pre-nested products as templates 
for ISLA. The results of the two approaches were compared and are shown in Figure 3.11. 
Both the approaches using the pre-nested NFL or p6-PR-RT products at their respective 
target dilutions as a template showed no amplification.  
 
a 




Figure 3.11: The result of using MDA amplified pre-nested products as a template versus using the pre-nested 
products directly as a template for ISLA. A - C (left-hand side), pre-nested NFL templates were amplified with 
MDA prior to ISLA, A - C (right-hand side), NFL pre-nested products were directly used as templates for ISLA. 
 
3.2.5. Random primer concentration optimisation  
Different random primer concentrations, 2 µM, 1.5 µM, 1 µM and 0.75 µM, were investigated 
for Step 2 of ISLA. The 5’LTR ISLA assay was attempted using 8E5 pre-nested NFL and 
p6-PR-RT products at their respective target dilutions as templates. In addition to this, the 
influence of the MDA amplification prior to Step 2 of ISLA was also investigated. Therefore, 
two different approaches for investigating the impact of using different random primer 
concentrations and MDA were established. The first approach used 8E5 pre-nested NFL or 
p6-PR-RT products at target dilution as templates for ISLA that were randomly primed using 
different primer concentrations. The second approach used 8E5 pre-nested NFL or 
p6-PR-RT templates that were amplified by MDA prior to the random priming step of ISLA. 
The use of different random primer concentrations was investigated in triplicate for both 
approaches. The results of the two approaches are shown in Figures 3.12 and 3.13. No 
amplification was observed in either approach.  
 
MDA step 
prior to ISLA 
No MDA step 
prior to ISLA 




Figure 3.12: The first approach investigating different random primer concentrations and no MDA amplification 
of the templates. M, 1kb molecular marker, 2 µM, 1.5 µM, 1 µM, 0.75 µM, random primer concentrations 
investigated in triplicate (A - C).  
 
 
Figure 3.13: The second approach investigating the use of different random primer concentrations on MDA 
amplified templates. M, 1kb molecular marker, 2 µM, 1.5 µM, 1 µM, 0.75 µM, random primer concentrations 
investigated in triplicate (A - C). 
 
3.2.6. Comparison of DNA polymerases for ISLA  
MyTaq™ Mix replaced RANGER Mix in the ISLA assay reactions to compare the efficacies 
of the two enzymes. The addition or exclusion of the MDA step prior to Step 2 of ISLA was 
also investigated. Therefore, several 8E5 pre-nested p6-PR-RT products at target dilution 
were subject to MDA amplification and used as a template to investigate ISLA with the 
MyTaq™ enzyme mix. An additional amplification was simultaneously conducted using the 
pre-nested products as a template with no MDA amplification. The comparison of the two 
approaches is shown in Figure 3.14. 
 
2 µM 1.5 µM 1 µM 0.75 µM 
2 µM 1,5 µM 1 µM 0,75 µM 
M            M 
M          M 




Figure 3.14: Results of ISLA with the MyTaq™ Mix in place of RANGER Mix. N, negative control, P, positive 
control which was 100 ng/µl of 8E5 DNA, L, 1kb molecular marker, 1 - 9, MDA amplified ISLA template, 1 - 6, 
No MDA prior to ISLA assay.    
 
3.2.7. Subtype B ISLA assay  
The subtype B ISLA assay published by Wagner et al. (2014) was attempted. Extracted 8E5 
DNA was linearly amplified as described in section 2.3.3.2.8.and the linear products served 
as a template for the published ISLA method. ISLA was attempted on 24 linearly amplified 
products. The results of the subtype B ISLA assay are shown in Figure 3.15. No successful 
amplification was observed. 
 
 
Figure 3.15: Results of the published Wagner et al. (2014) ISLA assay using linearly amplified 8E5 DNA as a 
template. M, 1kb molecular marker, A1 - B12, linearly amplified 8E5 DNA template.  
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3.2.8. Purification of ISLA products for sequencing  
The unique ISLA products selected for sequencing were highlighted in the previous sections. 
All of the products were gel excised and purified using the NucleoTraP®CR Kit. The 
absorbance of the purified products were measured with the NanoDrop™ 1000 
Spectrophotometer to determine their respective concentrations and purities and are shown 
in Table 3.1. As nucleic acids absorb at a wavelength of 260nm and proteins at a wavelength 
of 280nm, a ratio of absorbance at 260nm and 280nm (260/280) was used to assess the 
purity of the nucleic acid and a ratio measuring approximately 1.8 corresponds to ‘pure’ DNA 
and a ratio measuring approximately 2.0 is considered to be ‘pure’ for RNA.  
 
3.2.9. Direct sequencing of ISLA products by Sanger sequencing 
All the purified ISLA products presented in Table 3.1 were directly sequenced by Sanger 
sequencing with the designed 3’LTR Junction_seq or 5’LTR Junction_seq primers at CAF. 
The sequencing primer chosen was dependant on the ISLA approach that was utilised and 
are indicated in Table 3.1. A pGEM® positive control was included and successfully 
sequenced in all reactions, indicating that the sequencing reaction set up and sequencing 
conditions were optimal. The lengths of the resulting sequences ranged from 46 – 486 base 
pairs with an average length of 243 base pairs. ISLA samples 6d, B8, B12, 8 and 19 were 
excluded from further analyses as the designed 3’LTR and 5’LTR sequencing primers did 
not sequence these samples. In addition to the aforementioned samples, ISLA samples 
8 and 9 from Figure 3.10, were also excluded as both sequences had <100 base pairs. 
Therefore, all the remaining samples >100 base pairs were used to perform NCBI’s blastn 
followed by an alignment to the HIV Consensus C and HXB2 reference genomes, 
respectively. ISLA sample 5 was the only sample that returned a blastn result and showed 
an 87.13% percentage identity to a Sporobolomyces species available on GenBank 
(accession number: MG470907.1). No contigs were formed through sequence alignment to 
HIV Consensus C or HXB2.
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Table 3.1: NucleoTraP®CR gel excision purification results and the primer used for sequencing for each ISLA product 
ISLA approach Sample name Figure 
DNA concentration 
(ng/µl) 260/280 260/230 
Sequencing primer 
name  
3’LTR 6d 3.7 50.1 1,92 1,14 3’LTR Junction_seq 
5’LTR 
A11 (lower band) 
3.8 
39,8 1,87 1,11 
5’LTR Junction_seq 
A12 (lower band) 38,1 1,86 1,23 
B8 (lower band) 68,0 1,83 1,28 
B8 50,0 1,89 1,12 
B12 75,4 1,87 1,23 
D8 67,3 1,76 1,03 
5 
3.10 
44,6 2,06 1,41 
8a 32,9 2,35 1,09 
19 82,6 1,94 1,21 
8* 
3.9 
17,9 1,35 0,70 
9* 14,1 1,41 0,64 
17* 12,1 4,38 0,68 
* average of three readings  
Cloned samples   
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3.2.10. Cloning of ISLA assay products  
The primer binding sites of the 3’LTR Junction_seq and the 5’LTR Junction_seq sequencing 
primers occurred near the integration site thereby making recovery and identification of 
these sites unattainable. Several purified ISLA products were selected to be cloned into a 
plasmid vector and sequenced by Sanger sequencing. The purified ISLA products were 
ligated into a kit plasmid vector following the InsTAclone™ or the CloneJET™ cloning 
method (sections 2.3.3.6.2. and 2.3.3.6.3.) The names and sizes of the purified ISLA 
products chosen for cloning are shown in Table 3.2 together with their respective cloning kit 
and sequencing primers.  
 





Insert size in 
base pairs 
(approximate) 
Cloning kit Sequencing primers 


















3.2.10.1. Successful ligation confirmation of the fragment of interest into the kit 
plasmid vector  
3.2.10.1.1. InsTAclone™ PCR Cloning Kit  
ISLA product B8 was ligated into the pTZ57R/TA vector as described in section 2.3.3.6.2.1. 
The transformed bacterial cells were divided into three volumes and spread across the 
surface of a prepared LB agar plate as described in section 2.3.3.6.2.2. The 3 plates were 
observed for the presence of single colonies following the overnight incubation at 37°C. A 
single white-creamy colony was selected and grown in a bacterial culture overnight and 
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purified with the GeneJET Plasmid Miniprep kit (2.3.3.6.2.5.). The purified plasmid was 
diluted with nuclease-free water to 20 ng/µl for the DNA sequencing reaction and was 
sequenced by Sanger sequencing. 
 
3.2.10.1.2. CloneJET™ PCR Cloning Kit 
A total of 5 ISLA products, namely sample 8a, 19, 8, 9 and 17, were selected to be ligated 
into the pJET1.2/blunt cloning vector of the CloneJET™ PCR Cloning Kit. The method 
described in section 2.3.3.6.3.1. was followed to ligate the ISLA products into the cloning 
vector. Two selected volumes of the transformed bacteria (2.3.3.6.3.2.) for each ISLA 
product was spread across the surface of two LB agar plates. The plates were viewed 
following the overnight incubation at 37°C for the presence of single colonies. A colony PCR 
with a high-fidelity enzyme was performed on the selected colonies to confirm the presence 
of the ISLA products. The results of the colony PCR are shown in Figures 3.16, 3.17 and 
3.18. The colony PCR reactions from the fragments encircled in the figures were diluted in 
nuclease-free water to 20 ng/µl and sequenced by Sanger sequencing.  
 
 
Figure 3.16: Colony PCR results of ISLA samples 8a and 19. M, 1kb molecular marker, A1 - A10 and C1 - C4, 
single colonies selected from the plate inoculated ISLA sample 8a, B1 - B9, single colonies selected from the 
plate inoculated ISLA sample 19, C, CloneJET™ PCR Cloning Kit positive control.   
 




Figure 3.17: Colony PCR of ISLA samples 17 and 9 following the CloneJET™ PCR cloning procedure. L, 1kb 
molecular marker, a - h, ISLA sample 17 single colonies, i - x, ISLA sample 9 single colonies.  
 
 
Figure 3.18: Colony PCR results for ISLA sample 8 cloned by the CloneJET™ PCR Cloning Kit. L, 1kb 
molecular marker, a - z, single colonies selected from both inoculated LB agar plates.  
 
3.2.10.2. Sanger sequencing results of ISLA products cloned by the InsTAclone™ or 
CloneJET™ PCR cloning kits  
3.2.10.2.1. InsTAclone™ 
The forward and reverse sequencing of ISLA sample B8 was conducted in triplicate. A 
MUSCLE alignment with 100 iterations was done for the 3 forward and 3 reverse sequences, 
respectively, to generate a raw consensus sequence for each direction. The generated raw 
consensus sequences were aligned to each other resulting in an overlap of 350 base pairs 
shown in Figure 3.19. The forward and reverse raw consensi were individually loaded onto 
ISLA sample 17 ISLA sample 9 
Stellenbosch University  https://scholar.sun.ac.za
83 
 
NCBI’s blastn and both matched to the Eukaryotic synthetic construct chromosome 16 
nucleotide sequence (accession number: CP034494.1, percentage identity: 99.19% for 
forward and 98.63% for reverse consensus sequences). In addition, the consensi were 




Figure 3.19: MUSCLE alignment of the raw forward and reverse consensus sequences of ISLA sample B8. 
Grey overlapping sections indicate agreements between the consensi and the presence of colour within the 
grey sections indicate disagreements between the two consensi. 
 
3.2.10.2.2. CloneJET™ 
The 15 colony PCR fragments highlighted in Figure 3.16 from ISLA samples 8a and 19, 
were sequenced the pJET sequencing primer set in a forward and reverse sequencing 
reaction. Sequences with <100 base pairs were excluded from further analyses. NCBI’s 
blastn was performed on each raw sequence, followed by an alignment to HIV Consensus 
C. All the blastn results except for sample 8a C1 forward, returned matches to various HIV-1 
sequences available on GenBank. A total of 23 sequences matched to HIV-1 sequences, 
nine matched to accession number MN691959.1 (percentage identity average: 93.31%), 
seven matched to MN467309.1 (93.5%), three matched to MN989412.1 (97.31%) and the 
remaining four sequences returned matches to MN685352.1(96.30%), MN090293.1 
(82.86%), KX129262.1 (87.22%) and Z11530.1 (90.03%), respectively. A MUSCLE 
alignment with 100 iterations was performed with all the raw forward sequences. Cloned 
samples A4, A7, A8, A9, B5, B7 and C2 showed good agreement in overlapping regions 
and a forward consensus of 976 base pairs with 6 gaps was generated and aligned to the 
HIV Consensus C and HXB2 reference sequences. The forward consensus sequence 
aligned to HXB2 at 8604 - 9580 base pairs. The reverse raw consensus sequence was 
generated in the same way as the forward consensus sequence, however, cloned samples 
A4, B6, C1, C2 and C4 showed the most similarity across overlapping regions and a 
946 base pair consensus sequence with 6 gaps was generated. The raw reverse consensus 
sequence aligned to HXB2 at 6353 - 7292 base pairs with 6 gaps. The results of the 
alignments to the HXB2 reference genome are shown in Figure 3.20. and the raw forward 
and reverse consensi do not overlap. All the sequences contained the NFL HIV-1 PCR target 
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sequences but no human genome, therefore no integration sites were identified. Many gaps, 
insertions and deletions, and disagreements between the consensi and the reference 
genome were observed in the alignments to HIV Consensus C. 
 
  
Figure 3.20: Alignment of the raw forward and reverse consensus sequences to the HXB2 reference genome. 
HXB2 reference genome is indicated in green and the areas where the two consensi best align to the reference 
genome are indicated in blue.  
 
Three resulting fragments from the colony PCR of cloned ISLA samples 8, 9 and 17 were 
selected for sequencing and are highlighted in Figures 3.17 and 3.18. The resulting raw 
sequences obtained by Sanger sequencing were subject to NCBI’s blastn and ISLA samples 
9 and 17 a returned a “no significant similarity” result. However, for ISLA sample 8, the blastn 
of the raw forward and reverse sequences showed a 100% percentage identity to a cloning 
vector sequence on GenBank (accession number: KP223705.1). The raw sequences were 
also aligned to HIV Consensus C and HXB2 and no contigs were identified. 
 
3.3. ONT sequencing results  
3.3.1. Premium whole genome amplification  
3.3.1.1. Purification of MDA amplified products 
Multiple MDA reactions were conducted using a 8E5 NFL pre-nested product as a template 
(referred to as the NFL MDA amplified product in the following sections) for optimisation. 
Several wells containing the NFL MDA amplified product were combined into a 1.5 ml tube 
and was used to investigate all methods of purification. This allowed for the comparison 
between methods and the determination of the best method of purification. Prior to 
purification, the concentration and purity of the combined NFL MDA amplified product was 
measured using the NanoDrop™ 1000 Spectrophotometer and the Qubit® 2.0 Fluorometer 
and the result is shown in Table 3.3 below.  
 





Several methods for purifying the NFL MDA amplified product were investigated and have 
been described in section 2.3.4.3.1. Table 3.4 shows the results of these purification 
methods. Due to the concentration and volume requirements for downstream analyses, a 
limited amount of purified sample remained for the quality and quantity determination. 
Therefore, where sufficient product remained both NanoDrop™ 1000 Spectrophotometer 
and Qubit® 2.0 Fluorometer measurements were taken and for purified samples with limited 
volume remaining only a Qubit® 2.0 Fluorometer measurement was obtained.  
 















AMPure XP bead 
purification 
(2.3.4.3.1.1) 
   94 4,61 









339,7 1,82 2,24 2060 100,94 
In-house 
(2.3.4.3.1.2.3.) 
140,5 1,68 2,28 2020 98,98 
*total ng in the remaining 49µl for downstream analysis 
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 















NFL MDA product 623,6 1,90 1,72 2320 113,68 
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 




3.3.1.2. T7 Endonuclease I digestion 
3.3.1.2.1. Optimisation of T7 Endonuclease I digestion  
The MRC Holland ethanol precipitation method was identified as the best method for 
purifying NFL MDA amplified products as shown in Table 3.4. This purification method was 
therefore used to purify sufficient NFL MDA amplified product to optimise the T7 
Endonuclease I digestion step in ONT’s Premium whole genome amplification protocol. As 
mentioned in section 2.3.4.3.2, an initial input concentration of 1.5 µg of the purified NFL 
MDA amplified product was investigated, however, a rapid decrease in the concentration of 
the product following the digestion with the T7 Endonuclease I enzyme was measured and 
the alternative method using an input concentration of 3.5 µg was investigated with an 
adjusted incubation step based on the recommendations of other ONT users. The resulting 
concentrations of T7 Endonuclease I digested products were determined by the 
NanoDrop™ 1000 Spectrophotometer and are shown in Table 3.5. Overall, a significant loss 
in concentration was observed with both input concentrations.  
 
Table 3.5: Concentration of T7 Endonuclease I digested products 
Input concentration of purified 
NFL MDA amplified product 
DNA 
concentration 
(ng/µl) 260/280▪ 260/230 
1.5 µg 86,0 1,44 0,92 
3.5 µg 127,2 1,55 1,15 
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 
 
3.3.1.2.2. Purification of T7 Endonuclease I digested products 
The products from both 1.5 µg and 3.5 µg input concentrations used in the T7 Endonuclease 
I digestion attempts were used to investigate various purification methods. The methods 
utilised in the purification of these digested products were described in section 2.3.4.3.3. 
Initial purification attempts were investigated using the digested product from the 1.5 µg 
input concentration reaction, however, due to low recovery following purification, the method 
was changed to the 3.5 µg input concentration reaction. Therefore, ONT’s recommended 
purification method using AMPure XP beads with a custom buffer system (section 
2.3.4.3.3.1) was investigated using both T7 Endonuclease I digested products as it yielded 
the best results for the initial 1.5 µg input concentration reaction. Table 3.6 shows the various 
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purification methods that were used with the respective input concentrations with the 
resulting concentrations and purities of the products for each method measured by the 
NanoDrop™ 1000 Spectrophotometer. Furthermore, since the MRC Holland ethanol 
precipitation method gave the best results in the NFL MDA amplified product purification, 
the method was investigated with an overnight incubation at -20°C. 
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Table 3.6: Purification method results used on T7 Endonuclease I digested products  




(ng/µl) 260/280▪ 260/230 
AMPure XP with custom buffer 
(2.3.4.3.3.1.) 
0,6 0,87 Invalid 
1,3 1,01 1,54 
1,2 2,56 0,84 
MRC Holland Ethanol precipitation  
(2.3.4.3.1.2.2.) 
0,2 Invalid 0,18 
NucleoSpin® 
(2.3.4.3.3.5.) 
3,3 2,18 0,27 




(ng/µl) 260/280▪ 260/230 
AMPure XP with custom buffer 
(2.3.4.3.3.1.) 
0,3 Invalid Invalid 
AMPure XP bead purification 
(2.3.4.3.3.2.) 
Invalid 0,86 0,79 
MRC Holland Ethanol precipitation 
(-20°C incubation) 
(2.3.4.3.3.3.) 
11,6 2,36 1,90 
NucleoTraP®CR  
(2.3.4.3.3.4.) 
0,7 0,64 0,37 
Invalid indicate blank readings that were higher than sample readings possibly due to the presence of ethanol  
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 
 
3.3.1.3. ONT sequencing of the NFL MDA amplified product  
Additional 8E5 NFL MDA amplified product was generated, the 3.5 µg T7 Endonuclease I 
digestion method was used to remove hyperbranched structures and the products were 
purified using the best methods of purification prior to DNA preparation and sequencing on 
the GridION. The MRC Holland ethanol precipitation method was used to purify the NFL 
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MDA amplified product and the T7 Endonuclease I digested product, for the latter, the 
adapted method using the overnight incubation at -20°C was used instead of the 15-minute 
incubation on ice. The concentrations of the resulting products were measured with the 
NanoDrop™ 1000 Spectrophotometer after various steps to determine where significant 
losses in concentration and purity occurred and to determine whether further processing of 
the product could occur for ONT sequencing. The resulting concentrations and purities after 
the respective purification steps are displayed in Table 3.7. 
 
Table 3.7: Concentrations and purity of the product after various steps of purification 
Sample name 
DNA concentration 
(ng/µl) 260/280▪ 260/230 
NFL MDA product 542.3 1.88 1.56 
Before T7 Endonuclease I digestion 
Purified NFL MDA products 
737 1.77 2.20 
786.6 1.79 2.25 
After T7 Endonuclease I digestion  
Purified T7 Endonuclease I digested products  
5.5 1.74 5.37 
2.4 1.15 Invalid 
Invalid indicate blank readings that were higher than sample readings possibly due to the presence of ethanol  
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 
 
Further investigation of the NFL MDA amplified product was done to determine if the 
fragment size corresponded to the expected 9kb fragment length by separation through gel 
electrophoresis. The result of the gel electrophoresis separation is shown in Figure 3.21. No 
band was visible upon analysis and the gel electrophoresis step was repeated for a second 
time under the same conditions and a third time using an E-Gel™ Agarose Gels with 
SYBR™ Safe DNA Gel Stain, 1.2% (Invitrogen, USA) to confirm the result. All three 
investigations yielded the same result. Due to the insufficient concentration of the purified 
T7 Endonuclease I digested product, in conjunction with no visible 9kb fragment, ONT 
sequencing of the NFL MDA product did not proceed.  
 




Figure 3.21: The NFL MDA amplified product was not visible following separation by gel electrophoresis and 
exposure to UV light. L, 1kb molecular maker, 1, NFL MDA amplified 8E5 product. 
 
ONT’s Premium whole genome amplification protocol appeared to be the ideal method for 
identifying the integration sites of HIV-1. Although the processing of the 8E5 NFL MDA 
amplified product yielded unexplained results, the integration site of a unique patient sample 
needed to be identified for a PhD student project. This sample was first amplified by the NFL 
PCR to identify single genome amplified products using Poisson’s distribution. The 
pre-nested NFL products corresponding to wells containing single genome amplified 
products were MDA amplified and processed following the Premium whole genome 
amplification protocol to be sequenced with the GridION. The optimised methods and 
purification steps were attempted on the patient sample and were compared to the 8E5 NFL 
MDA amplified product at various steps. The MDA amplification of the patient sample was 
conducted in quadruplicate and are labelled as NFL 1, NFL 2, NFL 3 and NFL 4. The 8E5 
and patient MDA amplified products were visualised by using the plate viewing method 
described in section 2.3.2.3.3.1. and the concentrations and purities of the products were 
measured with the NanoDrop™ 1000 Spectrophotometer prior to T7 Endonuclease I 
digestion. Due to the losses in concentration previously observed from the purification of the 
8E5 NFL MDA amplified product to the purification of T7 Endonuclease I digested products, 
the initial purification of the patient MDA amplified products was omitted in an attempt to limit 
losses in concentration. The pre-nested p6-PR-RT MDA amplified product that will be 
described in section 3.3.1.4. was also included in the comparison. The concentration and 
purity results measured by the NanoDrop™ 1000 Spectrophotometer of the various samples 
are shown in Table 3.8 and Figure 3.22. Patient samples NFL 2 and NFL 4 had the best 
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recoveries and the MDA amplified product and T7 Endonuclease I digested products for 
these samples were separated by gel electrophoresis to determine the size of the product 
and the results are shown in Figure 3.23. 
 




Table 3.8: Comparison of 8E5 NFL MDA amplified product and patient NFL MDA amplified sample pre-purification and post T7 Endonuclease I digestion 
purification 
  








(ng/µl) 260/280▪ 260/230 
NFL 
 
528,4 1,89 1,57  - - - 
p6-PR-RT  
 
621,5 1,90 1,71  Results in Table 3.9 section 3.3.1.4  
Patient sample identifiers  
 
   
NFL 1 
 
861,7 1,47 1,39  8,2 1,90 5,31 
NFL 2 
 
491,6 1,84 1,57  14,6 1,77 2,24 
NFL 3 
 
487,0 1,84 1,57  14,0 2,19 4,04 
NFL 4 
 
483,1 1,84 1,55  14,8 1,87 2,86 









Figure 3.22: Plate view of the 8E5 NFL and p6-PR-RT MDA amplified products and the patient NFL MDA 
amplified products. p6, 8E5 p6-PR-RT MDA amplified product, NFL, 8E5 NFL MDA amplified product, 
NFL1 - NFL4, patient NFL MDA amplified products. 
 
 
Figure 3.23: Patient NFL MDA amplified sample and T7 Endonuclease I digested sample. M, 1kb molecular 
marker, NFL2/NFL4, pre T7 Endonuclease I digestion, nfl2/nfl4, post T7 Endonuclease I digestion.  
 
3.3.1.4. Sequencing preparation of the p6-PR-RT MDA amplified product  
Extracted 8E5 DNA was amplified by the p6-PR-RT PCR and the pre-nested product 
corresponding to the nested wells that fluoresced under ultraviolet light were amplified by 
MDA (referred to as p6 MDA amplified product in the sections below) in an attempt to 
successfully recover the integration site of 8E5. The plate viewing of the p6 MDA amplified 
product is shown in Figure 3.22. ONT’s Premium whole genome amplification protocol was 
utilised and the p6 MDA amplified product replaced the NFL MDA amplified product as a 
template in the Premium whole genome amplification protocol. The p6 MDA amplified 
product was purified with the MRC Holland ethanol precipitation method (section 
2.3.4.3.1.2.2.) and 3.5 µg of purified product was used in the T7 Endonuclease I digestion 
reaction. The concentration and purity of the purified T7 Endonuclease I product was 
measured with the NanoDrop™ 1000 Spectrophotometer and was used to prepare the DNA 
library for ONT sequencing. The DNA library was purified with AMPure XP beads following 
ONT’s instructions and the concentration of purified library was measured with the Qubit® 
NFL1   NFL2   NFL3   NFL4 
M   NFL2   nfl2 NFL4   nfl4    M 
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2.0 fluorometer. The concentration and purity measurements mentioned in this section are 
shown in Table 3.9. 
 
Table 3.9: Purification results of the p6 MDA amplified product during ONT’s DNA library 
preparation 
 NanoDrop™ 1000 spectrophotometer 
Qubit® 2.0 
fluorometer 
Sample name  
DNA 
concentration 
(ng/ul) 260/280▪ 260/230 
DNA concentration 
(ng/ml) 
Purified p6 MDA product  621,5 1,90 1,71  
Purified T7 Endonuclease 
I digested product 
19,4 3,23 2,89  
DNA library    
<50 
Too low to read 
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 
 
The recovery of the purified T7 Endonuclease I digested product was lower than the 1 µg 
input that was required for ONT sequencing when using the Premium whole genome 
amplification protocol, however, the product was sequenced to determine the efficacy of the 
protocol and the GridION sequencing device.  
 
3.3.1.4.1. ONT sequencing results for the p6 MDA amplified product  
ONT’s MinKNOW software showed the real-time sequencing information such as the 
progression of the sequencing run of the p6 MDA amplified product as mentioned in section 
2.3.4.2. Overall, the nanopores were not saturated with a sufficient concentration of the DNA 
library as noted in Table 3.9. The ONT sequencing run for this sample contained less than 
4 000 sequences which is less than what is expected for this sequencing platform. 
Sequences with a Q score ≥7 were selected and aligned to the HXB2 reference genome. 
Massive gaps were observed in the alignment and the highest coverage occurred across 
the 1.2kb region that the p6-PR-RT PCR targeted. Therefore, using a longer PCR extension 
time did not allow for amplification across the site of integration and HIV integration sites 
were not recovered with this method.  
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3.3.2. Amplicons by Ligation  
3.3.2.1. Purification of provisionally intact NFL HIV PCR products 
Nine provisionally intact NFL HIV-1 patient samples were selected to be sequenced with 
ONT’s GridION. During the time of the project, seven were confirmed to be intact HIV-1 
proviral sequences by Illumina® MiSeq™ sequencing and consensus analyses (Katusiime 
et al., 2020). The remaining samples contained deletions and were classified as non-intact 
for this investigation. The seven intact and two non-intact samples were sequenced by ONT 
and were included in the downstream consensus construction, sequence analyses and 
sequencing platform comparisons.  
 
The nine nested NFL amplicons were separated by gel electrophoresis to confirm that the 
9kb fragment of interest was present prior to ONT sequencing, these results are depicted in 
Figure 3.24 and the 9kb fragments of interest are encircled. The first two lanes in the figure 
contain the non-intact nested NFL products and the remaining lanes contain the seven intact 
nested NFL products from patient samples. These amplicons were purified with AMPure XP 
beads (2.3.4.4.1.) and the quantity and quality of the NFL amplicons pre- and 
post-purification were measured with the NanoDrop™ 1000 Spectrophotometer and are 
shown in Table 3.10. Each purified 9kb amplicon was processed to prepare a DNA library 
for ONT sequencing which included end reparation and preparation and the ligation of 
sequencing adaptors to the ends of the DNA fragment. The DNA libraries were purified with 
AMPure XP beads (2.3.4.4.3.) and the concentration and purity of each was measured with 
the NanoDrop™ 1000 Spectrophotometer and these results are included in Table 3.10. This 
measurement ensured that sufficient DNA library was available for successful ONT 
sequencing.  
 




Figure 3.24: The gel electrophoresis separation of nine provisionally intact NFL nested products showing the 
encircled ~9kb fragments in each lane to be sequenced. M, 1kb molecular marker, 1, 333716 P2D4, 2, 339606 
P3G8, 3, 339266 P5D4, 4, 339266 P1C7, 5, 339266 P1C8, 6, 339266 P2C7, 7, 339606 P3D8, 8, 339606 
P3G7, 9, 340116 P4D1. 
 
M    1     2     3     4      5     6     7     8     9    M 
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Table 3.10: Concentrations of the non-intact and intact NFL amplicons during ONT sequencing preparation 






(ng/µl) 260/280▪ 260/230 
 DNA 
concentration 
(ng/µl) 260/280▪ 260/230 
 DNA 
concentration 
(ng/µl) 260/280▪ 260/230 
333716 P2D4  ⃰ 476,5 1,74 1,30  131,2 1,90 2,36  - - - 
339606 
P3G8 573,2 1,76 1,34  138,7 1,90 2,36  31,9 1,73 1,42 
P3D8 894,1 1,78 1,25  146,4 1,94 2,35  23,8 1,83 1,36 
P3G7 455,2 1,74 1,24  157,7 1,97 2,37  30,1 1,78 1,35 
339266 
P5D4 797,9 1,81 1,27  107,7 1,90 2,26  28,3 1,87 1,62 
P1C7 691,2 1,78 1,33  97,5 1,95 2,07  31,6 1,81 1,53 
P1C8 436,1 1,81 1,31  127,9 1,98 2,32  34,3 1,75 1,34 
P2C7 575,2 1,78 1,37  78,2 1,99 2,28  145,9 1,79 1,33 
340116 P4D1 571,5 1,78 1,31  125,9 1,94 2,34  49,0 1,53 0,82 
* No DNA library sample remaining after purification for measurement 
        Indicates samples that have been identified as intact HIV-1 sequences  
▪ Ratio of ~1.8 corresponds to ‘pure’ DNA and a ratio of ~2.0 corresponds to ‘pure’ RNA 
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3.3.2.2. Analysing ONT sequencing in real-time  
The core functions of the MinKNOW software allows for the sequencing run to be monitored 
in real-time as mentioned in Step 6 of section 2.3.4.2. and allows for important information 
about the progression of the sequencing to be immediately relayed. The real-time run 
information dashboard shows information about the health and status of the nanopores, 
relays information on the condition of the flow cell (i.e. quality control) and also shows a 
histogram with the read length distribution. The health and status of the nanopores on the 
flow cell for a ONT sequencing run is shown in the Channels Panel in Figure 3.25, where 
each tile represents a single nanopore and bright green tiles correspond to pores that are 
actively sequencing, dark green shows pores that are available to sequence, dark blue tiles 
indicate pores that are recovering and light blue tiles are inactive pores. Figure 3.26 shows 
the total number of fragments of a specific length that have been sequenced and an average 
fragment length. This fragment length distribution was seen in most of the sequencing 
experiments with a peak at approximately 9kb. Bimodal peaks were observed in some of 
the Read Length Histograms, one peak occurred at the expected 9kb fragment length and 
another occurred between 2kb and 5kb. The sequencing runs for all nine of the NFL samples 
were stopped once sufficient coverage of the fragment of interest was obtained which 
equated to 40 - 70 GB of sequencing data for each sample. 
 
 
Figure 3.25: ONT real-time dashboard showing the Channels Panel and the status of the nanopores on the 
flow cell.  
 




Figure 3.26: ONT real-time dashboard showing a histogram of the read length of the fragments sequenced 
and the estimated amount of data generated for each read length after 2 hours of sequencing.   
 
3.3.2.3. Phylogenetic analysis and comparison of the Illumina® MiSeq™ and ONT 
sequencing methods 
The developed pipeline was used to construct the consensus sequences from the 
provisionally intact NFL HIV-1 patient samples that were sequenced by ONT’s GridION. The 
ONT and Illumina® MiSeq™ sequences were aligned using MUSCLE and a tree was 
generated using maximum parsimony with 5 random rearrangements. The phylogenetic tree 
is shown in Figure 3.27. The ONT and Illumina® MiSeq™ consensus sequences have been 
denoted and the sequences belonging to the same patient have been indicated on the 
righthand side of the figure. The comparison between the two sequencing platforms was 
further supplemented by Table 3.11 which shows the total aligned similarity percentage 
between the Illumina® MiSeq™ and ONT consensi of the same patient. Table 3.11 
therefore, shows how comparable ONT sequencing is to the golden standard Illumina® 
MiSeq™. All except one ONT consensus sequence showed a >99% similarity to the 
Illumina® MiSeq™ sequences. The nucleotide level disagreement between these platforms 
(<1% difference) was predominantly due to genomic regions with homopolymers (where 
ONT is known to have a higher read error) and the highly variable HIV-1 env gene, where 
the reads differ considerably from the reference genome. 
 




Figure 3.27: Maximum parsimony phylogenetic tree showing the sequencing results of the non-intact and intact 
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Table 3.11: Percentage aligned similarity between the ONT consensus and Illumina® MiSeq™ 
consensus sequences  




333716 P2D4 99.1 









340116 P4D1 99.3 
       Indicates samples that have been identified as intact HIV-1 sequences 
 
  




4 Discussion  
4.1. Summary and significance of findings  
The purpose of this investigation was to optimise and implement an assay that would detect 
the integration sites of intact HIV-1 proviral sequences identified in children belonging to the 
CHER cohort. As intact proviral sequences are rare, first detecting and enriching for them 
followed by the identification of their respective integration site would be beneficial as a 
technique like this is not currently available. The adapted ISLA subtype C and ONT’s 
Premium whole genome amplification protocol were utilised to achieve this. Furthermore, 
with increasing interest in the long-read length and real-time sequencing offered by 
third-generation sequencing technologies, ONT sequencing was investigated to determine 
if efficient, real-time and high accuracy sequencing was achievable by utilising ONT’s 
Amplicons by ligation protocol.  
 
4.1.1. ISLA subtype C assay  
The main objective of this study was focused on identifying integration sites. The ISLA 
subtype C assay was utilised as the method for identifying integration sites of intact proviral 
sequences and yielded unexpected results. The published ISLA method effectively 
described the identification of integration sites in HIV-1 subtype B patient samples although 
proviral integrity was not confirmed (Wagner et al., 2014) however, in the adapted HIV-1 
subtype C version the identification of integration sites was unsuccessful. Various 
differences can be described between the published ISLA assay and the assay that was 
optimised in our setting. The most distinct difference is due to the generation of starting 
material, Wagner et al (2014) used two forward primers in env and nef to generate linearly 
amplified templates and the adapted ISLA targeted the linearly amplified products in the 
background of a pre-nested NFL PCR. PCR reactions were optimized for exponential target 
amplification. However, PCR errors are common and often underappreciated, this includes 
off-target amplification when primers that are partial complements are extended under low 
stringency conditions, PCR product recombination, PCR induced mutations and 
primer-derived products including primer-dimers (Potapov & Ong, 2017, Zanini et al., 2017). 
The 5’-3’ exonuclease activity of Taq polymerase, could also destroy particular products 
generated by PCR as it digests products when the enzyme extending a primer encounters 
another template at a Y-junction which occurs when the product is at least partially 
Stellenbosch University  https://scholar.sun.ac.za
103 
 
complementary to the template. This could have hampered the recovery of integration sites. 
Our original expectation was that during PCR cycling, extension of the original template 
would generate one product per original template per PCR cycle that extends beyond the 
integration site junction (linear amplification of the original template) shown in Figure 4.1. 
However, DNA polymerase 5’-3’ exonuclease activity could have digested these products. 
Furthermore, the targeted area of the NFL primer sets undergo exponential amplification 
and therefore the template containing the integration site is likely present in low 
concentrations, if it has not been enzymatically digested. Therefore, ISLA assay primers 
may preferentially bind to the exponentially amplified templates instead as they are present 
in higher concentrations and consequently integration sites cannot be identified. A further 
noted difference between the assays is that the original primers were modified to bind to a 
subtype C HIV-1 genome. The Tm of the primers utilised in the original ISLA and the subtype 
C ISLA were similar and the published annealing temperatures from Wagner et al. (2014) 
were initially utilised. Due to the small differences in primer Tm, these annealing 
temperatures may have resulted in mispriming, limiting amplification across the integration 
site of the original integrated HIV template. For this reason, different annealing temperatures 
were investigated but integration sites were unrecoverable. In addition to the 
aforementioned differences, an MDA step was included in the ISLA subtype C assay which 
was not utilised in the original approach. The MDA step aimed to enrich the linearly amplified 
intact proviral sequences with the adjacent integration site as they were likely to be present 
in low concentrations as this would have allowed for a more efficient subtype C ISLA 
amplification from these templates.  
 
 
Figure 4.1: Example of the products that are produced during two rounds of PCR.        indicates the 
exponentially amplified region targeted by the primer set.            indicates the linearly amplified region where 
extension from the primer occurs beyond the targeted region. 
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Although integration sites were not identified through the ISLA subtype C assay, several 
unique fragments were amplified and sequenced to determine their significance. 
Twenty-three of the successfully sequenced cloned ISLA samples matched to HIV-1 
sequences available on GenBank. Moreover, the majority, equivalent to >39% (9 out of 23), 
of the sequences matched an intact proviral sequence that was published by Patro and 
colleagues in 2019. The remaining sequences matched to defective, mutant or RNA HIV-1 
sequences of unpublished methods and comparisons between the various methods is 
therefore not possible. As mentioned previously, the development of assays that allow for 
the identification of integration sites of intact proviral sequences is currently an important 
area of research as latently infected cells that harbour intact and potentially 
replication-competent viruses are important to identify as these cells lead to viral rebound 
upon cART cessation. Recently, two similar methods employing whole genome amplification 
of single cells were described by Einkauf et al. (2019) and Patro et al. (2019) to facilitate 
these identifications. Therefore, the fact the majority of the sequences in this study returned 
blastn matches to the clonally expanded intact HIV-1 subtype B proviral sequence from the 
Patro et al. study (2019) is significant as the methods described here and in the published 
article are somewhat similar. Both studies utilised an NFL PCR on single proviral genomes, 
although the primer sets were different, to generate a ~9kb HIV-1 template. Secondly, 
amplification by MDA was used in both studies however, Patro et al. (2019) enriched the 
genomic DNA prior to PCR amplification whereas our study first identified intact HIV-1 
proviral sequences and then utilised MDA to enrich for the intact proviral sequences present 
in the corresponding pre-nested NFL PCR wells. Comparisons between the method 
described by Einkauf et al. (2019), Patro et al. (2019) and the subtype C ISLA assay can 
also be described. Einkauf and colleagues (2019) employed a whole genome amplification 
approach with MDA on cells with single proviral genomes prior to a NFL amplification step 
similar to Patro et al. (2019) however, the NFL PCR targeted an ≥8kb region of HIV-1. A 
major similarity between the methods described in this study and those described by Einkauf 
et al. (2019) is that both studies utilised ISLA to identify integration sites. In addition, Einkauf 
et al. (2019) and colleagues confirmed integration sites by utilising two additional integration 
site assays in conjunction with ISLA, namely, the ligation-mediated PCR (LM-PCR) 
described by Serrao et al. in 2016 and the non-restrictive linear amplification–mediated PCR 
(nrLAM-PCR) described by Paruzynski et al. in 2010. The Patro et al. (2019) study 
investigated five patient samples and identified one expanded clone with an intact proviral 
sequence which was confirmed to be replication-competent by VOA. Whereas, the Einkauf 
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et al. (2019) identified eight clonally expanded cells harbouring intact proviral sequences 
among the three investigated patient samples.  
 
Intact proviral sequences are rare and the laborious steps of recovery have been described 
in many studies (Bruner et al., 2016, Bui et al., 2017, Katusiime et al., 2020) therefore, 
identifying the respective integration sites of intact proviruses is more labour intensive, 
complicated and time-consuming. Few clonally expanded cells harbouring intact proviral 
sequences have been described to date and although the ISLA subtype C assay approach 
was unsuccessful, it entailed a novel approach to recover these integration sites in 
comparison to methods that were recently described. Our approach to identifying 
integrations sites was unique as MDA is costly to execute on every well present on a 96 well 
PCR plate, therefore by identifying the wells that contain the intact proviral sequence first 
and then performing MDA on those wells only, would have significantly reduced costs 
related to identifying integration sites of intact HIV-1 proviral sequences, if these attempts 
had been successful.  
 
4.1.2. Identification of HIV-1 integration sites using ONT sequencing 
An alternative method for identifying the integration sites of intact HIV-1 proviruses was 
attempted as ISLA subtype C was unsuccessful, however, integration sites were also 
unrecoverable using the Premium whole genome amplification method from ONT. The 
method was attempted as published but significant losses in concentration of both the 8E5 
NFL and p6 MDA amplified products were observed and therefore, several other methods 
of purification were investigated. Although the MRC Holland Ethanol precipitation with the 
overnight - 20°C incubation method resulted in the best concentration and purity of the 
T7 Endonuclease I digested product, it did not yield a sufficient concentration to proceed 
with ONT sequencing as shown in Table 3.7. in the Results section. A comparison of the 
8E5 NFL MDA amplified product and the patient NFL MDA amplified products revealed that 
the former product could not be visualised by gel electrophoresis separation or plate viewing 
whereas the patient NFL MDA amplified products were visualised through both methods. 
Further comparisons showed that the spectrophotometric measurements of the 8E5 
NFL- and patient MDA amplified products measured as DNA. Taken together, the initial 
thoughts were that the 8E5 NFL MDA amplified product was not double-stranded but rather 
single-stranded as the EZ Vision™ DNA Dye would have bound to any double-stranded 
DNA present. Moreover, ONT devices are unable to sequence single-stranded DNA as the 
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sequencing adaptors, which contain important proteins that facilitate the binding to the 
sensor chip and sequencing of the fragment via the nanopore, will not ligate to the ends of 
these fragments. The p6 MDA amplified product which was also not visualised through the 
plate viewing method but was sequenced through ONT in an attempt to determine whether 
a low DNA library concentration could be sequenced and potentially resolve some of the 
questions concerning the structure of the non-visible MDA amplified fragment. The 
sequencing results of the p6 MDA amplified product revealed that the alignment to the HXB2 
consensus sequence contained numerous gaps and deletions which may have occurred as 
a result of the over frequent cutting of the fragment by the T7 Endonuclease I enzyme 
thereby resulting in the sequencing of very short fragments which complicate genome 
assembly. The unexpected cutting carried out by the T7 Endonuclease I enzyme has been 
hypothesised by many other ONT users although the method established by ONT has been 
successfully used in two recently published studies in different disciplines (Piñar et al., 2020, 
Harrop et al., 2020). Other potential problems that could have impeded successful 
sequencing by ONT may have occurred as MDA was utilised to enrich the intact proviral 
sequences and their integration site from a pre-nested NFL PCR product. As these 
templates are present in low concentrations sufficient enrichment may not have occurred as 
was described in the ISLA subtype C section above.  
 
4.1.3. Sequencing amplicons with ONT 
The major finding in this investigation was that ONT sequencing of products prepared with 
the Amplicons by Ligation sequencing protocol showed that ONT was an efficient 
sequencing technology that delivered long read lengths in real-time and generated 
sequences with acceptable read accuracy which can be used to construct accurate 
consensus sequences, due to sufficient coverage. ONT reports that a raw read accuracy of 
95% can be achieved with the broadly used R9.4.1 nanopores, which were used in this study 
and that these nanopores have shown the rapid generation of high-quality sequencing data 
and testing across multiple disciplines. The overall percentage similarity between the 
consensus sequences generated independently by ONT and Illumina® MiSeq™ was 
calculated at >99% for 8 of the 9 non-intact/intact HIV-1 proviral sequences. Illumina® 
MiSeq™ is considered the gold standard sequencing platform and has an average 
sequencing error rate of between 0.24% and 0.06% per base (Pfeiffer et al., 2018). Despite 
the higher read error of ONT (Weirather et al., 2017, Quainoo et al., 2017) agreement of 
ONT and Illumina® MiSeq™ consensus sequences were almost perfect except for HIV-1 
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env. Earlier studies reported higher error rates for ONT sequencing, a study in 2017 by 
Weirather et al. compared the error rates of PacBio® and ONT and reported error rates of 
13.217%, and 12.669%, respectively. By 2018, a study conducted by Jain and colleagues 
reported that the raw base-called error rate for ONT sequences decreased to <5%. 
Therefore, ONT’s sequencing technology has evolved and the quality of the sequencing 
data that is generated has significantly improved since its commercial release in 2014. The 
1% error of ONT consensus compared to reference Illumina® MiSeq™ consensus reported 
in this study, may be attributed to the following; 1) regions containing homopolymer stretches 
were poorly resolved by the R9.4.1 nanopores and basecalling algorithm which often cause 
deletions within those regions and therefore misalignments to reference sequences, 
2) sequences of acceptable quality were mapped to HIV-1 subtype C reference, the resulting 
coverage and mapping accuracy was lowest for the highly variable env region of HIV-1 
therefore resolving this region was complicated and 3) the original nested NFL PCR 
products used to identify intact proviruses by Illumina® MiSeq™ sequencing were depleted, 
therefore the pre-nested NFL PCR wells corresponding to the intact nested wells were 
amplified with the nested NFL primer set to generate products for ONT sequencing. 
Although a high-fidelity enzyme is utilised in the pre- and nested PCR reactions, some errors 
may have been introduced which could also contribute to the slight differences observed 
between the Illumina® MiSeq™ and ONT consensi. Many studies that have utilised ONT 
sequencing have been published, however, at the time of writing only two studies have used 
ONT sequencing to conduct research on HIV and this may be due to the varying reports on 
ONT read accuracy which are influenced by poor resolution of homopolymer and highly 
variable regions. As HIV is a virus that rapidly mutates it’s important to utilise a sequencing 
platform that can accurately detect these mutations. The sequence accuracy from this study 
could in future be further improved upon by utilising the more accurate ONT R10.3 pores 
and by improving the HIV env alignment algorithms. Nevertheless, this study shows that 
ONT provides an accurate and fast option for HIV consensus sequence generation, enabled 
by the long-read lengths, which facilitate accurate alignment and deep sequence coverage 
which compensates for read error.  
 
4.2. Strengths and limitations of the study  
4.2.1. Strengths 
Several key strengths were identified in this study. The strengths of the ISLA subtype C 
assay are limited as many obstacles were encountered throughout the optimisation of the 
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assay. However, significant advances in technical experience and critical thinking were 
required to troubleshoot and potentially resolve the problems that were encountered. The 
majority of the key strengths of this investigation were identified in ONT sequencing. This 
third-generation sequencing technology allowed for the effortless sequencing of long 
fragments in real-time and a high coverage across the amplified ~9kb HIV-1 genome was 
achieved which allowed for accurate consensus sequences to be generated. Despite the 
higher ONT read error, the approach to obtain consensus sequences provided a very good 
agreement and comparable accuracy to that obtained with Illumina® MiSeq™. A further 
strength is that ONT does not require fragmentation and genome assembly is, therefore, 
less complex and faster. Furthermore, once sufficient coverage is achieved the sequencing 
run can be terminated, and the remaining resources can be reallocated which reduces the 
cost of sequencing. ONT is an in-development technology and the technology significantly 
improves in short periods of time with user input which is provided through the nanopore 
community platform. ONT often updates and releases new software and chemistry based 
on the requirements of their users to improve sequencing quality and accuracy. Multiple 
steps in ONT’s protocols can be altered to improve the quality of the sequencing data and 
includes changes to AMPure XP bead ratio in the purification steps and the ratio of the 
sequencing adaptors added during the adaptor ligation step. As ONT is a user-orientated 
sequencing technology any problems that are encountered are quickly resolved by their 
team of experts.  
 
4.2.2. Limitations 
A number of limitations were encountered in this study. Firstly, the success of the ISLA 
subtype C assay could only be determined after receiving the sequencing data as there are 
no checkpoint steps between the start of ISLA and the Sanger sequencing. Through 
discussions with the group that established ISLA (Wagner et al., 2014), it became clear that 
the formation of the loop is generated under very specific conditions that need to be strictly 
adhered to and any deviation will result in no loop formation and therefore no recovery of 
integration sites. It is possible that the adjustments made to the original ISLA interfered with 
the loop formation step. Limitations that were encountered with ONT sequencing included 
the fact that a high concentration of pure DNA was required for successful high coverage 
sequencing whereas particular second-generation sequencing platforms such as Illumina® 
require very low DNA inputs. Low concentration DNA libraries can be sequenced by ONT 
but the data often contains gaps, gives low coverage and results in the rapid exhaustion of 
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the nanopores which has a negative impact on the cost of sequencing as flow cells will be 
discarded after a single use. Efficient bioinformatic pipelines are not as readily available for 
ONT sequencing as they are for second-generation sequencing technologies, hence the 
inclusion of a customised pipeline in this study. Particular to ONT is the iterative nature of 
improvements, which is both a strength and limitation. As the platform constantly improves 
there is a rapid expansion of research applications. Therefore, custom bioinformatics 
pipelines for a particular application such as HIV near-full-length sequencing had to be 
developed as they were not available. Updates to the MinKNOW software are continuously 
made which improves sequencing accuracy but may lead to delays in sequencing as some 
updates result in the device not working, this problem was encountered during this study. 
Library preparation protocols are regularly updated and new protocols are also included 
however, a protocol that is best suited to your needs may not be available yet and other 
protocols may require optimisation.  
 
4.3. Investigations and considerations of future studies  
The two methods that recently described the simultaneous identification of integration sites 
and proviral integrity utilise a whole genome amplification approach and use at least 
3 different amplification techniques for confirmation, making both approaches expensive, 
laborious and time-consuming (Einkauf et al., 2019, Patro et al., 2019). The ISLA subtype 
C assay and the Premium whole genome amplification approach described in this study was 
utilised in an attempt to eliminate the increased implications on cost, labour and time. 
Therefore, future studies should investigate efficient methods that allow for the direct 
identification of integration sites belonging to intact proviral sequences of HIV-1. 
Furthermore, third-generation sequencing technologies such as PacBio® and ONT were 
designed to overcome the limitations present in second-generation sequencing, such as the 
relative short read-length and long sequencing turnaround time, and facilitate the 
progression towards faster, cheaper sequencing and potentially efficient identification of 
integration sites. The initial error rates reported for these technologies were not comparable 
to those of second-generation sequencing technologies however, recent reports have 
suggested otherwise and this study further confirms that ONT sequencing, when 
accompanied by a bioinformatics pipeline that corrects for sequencing error during 
consensus assembly offers an efficient, rapid and reliable third-generation sequencing 
technology. Future studies should investigate the error rate of the recently released R10.3 
nanopores as they have been specifically designed to overcome the errors encountered 
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when sequencing homopolymer regions with the R9.4.1 nanopores which were used in this 
study. The ability to barcode samples with ONT sequencing allows for multiple samples to 
be sequenced simultaneously, it is also possible to interrupt runs once sufficient coverage 
is attained with a ‘read until’ approach, which allows for reuse of flow cells, thereby reducing 
costs. In future, the effect of barcoding multiple HIV-1 samples and the ability to effectively 
resolve highly variable regions, when using R10.3 nanopores should be investigated as a 
lower overall coverage per a sample is achieved when multiple samples are sequenced.  
 
4.4. Conclusion 
The integration sites of intact HIV-1 proviral sequences could not be recovered with either 
of the approaches that were attempted in this study, which included; the adapted subtype C 
ISLA assay and the altered ONT Premium whole genome amplification protocol. The 
recovery of integration sites from rare intact HIV-1 proviruses is difficult and cumbersome 
as has been described here and in other investigations. Assays investigating the clonal 
expansion of intact proviruses require further development and optimisation to ensure 
efficient, cost- and time-effective methods are established. As these investigations will allow 
for a better understanding of how to eliminate the latent reservoir of HIV-1 infected cells 
harbouring intact provirus, responsible for persistent HIV-1 infection, without disrupting the 
normal immune functions of CD4+ T cells.  
 
The comparison of ONT and Illumina® MiSeq™ consensi of the same patient samples 
showed an overall concordance of >99% except for one sample. Furthermore, as described 
in the Discussion section, it was bioinformatically challenging to align reads to the highly 
variable env region of the HIV-1 genome, which effectively reduced coverage and read 
accuracy for this region. This, together with the poor resolution of homopolymer regions and 
sequencing of reamplified pre-nested products may account for differences between the 
ONT and Illumina® MiSeq™ consensi. Overall, ONT’s third-generation sequencing 
technology was able to provide high coverage and accurate consensus sequence 
generation of the ~9kb intact and non-intact HIV-1 proviral fragments amplified by an NFL 
PCR. ONT sequencing should be utilised more frequently in research-based settings as it 
also allows for efficient, low cost and real-time sequencing and data analysis which is 
extremely useful as many of the currently preferred sequencing technologies have long run 
times, high reagent costs and often incur longer periods prior to sequence analysis. At the 
time of writing, only two published studies have utilised ONT for HIV-1 related research and 
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the findings provided in this study encourage further exploration and use of this sequencing 
technology especially in research areas that require fast confirmatory results or in studies 
where high coverage is required to construct accurate consensus sequences.  
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Addendum A  
SARS-CoV-2 in Cape Town, South Africa investigation report 
Molecular epidemiology and genetic diversity of SARS-CoV-2 in Cape Town, South Africa 
Susan Engelbrecht, Kayla Delaney, Bronwyn Kleinhans, Eduan Wilkinson, Houriiyah Tegally, Tania Stander, 
Gert van Zyl, Wolfgang Preiser, Tulio de Oliveira 
 
Introduction:  
SARS-CoV-2 is responsible for the COVID-19 disease and was originally reported during a 
local pneumonia outbreak of unknown origin in Wuhan City, China in December 2019. 
COVID-19 rapidly became an emerging pandemic and data reported by WHO on the 6th of 
September 2020 reported that a total of 26 763 217 cases have been confirmed and has 
resulted in 876 616 deaths globally [https://covid19.who.int/]. Furthermore, the data 
provided by WHO shows South Africa is ranked as the country with the 6th highest number 
of cases globally. As of yet, no vaccines or antiviral agents are available to combat the virus 
although many are currently in development or testing in clinical trials.  
 
In South Africa, early reports of the epidemic identified Cape Town in the Western Cape 
province as the epicentre. However, prior to this study the number of SARS-CoV-2 
introductions and the source of these introductions into Cape Town was unknown which 
lead to the following questions: 1) was the SARS-CoV-2 introduction into Cape Town a result 
of a single or multiple introductory event(s)? and 2) what was the source and timing of these 
events?  
 
This study aimed to track the start of the epidemic in Cape Town by sequencing forty-seven 
complete viral genomes from early SARS-CoV-2 samples by utilising third-generation 
sequencing offered by ONT. 
 
Methods:  
SARS-CoV-2 viral RNA was detected in patients by diagnostic real-time PCR, reverse 
transcription and PCR of the complete viral genome was completed with the PCR tiling 
method available at https://artic.network/ncov-2019. The amplified products were 
sequenced using ONT’s GridION device. The raw reads were assembled and the consensus 
sequences were obtained by utilising the bioinformatics pipeline available at 




The clades were assigned and quality assurance was performed in Nextclade 
[https://clades.nextstrain.org/]. Finally, the lineages were assigned using Pangolin (Rambaut 
et al., 2020)[https://cov-lineages.org/] and all the obtained sequences were deposited in 
GISAID [https://www.gisaid.org/].  
 
Results:  
The demographic information and Ct values of the patients were recorded and overall, lower 
Ct scores were recorded in younger patients, indicative of higher viral loads, and these 
samples resulted in higher genome coverage. Three clades, namely, 19A, 20A and 20B 
were identified by Nextstrain phylogenetic analysis and Nextclade. Each clade is defined by 
specific designated mutations whereas lineages were assigned by the Pangolin software. A 
lineage is defined as a cluster of sequences that have been observed in geographically 
distinct regions in conjunction with evidence of ongoing transmission within that region. Two 
unique variant mutations were identified in Cape Town. A5209G represented a new lineage 
with a specific amino acid mutation and A24862G was present at a much higher frequency 
in the Cape Town sequences in comparison to their global distribution. Overall, the clade 
and lineage data show that multiple introductory events of SARS-CoV-2 were responsible 
for the introduction into Cape Town. The data further indicates that all the introductions into 
Cape Town occurred between the last week of February and within the first two weeks of 
March 2020 prior to the enforcement of strict lockdown regulations in South Africa.  
 





Figure A1: Phylogenetic and clade analysis of the Cape Town Western Cape, South Africa SARS-CoV-2 
sequences. (A) A time-scaled Maximum likelihood tree showing a total of 3620 sequences together with the 
47 genotypes obtained from Cape Town with the major clades of SARS-CoV-2 indicated with by    . (B) Stacked 
bar plot showing the clade frequencies and distributions by region, clade 20A (where most of the Cape Town 
sequences lie) is over-represented and shows origins from Europe. (C) Monophyletic cluster indicated by * of 
the Cape Town sequences. This cluster shows the closest divergence to isolates that originated in the 
Netherlands and the emergence and presence of the unique Cape Town lineage and mutation (5209A>G) is 
shown within the cluster. 
 
Conclusion: 
The presence of clades 19A, 20A and 20B were observed through the genomic and 
epidemiological data which provided unique insights into the spread and transmission of the 
early SARS-CoV-2 epidemic in Cape Town, South Africa. Molecular clock analyses 
confirmed that all the introductions into Cape Town occurred within 3 weeks starting in the 
last week of February 2020, prior to lockdown in March 2020. One of the introductions, first 
identified in this study, diversified by acquiring the A5209G mutation prior to causing a large 
cluster outbreak. Observing and following the acquisition of mutations will allow for a better 
understanding of how the virus spreads between different locations within a city and 
throughout South Africa.  
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Average Read Length Histograms for the seven intact HIV-1 proviral sequences using 
ONT’s Amplicons by Ligation protocol for sequencing. The two non-intact samples are 
excluded as they were sequenced simultaneously (on separate flow cells) and individual 
Read Length Histograms were not available when using these sequencing settings.  
 
All histograms are based on the average read lengths that were sequenced within the first 
hour of the ONT sequencing run except for sample 339266 P5D4 which was taken 5 minutes 
into the sequencing run.  
 
 
Figure B1: Read length histogram for sample 
339266 P2C7 
 




Figure B3: Read length histogram for sample 
339266 P1C7  
 
Figure B4: Read length histogram for sample 
339266 P1C8 








Figure B6: Read length histogram for sample 
339606 P3G7 
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